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ABSTRACT 
Obesity represents a major health, social and economic burden to many developing and 
Westernized communities, with the prevalence increasing at a rate exceeding almost all 
other medical conditions. Despite major recent advances in our understanding of 
adipose tissue metabolism and dynamics, we still have limited insight into the 
regulation of adipose tissue mass in humans. Any significant increase in adipose tissue 
mass requires proliferation and differentiation of precursor cells (preadipocytes) present 
in the stromo-vascular compartment of adipose tissue. These processes are very 
complex and an increasing number of growth factors and hormones have been shown to 
modulate the expression of genes involved in preadipocyte proliferation and 
differentiation. A number of transcription factors, including the C/EBP family and 
PP ARy, have been identified as integral to adipose tissue development and preadipocyte 
differentiation. Together PP ARy and C/EBPa regulate important events in the 
activation and maintenance of the terminally differentiated phenotype. The ability of 
PP ARy to increase transcription through its DNA recognition site is dependent on the 
binding of ligands. This suggests that an endogenous PP ARy ligand may be an 
important regulator of adipogenesis. Adipose tissue functions as both the major site of 
energy storage in the body and as an endocrine organ synthesizing and secreting a 
number of important molecules involved in regulation of energy balance. For optimum 
functioning therefore, adipose tissue requires extensive vascularization and previous 
studies have shown that growth of adipose tissue is preceded by development of a 
microvascular network. This suggests that paracrine interactions between constituent 
cells in adipose tissue may be involved in both new capillary formation and fat cell 
growth. To address this hypothesis the work in this project was aimed at (a) further 
development of a method for inducing preadipocyte differentiation in subcultured 
human cells; (b) establishing a method for simultaneous isolation and separate culture 
of both preadipocytes and microvascular endothelial cells from the same adipose tissue 
biopsies; (c) to determine, using conditioned medium and co-culture techniques, if 
endothelial cell-derived factors influence the proliferation and/or differentiation of 
human preadipocytes; and (d) commence characterization of factors that may be 
responsible for any observed paracrine effects on aspects of human adipogenesis. 
Major findings of these studies were as follows: 
(A) Inclusion of either linoleic acid (a long-chain fatty acid reported to be a naturally 
occurring ligand for PP ARy) or Rosiglitazone (a member of the thiazolidinedione class 
of insulin-sensitizing drugs and a synthetic PPARy ligand) in differentiation medium 
had markedly different effects on preadipocyte differentiation. These studies showed 
that human preadipocytes have the potential to accumulate triacylglycerol irrespective 
of their stage of biochemical differentiation, and that thiazolidinediones and fatty acids 
may exert their adipogenic and lipogenic effects via different biochemical pathways. It 
was concluded that Rosiglitazone is a more potent inducer of human preadipocyte 
differentiation than linoleic acid. 
(B) A method for isolation and culture of both endothelial cells and preadipocytes 
from the same adipose tissue biopsy was developed. Adipose-derived microvascular 
endothelial cells were found to produce factor/s, which enhance both proliferation and 
differentiation of human preadipocytes. 
(C) The adipogenic effects of microvascular endothelial cells can be mimicked by 
exposure of preadipocytes to members of the Fibroblast Growth Factor family, 
specifically ~-ECGF and FGF-1. 
v 
(D) Co-culture of human preadipocytes with endothelial cells or exposure of 
preadipocytes to either ~-ECGF or FGF-1 were found to 'prime' human preadipocytes, 
during their proliferative phase of growth, for thiazolidinedione-induced differentiation. 
(E) FGF -1 was not found to be acting as a ligand for PP ARy in this system. 
Findings from this project represent a significant step forward in our understanding of 
factors involved in growth of human adipose tissue and may lead to the development of 
therapeutic strategies aimed at modifying the process. Such strategies would have 
potential clinical utility in the treatment of obesity and obesity related disorders such as 
Type II Diabetes. 
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1.1 INTRODUCTION 
Obesity and its related metabolic disorders are an increasing and major cause of 
morbidity and mortality in industrialized societies. Obesity is accompanied by 
several metabolic complications and has been increasingly recognized as a risk 
factor for chronic diseases such as non-insulin-dependent diabetes mellitus 
(NIDDM), dyslipidemia, and atherosclerotic cardiovascular diseases (Abate et al 
1995). The association between obesity and these disease processes is highly 
influenced by the regional location ofbody fat (Kissebah & Peiris 1989). Increasing 
abdominal (visceral) body fat is accompanied by progressively increasing plasma 
glucose, insulin, and triglyceride levels, decreasing HDL cholesterol concentration, 
and abnormal metabolic pathways predisposing to NIDDM, including marked 
peripheral insulin resistance (Kissebah & Peiris 1989). It is, therefore, important to 
define the mechanisms involved in regulation, not only of total fat mass, but also 
regional body fat distribution. 
Obesity is characterized by excessive accumulation of adipose tissue mass. This 
occurs in a setting of positive energy balance and involves both an increase in 
adipocyte triglyceride content (hypertrophy) and an increase in adipocyte number 
(hyperplasia) (Hauner 1990). Increases in adipocyte number occur via replication 
and differentiation of fibroblast-like adipose precursor cells (preadipocytes) 
contained within the stromo-vascular compartment of adipose tissue (Prins & 
O'Rahilly 1997). 
Progress has been made in understanding the processes of preadipocyte replication 
and differentiation by studying these processes in cell lines and primary culture of 
rodent origin. This has allowed us to begin to understand the cellular and molecular 
basis of adipose tissue growth in both physiological and pathophysiological states in 
rodents (Gregoire et al 1998). Less is known about the regulation ofthese processes 
in human preadipocytes. Future studies need to be aimed at gaining insight into the 
signaling processes involved in cell-cell or cell-matrix interactions that modulate 
transcriptional activity and adipocyte differentiation in human adipose tissue. 
Understanding how various molecules regulate human adiposity and energy balance 
in both physiological and pathophysiological situations remains to be elucidated. 
An understanding of these processes and how they interact may lead to the 
development of novel therapeutic approaches to the treatment and/or prevention of 
human obesity and related pathologies. 
In this thesis, the mechanisms involved in the regulation of human adipose tissue 
growth and development through the processes of replication and differentiation of 
adipose precursor cells will be examined. 
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1.2 LITERATURE REVIEW 
1.2.1 ADIPOSE TISSUE 
1.2.1 A Adipocyte Lineage 
The origins of the adipose cell and adipose tissue are still poorly understood and the 
molecular events leading to the commitment of the embryonic stem cell precursor to 
the adipocyte lineage remain to be characterized. Adipocyte precursors are believed 
to descend from multipotent embryonic stem cells (Dani et al 1997; Klaus 1997). 
These stem cells have the capacity to differentiate into the mesodermal cell types of 
adipocytes, chondrocytes, osteoblasts, and myocytes (Konieczny & Emerson 1984; 
Taylor & Jones 1979). In humans, white adipose tissue expansion takes place 
rapidly after birth as a result of increased fat cell size as well as an increase in fat 
cell number. It was previously believed that fat cell number was fixed during 
childhood and that the capacity to form new adipocytes was lost well before 
adulthood was reached (Sorisky 1999). This precept held that childhood-onset 
obesity was associated with an increase in fat cell number whilst the only cellular 
mechanism involved in adult-onset obesity was enlargement of existing fat cells 
(Hirsch & Knittle 1970; Salans et al 1973). More recent studies however have 
clearly shown that even at the adult stage the potential to generate new fat cells 
persists (Prins & O'Rahilly 1997) although the mechanisms controlling the cellular 
development of human adipose tissue are not well understood. 
1.2.1 B Role of Adipocytes 
Adipocytes play a central role in the regulation of energy homeostasis. In the past 
adipose tissue was thought to be a passive storage site for the largest energy reserve 
of the body. However, it is becoming increasingly clear that adipocytes are 
metabolically active cells that secrete proteins, enzymes, and potent autocrine, 
paracrine and endocrine factors (Cianflone 1997). For example, adipocytes 
contribute to the functional regulation of both the reproductive and immune systems 
(Loftus & Lane 1997). Also, adipocytes have been found to secrete factors known 
to play a role in immunological responses, vascular disease, and appetite regulation 
(Gregoire et al 1998). These factors include leptin, a peptide hormone that has been 
shown to have numerous effects on energy intake and metabolism, reproduction, and 
immune functions, and tumour necrosis factor-a (TNFa) a cytokine that has 
profound cachectic effects (Loftus & Lane 1997) and appears to have a role in 
insulin sensitivity (Weigle 1997). The number of products secreted by adipocytes 
also includes adipsin, agouti protein, angiotensinogen, plasminogen activator 
inhibitor-! (PAI-l), and transforming growth factor-~ (TGF-~) (Fruhbeck et al 
2001) and this list continues to grow, serving to demonstrate how metabolically 
active this tissue is. 
1.3 REGIONAL ADIPOSITY 
Epidemiological studies show a close associatio,n of upper-body obesity, in 
particular visceral obesity, with most of the accompanying metabolic and 
cardiovascular complications associated with the obese state (Amer 1997). There 
are differences in metabolic activity in adipocytes from different depots, with the 
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lowest activity in the subcutaneous gluteofemoral area, followed by the abdominal 
subcutaneous area, and highest activity in the visceral region (Amer 1997). For 
example, lipolytic hormones are most active in visceral fat and conversely anti-
lipolytic hormones have a greater inhibitory effect on lipolysis in subcutaneous 
versus visceral fat cells (Amer 1997). Taken together this means that increases in 
the concentration of any of the lipolysis-regulating hormones will result in more 
rapid fatty acid mobilization from visceral than subcutaneous adipose tissue (Amer 
1997). The mechanisms by which visceral obesity leads to complications are not 
well understood. However it is generally believed that the direct access of visceral 
fat to the liver via the portal vein allows increased delivery of free fatty acids to the 
liver. Elevated 'portal' fatty acids may cause glucose intolerance, hyperinsulinemia, 
and dyslipidemia (Frayn et al1997). Differences in gene expression exist between 
adipocytes from intra-abdominal and subcutaneous sites, for example, 
glucocorticoid receptor number is greater in visceral than subcutaneous adipocytes 
(Rebuffe-Scrive et al 1990) leading to differential effects of corticosteroids on 
regulation of adipose cell volume and number (Prins & O'Rahilly 1997). Also, 
overexpression of leptin mRNA has been reported in subcutaneous as compared to 
omental adipocytes (Montague et al1997). Therefore the two depots may contribute 
unequally to circulating leptin levels and thus to central regulation of overall 
adiposity (Prins & O'Rahilly 1997). 
Factors influencing patterns of adipose tissue deposition are largely unknown but 
depot-specific differences in factors affecting number and/or volume of adipocytes, 
or differential contributions to the adipose-hypothalamic 'feedback loop' from 
different depots, may play a role (Prins & O'Rahilly 1997). A greater understanding 
of mechanisms regulating regional adipose cell number and size may lead to 
interventions aimed at modifying adipose distribution rather than overall adiposity-
this could lead to a reduction in the pathophysiologies associated with obesity. 
1.4 ADIPOSE TISSUE ACCUMULATION 
Both number and size of existing fat cells contribute to the adipose tissue mass 
(Hauner et al 1989). Originally it was believed that the number of fat cells is fixed 
during childhood and that adult-onset obesity was characterized by enlargement of 
existing fat cells. It is now well established that fibroblast-like precursor cells 
(preadipocytes ), capable of undergoing replication and differentiation to the 
adipocyte phenotype, are present in adipose tissue (Hauner et al 1989). New 
adipocyte formation is a component of adipose tissue enlargement and is an ongoing 
process that occurs throughout life (Li et al 1998). Preadipocytes form a reservoir of 
cells within the stromo-vascular fraction of adipose tissue depots. This stromo-
vascular compartment consists of preadipocytes, endothelial cells and blood cells, 
and accounts for one- to two-thirds of adipose tissue, the remainder being mature 
adipocytes (Ailhaud et al 1992). A large number of growth factors and hormones 
have been shown to regulate the proliferation and differentiation of preadipocytes in 
culture. Those shown to have a mitogenic effect on rodent preadipocytes include 
insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), basic fibroblast 
growth factor (bFGF), and platelet-derived growth factor (PDGF) (Roncari & 
Thompson 1990). Factors affecting differentiation of preadipocytes include 
members of the peroxisome proliferator-activated receptor (PP AR) (Tontonoz et al 
1994c) and CCAAT enhancer binding protein (C/EBP) (Freytag & Geddes 1992) 
7 
8 
families of transcription factors, and vanous hormones including insulin, 
glucocorticoids and growth hormone (Hauner et al1987; Nixon & Green 1983). 
1.5 IN VITRO MODELS OF ADIPOCYTE DIFFERENTIATION 
Cell culture models have been instrumental in the understanding of adipocyte 
differentiation. Over the last 20 years, in vitro systems have been used extensively 
to study adipocyte differentiation. This has led to a greater understanding of the 
molecular and cellular events occurring when fibroblast-like preadipocytes 
differentiate into mature round fat cells with all the concomitant metabolic 
capabilities of this phenotype. Various mouse preadipose cell lines and primary 
cultures of adipose-derived stromo-vascular precursor cells from rodent and other 
mammals have been used. Studies using primary cultures of preadipocytes have 
proven to be tedious and difficult as both the number of preadipocytes available and 
their life span is quite limited. Also their differentiation response wanes with cell 
proliferation (Entenmann & Hauner 1996; Hauner et al 1989). Another drawback 
was that there is substantial heterogeneity in the extent of differentiation between 
samples from different donors (Sen et al2001). Therefore, it was a tremendous step 
forward in the study of the molecular events involved in adipogenesis when 
preadipocyte cell lines were developed. The most frequently used cell lines are 3T3-
F442A and 3T3-Ll. These were clonally isolated from Swiss 3T3 cells derived 
from disaggregated 17- to 19-day mouse embryos (Green & Kehinde 1975; Green & 
Kehinde 1976; Green & Meuth 1974). Another preadipocyte cell line, the Ob17 cell 
line, originated from fat tissue from an adult ob-/ob- mouse, which is a model for 
obesity and NIDDM (Ailhaud et al 1992). The 3T3-L1 preadipocyte cell line is the 
most extensively studied with respect to gene regulation during adipogenesis. Other 
cell lines and preadipocytes m pnrnary culture generally follow the same 
differentiation pathway but may differ as to their initial stage of 
commitment/differentiation (MacDougald & Lane 1995). Following hormonal 
induction of differentiation in 3T3-L1 cells the programmed induction of genes 
regulating lipoprotein lipolysis, fatty acid cellular uptake and synthesis of fatty acids 
and triglycerides occurs. These genes can be classified as markers of either early 
(commitment), middle, or late (terminal) differentiation (Cornelius et al 1994). 
Figure 1.1 shows the stages, which occur during adipocyte differentiation from the 
pluripotential stern cell to the mature adipocyte. Early markers are exemplified by 
lipoprotein lipase (LPL) and the a2 chain of type VI collagen, whereas terminal 
indicators include GLUT4, adipsin, fatty acid synthase, glycerol-3-phosphate 
dehydrogenase (G3PDH), and leptin (Cornelius, et al., 1994). This temporal 
expression of genes during adipocyte differentiation allows precise assessment of 
the stage of differentiation by assaying for the expression of relevant rnRNA or 
protein by Northern or Western blot analysis, or by the measurement of the 
appropriate enzyme activity. The use of cell lines in studies of adipogenesis have 
allowed a great expansion in the understanding of the factors and mechanisms 
involved in this process. However, current evidence indicates distinct differences in 
the way differentiation occurs in aneuploid 3T3 and Ob17 cells, and diploid (strorno-
vascular) preadipocytes. For example, the 13-2 adrenoceptor subtype in 
differentiated rat preadipocytes does not respond to catecholamine stimulation, 
whereas 3T3-L1 cells upon differentiation express 13-1 adrenoceptors responsive to 
catecholarnines (Lai et al 1982; Li et al 1989b). Cat serum does not support 
differentiation of 3T3 cells, but induces significant adipose conversion of rat 
preadipocytes in primary culture (Li et al 1990). Epidermal Growth Factor (EGF) 
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Figure 1.1: Stages in adipocyte differentiation. As the pluripotential precursor stem cell differentiates to 
the mature adipocyte (centre of diagram), its cell-fate becomes restricted first to that of the multipotential 
mesenchymal cell type with an ability to give rise to preadipocytes as well as myoblasts and chondroblasts. 
Following subsequent environmental and gene expression cues, the preadipocyte becomes committed to its 
terminal differentiation pathway. A presumed master regulatory gene expressed at the mesenchymal stage 
commits cells to the preadipocyte lineage. Differentiation is divided into early, mid and late terminal 
phases. The corresponding pattern of gene expression is shown to the right with broken lines indicating 
possible continued expression (from Smas & Sul1995). 
has been reported to stimulate adipose conversion of 3T3-L1 cells (Schmidt et al 
1990), but has been observed by several investigators to inhibit normal rat 
preadipocyte differentiation in culture (Li et al 1994; Serrero 1987). Prostaglandin 
F2 alpha (PGF2a) induces conversion of 3T3 fibroblasts into adipose cells (Russell 
& Ho 1976) but has been shown to be a potent differentiation inhibitor of adipocyte 
precursors in primary culture (Serrero & Lepak 1995). Further, differentiation is 
obligatorily coupled to growth arrest followed by a limited number of cell divisions 
in the case of aneuploid 3T3 and Ob17 cells (Ailhaud et al 1989; Green & Meuth 
1974). However, primary preadipocytes are capable of maturing in vitro without 
prior clonal expansion or proliferation (Li et al 1989a; Li et al 1989b; Shillabeer et al 
1989). The differences outlined above show that data obtained from studies using 
aneuploid 3T3 and Ob17 cells should be generalized with caution and may not be 
directly extrapolated to primary preadipocytes. The use of cell lines has allowed an 
important understanding of the adipogenic process; however, to understand this 
process in humans it is necessary to validate these results using primary cultures of 
human preadipocytes. Primary cells are diploid and therefore reflect the in vivo 
situation better than aneuploid cell lines. Second, they can be derived from adipose 
tissue obtained from various species at different postnatal stages of development and 
from various adipose depots (Bjorntorp et al1982; Deslex et al 1987a; Deslex et al 
1987b). The latter is of particular interest in human studies as differences found in 
cells from subcutaneous and visceral sites may have major physiological 
significance. 
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1.5.1 Factors affecting adipose conversion 
Various hormones and factors have been identified which can induce adipose 
conversion in preadipocyte cell lines (Ailhaud et al1992; Butterwith 1994). Factors 
that promote adipocyte differentiation in mouse cell lines include insulin, insulin-
like growth factor-1 (IGF-1), tri-iodothyronine (T3), cyclic AMP (cAMP), 
glucocorticoids, prostaglandins, arachidonic acid, and growth hormone (GH) (Amri 
et al1994; MacDougald & Lane 1995; Nixon & Green 1983; Safonova et al1994). 
The role of various growth factors in adipose conversion is controversial with 
conflicting data reported for a number of growth factors including platelet-derived 
growth factor (PDGF), fibroblast growth factor (FGF), and epidermal growth factor 
(EGF) (Gregoire et al1998; Hauner et al1995). The currently available data on the 
role of growth factors in the development of adipose tissue differ depending on the 
cell model and the culture conditions, but many studies have reported inhibitory 
effects (Hauner et al 1995). Unlike IGF-1, which promotes preadipocyte 
differentiation (MacDougald & Lane 1995), other growth factors and cytokines are 
generally considered as inhibitors of adipocyte differentiation. It has been suggested 
that this is due to their mitogenic effects, since cell growth and differentiation are 
usually considered to be mutually exclusive events (Gregoire et al 1998). It has 
been found that not all cell lines require the same differentiation inducers, which 
may reflect the different stages of adipocyte development in which different 
immortalized preadipocyte cell lines are arrested (Smas & Sui 1995). However, it 
is clear that during adipocyte differentiation there is involvement of several second 
messenger pathways. These include tyrosine kinase pathways activated by IGF-1 
and/or insulin, cAMP-activated protein kinase A, protein kinase C, and nuclear 
receptors activated by fatty acids and peroxisome proliferators (MacDougald & 
Lane 1995; Smas & Sul 1995). The agents most widely used, usually in 
combination, to differentiate 3T3-L1 preadipocytes and other preadipocyte cell lines 
include glucocorticoids, high levels of insulin (which act through the IGF-1 
receptor), and methyl-isobutylxanthine (MIX) which is a cAMP phosphodiesterase 
inhibitor (Smith et al 1988). Growth hormone has also been identified as a serum 
factor required for induction of adipocyte differentiation (Nixon & Green 1983; 
Nixon & Green 1984). It has been shown to function by stimulating preadipocytes 
to synthesize and secrete IGF-1 which then has a paracrine/autocrine effect on 
preadipocyte differentiation (Nougues et al 1993). This effect can be mimicked in 
vitro by the presence of supraphysiologica1 concentrations of insulin that act via 
IGF-1 receptors (Cornelius et al1994). 
Studies looking specifically at the differentiation of stromo-vascular cells from 
human adipose tissue have shown that these cells are resistant to differentiation if 
cultured under serum-containing conditions (Hauner 1990). However, when 
cultured in serum-free, chemically-defined conditions, a high proportion of cells are 
capable of developing into adipocytes. This suggests that in vitro this fraction of 
adipose tissue is far less heterogeneous with regard to cell-type than originally 
believed (Hauner 1990). In these cells adipose differentiation is promoted by 
addition of insulin, triiodothyronine, cortisol and cAMP-elevating agents to a serum-
free medium (Hauner 1990). 
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1.6 ADIPOSE TISSUE GROWTH 
1.6.1 Replication 
A large number of studies have investigated the regulation of adipocyte precursor 
cell differentiation but few have dealt with the control of cell proliferation. As the 
mature adipocyte has little or no capacity for cell division the hyperplastic capacity 
of adipose tissue resides in the fibroblast-like preadipocyte pool (Butterwith 1994). 
A number of growth factors have been shown to exert considerable effects on DNA 
synthesis in preadipocytes in vitro. These growth factors include IGF-1 (insulin-like 
growth factor-1), PDGF (platelet derived growth factor) and TGF-a (transforming 
growth factor-a) (Butterwith & Goddard 1991). A number of these growth factors 
are expressed in preadipocytes in vitro and may therefore have an autocrine-
paracrine role (Butterwith 1997). Another growth factor which is suggested to have 
an endocrine role in preadipocyte proliferation is EGF (epidermal growth factor). 
These factors in combination with either acidic or basic FGF (fibroblast growth 
factor) show significant synergistic stimulation of DNA synthesis in preadipocytes 
(Butterwith et al 1993). Studies have suggested that both basic and acidic FGF are 
potentially important regulators of adipocyte hyperplasia and that their effect is 
modulated by constituents of the extracellular matrix and the presence of other 
growth factors (Butterwith et al1993). In both animals and humans, before or after 
birth, the growth of adipose tissue is dependent on the prior development of blood 
vessels (Crandall et al 1997; Shillabeer et al 1996). This requirement for new blood 
vessel development prior to preadipocyte proliferation suggests paracrine 
interactions between preadipocytes and endothelial cells. This may be a mechanism 
whereby adequate blood and nutrient flow to the fat depots can be maintained (Lau 
et al 1996). Increased growth of human preadipocytes has also been demonstrated 
in cells exposed to conditioned medium from mature adipocytes (Considine et al 
1996). These results indicate that both microvascular endothelial cells and mature 
adipocytes release soluble factors, which affect the growth of preadipocytes in vitro. 
Exposure of human preadipocytes in vitro to foetal calf serum results in a marked 
stimulation of cell proliferation but also in a dramatic decrease in the rate of adipose 
differentiation (Hauner et al 1989). The growth factors shown to have a 
proliferative effect on preadipocytes are also known to inhibit differentiation of 
human preadipocytes in vitro (Roncari & Le Blanc 1990a). It appears that 
replication and differentiation of preadipocytes, although both required for adipose 
tissue expansion, are mutually exclusive processes (at least in vitro) controlled by a 
balance of opposing cellular signals. 
1.6.2 Differentiation 
The differentiation of preadipocytes to mature adipocytes includes activation of 
adipogenic gene expression and induction of insulin sensitivity (Spiegelman & Flier 
1996). During the growth phase, preadipocytes are morphologically similar to 
fibroblasts (Loffer & Hauner 1987). At confluence, induction of differentiation by 
appropriate treatment leads to drastic cell shape changes. The preadipocyte converts 
to a spherical shape, accumulates lipid droplets, and progressively acquires the 
morphological and biochemical characteristics of the mature adipocyte (Hauner 
1990). These morphological changes are accompanied by trans-activation of genes 
that encode a large number of new proteins involved in creating and maintaining the 
adipocyte phenotype (MacDougald & Lane 1995). The appearance of these 
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differentiation-dependent proteins occurs in a definitive temporal sequence (Loffer 
& Hauner 1987; MacDougald & Lane 1995), reflected by the appearance of early, 
intermediate, and late mRNA/protein markers and triglyceride accumulation. These 
changes take place primarily at the transcriptional level, although posttranscriptional 
regulation occurs for some adipocyte genes (Moustaid & Sul 1991; Wilkison et al 
1990). In addition to the activation of genes, there is also repression of genes that 
are inhibitory to adipogenesis or simply unnecessary for adipose cell function 
(Cornelius et al1994). 
1.7 TRANSCRIPTIONAL REGULATION 
Proliferation and differentiation of preadipocytes and the development of obesity is a 
complex process. Figure 1.2 illustrates how this process is controlled by the 
interplay of intracellular factors and signals from the environment (Auwerx et al 
1996). This adipocyte differentiation process is characterized by dramatic 
morphological and biochemical changes. Over the past few years it has been shown 
that adipose conversion of preadipocytes is orchestrated by a set of inter-
dependently acting transcription factors. Most notable of these are the CCAA T 
enhancer binding proteins (C/EBPs) and peroxisome proliferator activated receptor y 
(PPARy) (Forman et al 1995; MacDougald & Lane 1995). Expression and activity 
of these factors is controlled by hormonal regulators which act by ligand binding, 
post-transcriptional modification, and protein-protein interactions (Loftus & Lane 
1997). 
Figure 1.2 
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Figure 1.2: Interactions between nutritional factors, hormonal factors, and 
transcription factors, can lead to adipocyte differentiation and obesity (from Auwerx 
et al, 1996). 
1.7.1 C/EBP 
Members of the C/EBP family were the first transcription factors demonstrated to 
play a major role in adipocyte differentiation. These transcription factors have a 
basic transcriptional activation domain and an adjoining leucine zipper motif, which 
provides the ability for homo- and heterodimerization (Cornelius et al 1994). This 
dimerization of C/EBP family members allows fine-tuning of the control of 
adipocyte gene expression. Members of this family which are expressed at specific 
times during adipogenesis include a, 0, and o (Cao et al 1991). Although not 
strictly adipocyte specific, the temporal and spatial manner in which they are 
expressed during adipocyte conversion is consistent with a distinct regulatory role 
for each protein (Ron & Habener 1992). C/EBP0 and C/EBPo are present in 
preadipocytes, and their levels increase transiently early in differentiation (Wu et al 
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1996). They have been reported to play an important role in early adipocyte 
differentiation by relaying the effects of hormonal stimulants, such as 
glucocorticoids, and insulin, and stimulators of the cAMP signaling pathways (Yeh 
et al 1995). It has been demonstrated that C/EBPP and possibly C/EBPo are 
involved in induction of PP ARy expression in preadipocytes thus triggering 
differentiation (Wu et al 1995; Yeh et al 1995). C/EBPa has been found to be 
expressed in adipose tissue, liver, intestine, and lung (Birkenmeier et al 1989). 
These are all tissues with high lipogenic capacity. C/EBPa is induced relatively late 
during adipogenesis in vitro, after the induction of PP ARy but preceding the 
synthesis of many of the enzymes and proteins characteristic of fully differentiated 
cells (Wu et al 1998). C/EBPa has been demonstrated to have anti-mitotic activity 
and is implicated in the termination of the mitotic clonal expansion that occurs early 
in the differentiation program (Christy et al1991; Grimaldi 2001). Extensive studies 
from several groups have firmly established the regulatory role of C/EBPa in 
adipocyte differentiation. Firstly, several genes encoding adipocyte-specific genes 
have been shown to be selectively transactivated by C/EBPa. These include 
stearoyl CoA desaturase, the insulin-responsive glucose transporter, GLUT4, the 
fatty acid binding protein, aP2, and leptin. Further, mutation of the C/EBPa site in 
these genes abolishes transactivation (Christy et al 1989; Hwang et al 1996; 
Kaestner et al 1990; McKeon & Pham 1991; Ross et al 1990). Another line of 
evidence shows that the use of antisense mRNA to C/EBPa blocks the terminal 
differentiation of a number of adipose cell lines (Lin & Lane 1992; Samuelsson et al 
1991; Umek et al 1991). Finally, adipocyte differentiation can be induced in non-
adipocyte fibroblastic cell lines by ectopic or gratuitous expression of C/EBPa 
(Freytag & Geddes 1992; Freytag et al 1994; Lin & Lane 1994; Umek et al 1991). 
C/EBPa has been implicated in the processes of adipogenesis, lipogenesis and the 
induction of insulin sensitivity (Birkenmeier et al 1989; Wang et al 1995; Wu et al 
1999) it therefore plays an important and complex role in adipocyte differentiation 
and maintenance of this phenotype. C/EBPa together with PP ARy regulate 
important events in the activation and maintenance of the terminally differentiated 
phenotype (Wu et al 1996). PP ARy has been implicated in the activation of C/EBPa 
gene expression and together these two factors have a synergistic effect on the 
cascade of gene transcription during preadipocyte differentiation (Wu et al 1995). 
The process of adipogenesis involves the sequential expression of the transcription 
factors, CEBPj3, C/EBPo, PP ARy and C/EBPa (Tanaka et al 1997). The 
transcriptional activity of each of these is modulated by hormones and other factors 
(see Figure 1.3) (Loftus & Lane 1997). 
Figure 1.3: 
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Figure 1.3: Factors involved in the regulatory interplay among transcription factors implicated 
in adipose differentiation. The central transcriptional control pathway involves sequential 
expression of specific transcription factors. These are C/EBP~, C/EBP8, PP ARy and C/EBPu. 
Glucocorticoids and agents that elevate cAMP induce C/EBP8 and C/EBP~ respectively, which in 
tum induce PPARy and C/EBPu. ADD-1/SREBPl is another transcription factor which acts in this 
system by potentiating the activity of PPARy. C/EBPu and PPARy then induce genes that give rise 
to the adipocyte phenotype. Grey arrows indicate transcriptional activation of target genes and black 
arrows indicate the external signaling pathways implicated in expression or activation of the various 
transcription factors (from Loftus & Lane, 1997 and Grimaldi, 2001). 
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1.7.2 PPARy 
The PP ARs belong to the type II nuclear hormone receptor superfamily. This family 
comprises the steroid, retinoid, and thyroid hormone receptors which are all ligand-
activated transcription factors (Kliewer et al 1994 ). The PP ARs regulate 
transcription through binding of PP AR-RXR heterodimers to a response element 
consisting of a direct repeat of the nuclear receptor hexameric DNA recognition 
motif (PuGG-TCA) spaced by one nucleotide (DR-I) (Tontonoz et al 1994b). 
Numerous genes whose products are involved in lipid metabolism have been found 
to contain PPAR binding sites (Klaus 1997). Currently, three members ofthe PPAR 
subfamily of nuclear hormone receptors, a, !3, and y have been described (Dreyer et 
al 1992; Kliewer et al 1994; Tontonoz et al 1994c). All members of the PPAR 
family are expressed to some extent in adipose tissue with PP ARa being less 
adipogenic than PP ARy. It has previously been reported that PP ARo has no effect 
on adipogenesis (Brun et al 1996) but recent reports implicate this transcription 
factor in the fatty acid-induced proliferation of preadipocytes and it has been 
suggested that this mechanism is responsible for the hyperplastic development of 
adipose tissue that occurs in animals fed high-fat diets (Jehl-Pietri et al 2000). 
However, PP ARy is the only one highly enriched in adipose tissue (Chawla et al 
1994; Tontonoz et al 1994b) and has been shown to be a key factor both for 
adipocyte differentiation and also for maintaining the expression of fat-specific 
genes and thus the adipocyte phenotype (Vidal-Puig et al 1997). PP AR response 
elements as well as C/EBP-binding sites have been identified in several adipose-
specific gene promoters, including those of aP2 (Christy et al1991; Tontonoz et al 
1994b ), phosphoenolpyruvate carboxykinase (PEPCK) (Tontonoz et al 1995), and 
stearoyl-CoA desaturase 1 (SCD1) (MacDougald & Lane 1995). The cloning of 
mammalian PP ARy and its link with adipogenesis came from analysis of the aP2 
gene, an abundant adipocyte-specific fatty-acid binding protein (Tontonoz et al 
1994a). The transcription factor, ARF6 (adipocyte regulatory factor 6), was 
identified as an important regulator of adipogenic gene expression, including 
expression of aP2. Regulation was found to occur via binding of an enhancer in the 
aP2 promoter (Tontonoz et al1994a). In addition, ARF6 DNA recognition sequence 
contains a DR-1 hormone response element (Tontonoz et al 1994a), where 
homodimers and heterodimers of the retinoid X receptor have been shown to 
preferentially bind (Mangelsdorf et al 1991; Zhang et al 1992). Subsequently it has 
been demonstrated that ARF6 is a heterodimeric complex of two nuclear hormone 
receptors, PPARy and RXRa (Tontonoz et al1994a). The identification ofPPARy 
in the ARF6 complex, together with the abundance and tissue-specificity of PP ARy 
expression, suggested the importance of this factor in the regulation of adipocyte-
specific gene expression (Tontonoz et all994a). Evidence for the regulatory role of 
PP ARy in adipogenesis was obtained through ectopic expression of this receptor. 
When expressed with viral vectors in fibroblasts these cells were subsequently 
converted to the adipocyte phenotype when exposed to PP ARy activators or ligands 
(Tontonoz et al1994c). However, the ability ofPPARy to promote differentiation is 
not limited to fibroblasts as ectopic expression of this factor has been shown to 
cause "transdifferentiation" of cultured myoblasts to adipocytes (Tontonoz et al 
1994c). This adipogenic activity of PPARy has been demonstrated to be through 
transcriptional activity, as a point mutation in the DNA binding region completely 
abolished this activity (Tontonoz et al 1994c ). Thus, PP ARy appears to function as 
both a direct regulator of many fat-specific genes and also as a "master" regulator 
that can trigger the entire program of adipogenesis (Spiegelman & Flier 1996). Since 
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PP ARy activation results in the expression of most or all of the program of 
differentiation, including C/EBPa, it has been suggested that cooperation between 
PP ARy and C/EBPa brings about maximal differentiation and a full program of 
lipogenesis (Hu et al1995). In addition, PPARy and the C/EBPs activate expression 
of one another (Christy et al 1991). Thus, PPARy and C/EBPa may promote 
maintenance of the differentiated state by reciprocal activation. This cross-
regulation between PP ARy and C/EBPa has been demonstrated to be a key 
component ofthe transcriptional control ofthe adipocyte lineage (Wu et al1999). 
1.7.3 PPARy Ligands 
As a member of the nuclear receptor family, the ability of PP ARy to increase 
transcription through its DNA recognition site (DR-1) depends on the binding of 
ligands (Chawla et al 1994; Zhang et al 1996). In 3T3-Ll cells PPARy mRNA 
appears early in the terminal stage of preadipocyte differentiation and the 
transcriptional activities of the protein are activated by ligand binding (Chawla et al 
1994; Zhang et al 1996). Both synthetic and naturally occurring ligands for PP ARy 
have been identified. 
1.7.3A Synthetic ligands 
It has been demonstrated that members of the thiazolidinedione class of drugs are 
highly selective ligands of PP ARy and act as potent regulators of adipocyte 
development (Forman et al 1995). Thiazolidinediones are antidiabetic agents that 
increase the insulin sensitivity of target tissues (adipose tissue, skeletal muscle, 
liver) in Type II diabetes. This class of drugs significantly reduces glucose, lipid 
and insulin levels in diabetes associated with obesity (Lehmann et al 1995). There 
had been earlier reports of thiazolidinediones inducing adipogenesis in preadipocyte 
cell lines, however, the mechanism of this action was unknown (Spiegelman 1998). 
Evidence for their role as PP ARy ligands and activators came when the 
thiazolidinedione, pioglitazone, was found to increase transcriptional activity of the 
aP2 enhancer. This increased activity was through the differentiation-linked DNA 
site, adipocyte regulatory element 6 (ARE6) (Harris & Kletzien 1994). The identity 
of the ARE6 binding factor was subsequently found to be the PP ARy-RXR 
heterodimer (Spiegelman 1998). Further studies found that other members of the 
thiazolidinedione class of drugs were direct ligands of PP ARy with positive activity 
on gene transcription (Forman et al 1995; Lehmann et al 1995). Importantly, the 
thiazolidinediones were found to have minimal activity toward the other PP AR 
subtypes (PP ARa and PP AR8) and were therefore highly selective for PP ARy 
(Spiegelman 1998). Further, this class of drugs was found to be potent and effective 
at inducing adipose conversion in cells which contained endogenous or ectopically 
expressed PPARy (Forman et al1995; Lehmann et al1995). 
1.7.3B Natural ligands 
The finding that thiazoldinediones were selective ligands and activators of PP ARy 
enabled the development of displacement assays that were able to identify natural 
ligands of PP ARy (Spiegelman 1998). A number of polyunsaturated fatty acids and 
eicosanoid derivatives were initially screened for PP ARy binding activity. By 
assaying arachidonate metabolites for their capacity to activate PP AR, the 
prostanoid 15-deoxy-L'l12' 14-prostaglandin J2 has been identified as both a naturally 
occurring ligand for PPARy and an inducer of adipogenesis (Forman et al 1995). 
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Studies on prostaglandin hormones show that they usually act via cell surface 
receptors, however it has been postulated that these lipids can permeate cell 
membranes and enter the nucleus (Spiegelman & Flier 1996). More recently, 
several polyunsaturated fatty acids, including derivatives of linoleic acid, have also 
been found to directly bind PPARy (Kliewer et al1997; Nagy et al 1998; Tontonoz 
et al 1998). It is possible that all of these molecules may be important ligands in 
vivo however their binding affinities are relatively low, in the range of 2-50 f.!mol/1 
(Spiegelman 1998). The dissociation constants of most nuclear receptors for their 
endogenous ligands are in the low nmol/1 range (Spiegelman 1998). Also it is not 
clear if these molecules can reach the nucleus of relevant tissues at the 
concentrations required. PPARy may be a 'promiscuous' receptor for many fatty 
acids with low affinity or possibly has a more limited number of specific, high-
affinity ligands (Spiegelman 1998). Therefore, much current research is focusing on 
identifying the endogenous ligand. It has been proposed that a PP ARy ligand related 
to PGJ2 is endogenously produced during adipogenesis. However, expression of the 
enzyme required for 15-dPGJ2 synthesis from PGD has not been established in 
adipocytes. It is therefore possible that prostaglandins or other PP ARy ligands may 
be derived from paracrine or endocrine sources and these could then influence the 
process of adipocyte differentiation (Reginato et al1998). 
The above information demonstrates that prostanoids and antidiabetic 
thiazolidinediones can initiate key transcriptional events in the differentiation of 
preadipocytes to the mature phenotype. This occurs via a common nuclear receptor 
signaling pathway. These studies suggest a pivotal role for PP ARy and its 
endogenous ligand in adipocyte development and glucose homeostasis (Forman et al 
1995). Identification of the endogenous ligand may allow pharmacological control 
of adipocyte gene expression and/or differentiation using specific activators or 
inhibitors of PPARy (Tontonoz et al 1994c). Thus PPARy may be a target for 
intervention in metabolic disorders (Tontonoz et al1994c). 
1.7.4 RXR 
As noted previously, PP ARs bind to DNA as a heterodimeric complex with the 9-cis 
retinoic acid receptors (RXRs) (Schoonjans et al 1997). The positive regulation of 
gene expression by PP ARs through heterodimerization with the RXR indicate that 
the retinoid and peroxisome pro1iferator signaling pathways converge through the 
direct interaction of their respective nuclear hormone receptors (Kliewer et al 1992; 
Miyata et al 1994). Ligands specific for RXR can also promote transcriptional 
activation by PPARs (Mukherjee et al 1997b; Tontonoz et al 1997). Retinoic acid 
has been reported to inhibit adipogenesis through post-transcriptional mechanisms 
that are not fully understood (Antras et al1991; Kamei et al1992). However, at low 
doses (1 - 10 nM) retinoic acid has also been found to enhance adipogenesis (Dani 
et al 1997; Safonova et al 1994). The PPAR/RXR complex is dependent on ligand 
activation not only of PPARy but also of RXR (Mukheljee et al 1997a). 9-cis 
retinoic acid can activate both RAR (retinoic acid receptor) and RXR receptors and 
all-trans retinoic acid is able to isomerize to 9-cis retinoic acid in most cell types 
(Kojima et al 1994). It seems that the effects ofretinoids on adipogenesis depend on 
a complex balance between retinoic acid metabolism and relative RAR and RXR 
receptor availability in the cell. RXR preferentially forms heterodimers with RAR 
and this complex has been found to be inhibitory to adipogenesis (Villarroya et al 
1999). During adipocyte differentiation the expression of the RXR isoforms is up-
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regulated (Chawla & Lazar 1994). It has been suggested that the relative reduction 
in RAR expression may be conducive to RXR forming heterodimers with PP ARy 
instead ofRXR/RAR dimers (Villarroya et all999). 
1.7.5 ADDl!SREBPl 
In addition to C/EBP and PP AR another factor has been shown to potentiate the 
transcriptional activity of PPARy. This transcription factor, ADD1/SREBP1 
(adipocyte differentiation and determination factor 1/sterol response element binding 
protein 1), is a member of the basic helix-loop-helix family. It was independently 
identified both as a potential regulator of adipogenesis (Tontonoz et al 1993), and as 
a key factor in cholesterol homeostasis (Yokoyama et al 1993). Evidence for the 
importance of this factor in adipocyte development comes from experiments 
demonstrating that expression of a dominant negative mutant markedly inhibited 
adipose conversion of 3T3-Ll preadipocytes (Kim & Speigelman 1996). Secondly, 
under conditions favoring adipogenesis, the factor can increase the percentage of 
fibroblasts that undergo differentiation from 2-3% to 15-20% (Kim & Speigelman 
1996). This effect is due, at least in part, to an influence on PPARy activity, since 
cotransfection with ADD1 causes a 3 to 4 fold increase in the DNA binding activity 
of PP ARy (Kim & Speigelman 1996). There is, however, no similar influence on 
the activity of C/EBPa through its DNA recognition sequence (Kim & Speigelman 
1996). One mechanism suggested for this enhancement is the increased production 
of fatty acid activators of PPARy. Because ADD1/SREBP1 can increase the 
expression of several key genes of fatty-acid metabolism, such as fatty acid synthase 
and lipoprotein lipase, and it also has a positive effect on PP ARy activity, it seems 
plausible that this cooperation is through the generation of endogenous ligands for 
PP ARy (Spiegelman 1998). 
1.7.6 Summary of Transcriptional Regulation 
The preceding overview of transcriptional regulation of adipocyte differentiation 
suggests a regulatory loop involving the key adipogenic factors (see figure 1.4). 
Figure 1.4 
ADDl/SREBl Other pathways 
Inductive cues 
(Hormones) 
~igan/ 
~ 
C/EBP~ 
_______. C/EBPo? 
Figure 1.4: Regulatory Loop Controlling Adipogenesis 
Adipocyte genes 
Insulin sensitivity 
Adipocyte differentiation involves the interaction and regulation between transcription factors 
C/EBPs and PP ARy. C/EBP~ and o play an important role in activating PP ARy expression 
during early stages of differentiation. ADD1/SREBP1 potentiates the transcriptional activity of 
PPARy probably through the production of endogenous ligands for PPARy. Upon ligand 
activation, PP ARy induces the expression of C/EBPa. as well as other adipocyte genes. Through 
a positive feedback loop C/EBPa. maintains the expression of PPARy. PPARy and C/EBPa. 
cooperate to promote adipocyte differentiation, including adipocyte gene expression and insulin 
sensitivity (from Wu et al, 1999). 
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Two members of the C/EBP family, C/EBP!3 and C/EBP8, are expressed early 
during adipogenesis. This has been reported to increase the expression of PP ARy in 
response to certain hormones (Spiegelman & Flier 1996). This leads to expression 
of C/EBPa which synergizes with PP ARy in effecting growth an-est of 
preadipocytes and initiating a transcriptional cascade which culminates in the 
adipocyte phenotype (Boone et al 2000). This regulatory loop, proposed in figure 
1.4, requires the generation of an endogenous PP ARy ligand. The binding of ligands, 
perhaps generated by the action of ADD1/SREBP1, triggers the full differentiation 
response, with C/EBPa and PP ARy cross-regulation thought to be important in 
maintaining the differentiated state once it has been initiated. 
1.8 LOCAL REGULATORY MECHANISMS IN 
ADIPOSE TISSUE 
The size and number of mature adipocytes affecting adipose tissue mass in humans 
are attributes that appear to be regulated in a co-ordinated manner. For example, 
weight increase is associated with increased adipocyte volume and number. 
Conversely, when weight loss occurs, adipocyte volume and number also appear to 
decrease (Prins & O'Rahilly 1997). This suggests that paracrine/autocrine factors 
may be involved in the co-ordinate control of both cell number and cell mass during 
adipose tissue growth. The signaling pathways involved are as yet unknown. 
1.8.1 Microvascular Endothelial Cells 
Adipose tissue is the major site of energy storage in vertebrate animals (Claffey et al 
1992). It is also an endocrine organ synthesizing and secreting important molecules 
involved in regulation of energy balance (Crandall et al 1997). Therefore adipose 
tissue requires extensive vascularization for proper function (Claffey et al 1992). 
Developmentally-regulated angiogenesis has been studied in adipose tissue and it 
has been found that the development of the vascular bed is tightly connected to both 
the number and size of differentiating adipocytes (Claffey et al 1992). Adipose 
tissue microcirculation is unique within the vascular system due to a capacity for this 
tissue to grow throughout adult life (Crandall et al 1997). If, as in foetal 
development, an established vascular network precedes adipogenesis in the 
development of human obesity it seems reasonable to postulate the presence in 
vascular tissues of factors which affect the proliferation and differentiation of 
preadipocytes. 
Paracrine interaction between preadipocytes and microvascular endothelial cells 
(MVEC) has indeed been reported to play a role in the regulation of adipose tissue 
growth in rats (Varzaneh et al 1994). Stimulation ofpreadipocyte replication in rats 
by factor(s) released by microvascular endothelial cells has been demonstrated in 
vitro (Varzaneh et al 1994). Endothelial cells have been found to secrete basic 
fibroblast growth factor which is sequestered in the matrix and stimulates replication 
of preadipocytes (Brooks et al 1991). Similarly, it has been reported that 
extracellular matrix factors, secreted by MVEC, also play a role in determining the 
changes in gene expression associated with the differentiation of preadipocytes 
(Varzaneh et al 1994). In vivo, both proliferative and differentiating factors may act 
together to promote the expansion of adipose tissue. Another mechanism by which 
microvascular endothelial cells may regulate preadipocyte differentiation is by the 
production of prostaglandins, specifically prostaglandin D2 (PGD2) (Bacic et al 
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1992). PGD2 is a cyclo-oxygenase product of arachidonic acid metabolism (Vane et 
al 1990). Studies have demonstrated that PGD2 is synthesized and secreted by 
endothelial cells (Bacic et al1992). PGD2 is the precursor molecule for the unusual 
prostanoid 15d-PGh which has been found to be a naturally occurring, high affinity 
ligand for PPARy (Forman et al1995; Krey et al1997). 
There is a large amount of evidence that endothelial cells are able to specifically 
modulate the properties not only of preadipocytes but also of other mesenchymal 
cells through the paracrine activity of soluble products produced in specific tissues. 
For example, microvascular endothelial cells have been found to play a role in both 
proliferation and differentiation of smooth muscle cells (Dodge et al 1993). These 
effects have been found to be mediated by diffusible factors (Dodge et al 1993). 
Endothelial cells have also been shown to play an active role in the bone marrow 
stromal microenvironment, acting as a cell source of a number of growth factors that 
effect haematopoiesis (Davis et al 1997). Endothelial cells have common as well as 
specialized roles in different tissues and organs and it is possible that endothelial 
cells from human adipose tissue have unique activities necessary for preadipocyte 
proliferation/differentiation. It is also possible that these effects are different in the 
different adipose tissue depots. 
1.8.2 Properties of Microvascular Endothelial Cells 
An increased recognition of the role of endothelial cells in both development and 
disease processes has led to increased in vitro studies using these cells. However, 
the cells most often used for these studies do not reflect the in vivo heterogeneity of 
endothelial cells (Craig et al 1998). Endothelial cells are as diverse in structural and 
biochemical characteristics as the organs and tissues in which they are found 
(Gerritsen 1987; Page et al 1992). Until recently almost all in vitro studies of human 
endothelial cells have relied on cells derived from human umbilical veins (HUVEC) 
due to their relative ease of isolation and culture (Ades et al 1992). However, most 
of the diverse physiological activities of endothelial cells occur at the level of the 
microvasculature (Ades et al 1992). It has also become apparent that endothelial 
cells derived from the microvascular structures of specific tissues differ significantly 
from large-vessel endothelial cells (Folkman et al1979; Hull et al1996; Kubota et al 
1988). The isolation of microvessel endothelial cells is technically demanding and 
time consuming (Hewett et al 1993), however it is important in studies using 
endothelial cells that the cells are isolated from vessels of the appropriate size and 
organ in order to better reflect the in vivo context (Craig et al 1998). 
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CHAPTER2 
Hypotheses and Aims 
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2.1 RELEVANCE OF PROJECT TO LITERATURE REVIEWED 
The processes of replication and differentiation of human preadipocytes and the 
roles these processes play in different adipose tissue depots are not well understood. 
However, over the past few years an increased understanding of factors involved in 
transcriptional regulation of adipose conversion has been gained mainly through the 
study of cell lines of rodent origin. Findings of the cooperative function of PP ARy 
and C/EBPa as the key transcription factors for adipocyte gene activation and 
differentiation has been pivotal to our understanding of adipogenesis at the 
molecular level. Endocrine and paracrine factors have been reported to be involved 
in regulation of adipose tissue mass, however the mechanisms are not well 
understood. It has been reported in rodent studies that microvascular endothelial 
cells secrete paracrine factors which are involved in regulation of growth and 
differentiation of a variety of mesenchymal cells, including adipose precursors. It is 
important to note that during foetal development an established vascular network 
precedes adipogenesis. Adipose tissue and the associated microcirculation are 
unique within the vascular system due to the capacity of this tissue to develop 
throughout adult life. If, as in foetal development, an established vascular network 
precedes adipogenesis in the development of human obesity then elucidation of the 
factors and mechanisms involved is important. An understanding of the paracrine 
interaction between preadipocytes and microvascular endothelial cells may lead to 
the identification of regulatory stages in adipose tissue development, from both an 
angiogenic and an adipogenic aspect. 
This review demonstrates that there are major gaps in our current knowledge of the 
complexity involved in the regulation of adipose tissue growth by paracrine factors. 
This has prompted us to investigate the role that microvascular endothelial cells 
from adipose tissue play in the processes of replication and differentiation of 
primary cultures of human preadipocytes from subcutaneous and omental sites. This 
system may also allow identification of the physiologicalligand(s) for PPARy. 
2.2 HYPOTHESES 
a) endothelial cells secrete factors which affect the rate of human preadipocyte 
proliferation and differentiation; 
b) these factors act by regulating the activity of PP ARy possibly by acting as 
endogenous ligands ofPPARy. 
2.3 AIMS 
1. To further develop a model system of human preadipocyte differentiation. 
2. To develop techniques for isolation and culture of preadipocytes and 
microvascular endothelial cells from human adipose biopsies of subcutaneous 
and omental origin. 
3. To examine the effect of conditioned medium from adipose tissue-derived 
endothelial cells on the rate of preadipocyte proliferation and differentiation. 
4. To examine the effects of this conditioned medium/co-culture system on the 
transcriptional activity of PP ARy. 
5. To determine if factors produced by endothelial cells have a role in PP ARy 
activation and preadipocyte differentiation. 
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CHAPTER3 
Differentiation of human preadipocytes in 
response to known activators of PP ARy 
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3.1 Introduction 
Adipocyte hyperplasia occurs by the proliferation and differentiation of adipocyte 
precursor cells (preadipocytes) (Butterwith 1994). It is now well established that 
these fibroblast-like cells, capable of undergoing differentiation into adipose cells, 
are present in the adipose tissue of various species including human (Hauner et al 
1989). Many studies employ animal derived-primary cultured preadipocytes and 
cell lines to determine the molecular details of adipocyte differentiation (Smas & Sul 
1995). These studies have provided insight into events involved in the adipocyte 
differentiation process, but to fully define what factors are involved in human 
adipogenesis we need to examine these processes in human preadipocytes. The 
culture conditions used in differentiation studies in animal cell models have induced 
only limited differentiation in human preadipocytes (Hauner et al 1989). Unlike 
mouse cell lines (Gregoire et al 1990), human preadipocytes do not differentiate in 
the presence of serum therefore the development of a chemically defined serum-free 
medium containing inducers of differentiation including insulin and glucocorticoids 
enabled the study of these processes in human tissue (Deslex et al 1987b; Hauner et 
al 1989). However, the percentage of cells differentiating when maintained in this 
medium was still quite low in subcultured preadipocytes which had been previously 
grown in serum-containing medium (Gregoire et al1998). Recent work has shown 
that inclusion in this serum-free differentiation medium of a thiazolidinedione 
compound increases the degree of differentiation in subcultured human 
preadipocytes (Adams et al 1997; Montague et al1998). This compound is reported 
to act as a ligand for the adipogenic transcription factor, peroxisome proliferator 
activated receptor- (PP AR)y (Lehmann et all995). 
Adipocyte differentiation is regulated by members of the CCAA T enhancer binding 
protein (C/EBP) and peroxisome proliferator-activated receptor (PP AR) 
transcription factor families (Loftus & Lane 1997), which control the expression of 
genes involved in creation and maintenance ofthe adipocyte phenotype. PPARy has 
been described as a central regulator of fat cell differentiation (Spiegelman 1998) 
and in 3T3-Ll adipocytes it has been shown to act in synergy with insulin in the 
transactivation of adipocyte-specific gene expression (Zhang et al 1996). Members 
of the thiazolidinedione class of insulin-sensitizing drugs are highly selective ligands 
and activators of PP ARy and act as potent regulators of adipocyte development 
(Forman et al 1995). Linoleic acid derivatives including 9- and 13-
hydroxyoctadecadienoic acid (Nagy et al 1998), and arachidonic acid derivatives 
including 15-deoxy-L112' 14-prostaglandin J2 (Forman et al 1995), have also been 
shown to activate PP ARy although the mechanism of activation is unclear. 
Thiazolidinediones (TZD) are antidiabetic agents that increase the insulin sensitivity 
of target tissues in non-insulin-dependent diabetes mellitus. This class of drugs 
significantly reduces glucose, lipid, and insulin levels in diabetes associated with 
obesity (Lehmann et al1995). The adipogenic activity ofTZDs has previously been 
shown to be much more pronounced in preadipocytes of subcutaneous origin, with 
omental preadipocytes being refractory to the differentiation promoting effects of 
these compounds (Adams et all997). 
PP ARy is involved in transcription of a number of genes required for lipid 
metabolism including lipoprotein lipase (LPL), glycerol-3-phosphate dehydrogenase 
(G3PDH) (MacDougald & Lane 1995), and leptin (Hwang et al 1997). Leptin is 
37 
38 
produced in mature adipocytes and circulating leptin levels have been reported to 
reflect adipose tissue stores (Considine & Caro 1997). Leptin is considered to be an 
important signal involved in the regulation of energy stores through centrally 
mediated effects on ingestive behaviour and metabolism (Flier 1997; Joannic et al 
1998). Leptin gene expression has been shown to be greater in subcutaneous than in 
visceral adipose tissue (Masuzaki et al 1995b; Montague et al 1997; Montague et al 
1998). 
This study investigated the effects of the thiazolidinedione, Rosiglitazone, and the 
essential dietary fatty acid, linoleic acid, on triglyceride accumulation and 
biochemical differentiation in human omental and subcutaneous preadipocytes. The 
effects of Rosiglitazone and linoleic acid on leptin production and insulin-stimulated 
glucose uptake in subcutaneous preadipocytes were also compared. Activation of 
PP ARy in response to Rosiglitazone and linoleic acid was assessed using a reporter 
construct assay in JEG-3 cells transfected with a chimeric receptor containing the 
hPPARy hormone-binding domain. We aim to further develop the conditions for 
optimal induction of adipose differentiation in subcultured human preadipocytes. 
3.2 MATERIALS & METHODS 
All chemicals were obtained from Sigma-Aldrich, Castle Hill, Australia, unless 
otherwise stated. 
3.2.1 Subjects. Paired omental (0) (intra-abdominal) and abdominal subcutaneous 
(S) adipose tissue biopsies were obtained from 5 male (average age 55 years, range 
39-69 yrs; average BMI 26, range 23-32) and 8 female (average age 48 years, range 
35-75 yrs; average BMI 29, range 24-35) patients undergoing elective open-
abdominal surgery. None of the patients had diabetes or severe systemic illness and 
none were taking medications known to affect adipose tissue mass or metabolism. 
The protocol was approved by the Research Ethics Committees of the Princess 
Alexandra Hospital and the Queensland University of Technology. All patients 
gave their written informed consent. 
3.2.2 Isolation and culture of stromal-vascular cells. Biopsies were transported to 
the laboratory in Ringers solution (Baxter Healthcare, Old Toongabbie) (transport 
time 15 min.), and preadipocytes and adipocytes were obtained by collagenase 
digestion and centrifugation as previously reported (Prins et al 1994). The 
stromovascular pellet was suspended in DMEM/Ham's F-12 1:1 containing 100 IU 
penicillin, 1001-Lg/mL streptomycin, 2mM L-glutamine (all ICN Biomedical 
Australasia Pty Ltd) and 10% foetal bovine serum (v/v) (FBS) (Commonwealth 
Serum Laboratories, Brisbane). Cultures were grown for 2-3 months and maintained 
at 37°C with 5% C02• Cells were used in experimental work at passage 2 and 3. 
3.2.3 Isolation and culture of human dermal fibroblasts. Human skin fibroblasts 
were obtained by punch biopsy from one male (age 52 yrs; BMI 24) and one female 
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(age 32 yrs; BMI 25) donor and cultured under identical conditions as the human 
adipose stromal-vascular cells. 
3.2.4 Induction of adipose differentiation. At confluence, following the final 
passage, cells were refed with a chemically defined serum-free medium (SFM) 
consisting of DMEM!Ham's F-12 1:1 containing 100 IU penicillin, 100 J.Lg/mL 
streptomycin, 2mM L-glutamine, 15mM NaHC03, 15mM HEPES, 33~-tM biotin, 
17~-tM pantothenate, 0.5J.LM insulin, 0.2nM T3, 0.1J.LM cortisol, 10~-tg/mL transferrin 
and, for the first 3 days, 0.25mM 1-methyl-3-isobutylxanthine (Hauner 1990). 
Cultures were maintained either in this SFM or with added 0.1J.LM Rosiglitazone 
and/or 1 00~-tM linoleic acid for a period of 21 days with changes of medium every 2 
or 3 days. The linoleic acid treatments also contained 0.1mg/mL fatty-acid free 
bovine serum albumin (no bovine serum albumin was present in the Rosiglitazone 
only treatments). The concentrations of Rosiglitazone, linoleic acid, and bovine 
serum albumin used in this work were determined following preliminary dose-
response and toxicity studies (data not shown). The concentration of linoleic acid 
used is within physio1ogicallevels of this fatty acid in human plasma (Emken et al 
1994; Jungling & Kammermeier 1988). 
3.2.5 Assessment oftriglyceride accumulation. 
3.2.5A Cell Counts. After 21 days treatment in differentiation medium the number 
of lipid containing cells in each treatment was estimated under phase contrast 
microscopy using a 1 mm2 micrometer grid (Neubauer, West Germany) at 100-fold 
magnification. Based on a previously reported method (Gregoire et al 1990) the 
cells were distributed into 5 stages of maturation according to their morphology and 
lipid content, from a fibroblastic cell to a rounded, lipid laden cell (Fig. 3.2B 
photomicrographs). For each treatment 10 different areas were examined and both 
total number of cells and percentage of lipid-containing cells were evaluated. The 
results are the average of separate counts carried out by myself and one independent 
investigator blinded to treatment type. 
3.2.5B Nile Red Assay. For determination of triacylglycerol accumulation, 
preadipocytes were treated with differentiation medium for a period of 21 days in 6 
well plates. After this time the cells were washed with phosphate-buffered saline 
(PBS) and removed from the plate surface following incubation in a minimal 
amount of trypsin-versene. Triacylglycerol accumulation was assessed as 
previously described (Rutley et al 2001 b) using a spectrofluorometric assay for non-
polar lipid. PBS containing Nile Red, at a final concentration of 1 J..Lg/mL, was added 
to each well and cells were incubated at room temperature for 5-7 minutes. 
Fluorescence was measured at room temperature in a spectrofluorometer 
(Aminco.Bowman Series 2 Luminescence Spectrometer) at 488 nm excitation I 540 
nm emission. Results were normalized to protein using the Bradford method 
(Bradford 1976). 
3.2.6 Assessment o(differentiation 
3.2.6A Expression of differentiation markers. Total RNA was prepared from cells 
using the method ofChomczynski and Sacchi (Chomczynski & Sacchi 1987). RNA 
concentrations were quantitated by absorbance at 260nm on a UV-visible 
spectrophotometer (Shimadzu Scientific Instruments, Inc., Columbia, MD). For 
Northern analysis, 20J..Lg of RNA was denatured in formamide/formaldehyde and 
electrophoresed in formaldehyde-containing 1% agarose gels (w/v). Ethidium 
bromide staining was used on all gels to determine equal loading and quality of the 
RNA. RNA was transferred to GeneScreen Plus nylon-based membranes (Dupont, 
Boston, MA) by vacuum blotting. Prehybridization was performed at 42°C for 6 h 
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in 50% formamide (v/v), 5 x SSPE, 5 x Denhardt's reagent, 1% SDS (w/v), and 
50!lg/mL denatured salmon sperm DNA. Hybridization was carried out at the same 
temperature for 20 h in hybridization solution similar to prehybridization solution 
but containing 7% dextran sulphate (w/v) and lacking salmon sperm DNA. The 
hybridization solution also contained a 32P-labelled eDNA probe (approx. 2 x 106 
cprn/mL). Labelled eDNA probes were synthesized by random-prime labelling with 
[a32P] dCTP using Gigaprime DNA labelling kit (GeneWorks, Adelaide). The 
probes were kindly provided by Dr M Schotz (UCLAIV A Medical Center) for 
human LPL eDNA (2.4 kb), Dr L. Kozak (Jackson Laboratory) for G3PDH eDNA 
(0.8 kb) (Ireland et al 1986), and DrY. Ogawa (Kyoto University) for ob eDNA (1 
kb) (Masuzaki et al 1995a). After hybridization, membranes were washed in 2 x 
SSPE for 30 min at room temperature, and in 2 x SSPE + 0.1% SDS (w/v) at 60°C 
for 20 min. Membranes were analyzed by autoradiography carried out at -80°C 
using BIOMAX MS film (Eastman Kodak, Rochester, NY) and an intensifying 
screen. 
3.2.6B Glycerol-3-phosphate dehydrogenase (G3PDH) activity. Activity was 
assessed as previously described (Rutley et al 2001b). Briefly, preadipocytes 
cultured in 25cm2 flasks were washed in PBS (pH 7.4), harvested into 1 mL of ice-
cold harvest solution (50 mM Tris, pH 7.5, 1 mM EDTA and 500!-LM DTT) and 
transferred to a prechilled microtube. Cells were disrupted by sonication and lysates 
were centrifuged at 12000 g for 15 min. at 4°C. The supernatant was then assayed 
for G3PDH activity in a final concentration of 100 mM triethanolamine-HCl (pH 
7.5), 2.5 mM EDTA, 50!lM DTT and 0.24 mM NADH. The reaction was initiated 
by addition of dihydroxyacetone phosphate (DAP) (final concentration of 0.4 mM) 
in a 0.5 mL volume (250!-LL supematant/240!-LL assay mixture/1 O!lL DAP). The 
reaction was followed at A34o in a spectrophotometer (Shimadzu) at 30°C over a 1-
cm light path for 4 min to obtain an initial reaction rate. Each of three 25cm2 flasks 
was assayed in duplicate with a suitable reagent blank containing distilled water 
instead of the enzyme's substrate. An aliquot of the supernatant was assayed for 
protein using the Bradford method (Bradford 1976). The results were expressed as 
milliunits per milligram (mU/mg) supernatant protein, with lmU of enzyme activity 
being the amount catalyzing the oxidation of 1 nmol NADH per min (calculated 
using the nM extinction coefficient ofNADH at 340 nm as 6.22x10-3). 
3.2. 6C Leptin secretion. At day 21 of preadipocyte differentiation the medium was 
removed (after 48 hours on the cells) and leptin levels measured by RIA using a 
commercially available human leptin assay kit (Linco Research, Inc. Missouri) as 
per manufacturer's instructions. 
3.2.6D Assessment of PPARy activation. Transcriptional activation by 
Rosiglitazone and linoleic acid was compared using a chimeric receptor containing 
GAL4 DNA-binding domain linked to the hPPARy hormone-binding domain co-
transfected with UASTKLUC luciferase reporter. The internal control reporter RL-
CMV (Promega, Madison WI) contains Renilla luciferase under the constitutive 
expression promoter CMV. JEG-3 cells were cultured on 24 well plates in 
DMEM/Hams F12 (v/v 1:1) media (ICN biomedical) supplemented with 10% fetal 
calf serum (v/v) (CSL), penicillin/streptomycin and glutamine. Cells were 
transfected with lOng of reporter expression vector GAL4-PPARy, SOOng 
UASTKLUC and 25ng RL-CMV by 4 hour exposure to calcium phosphate. 
Following a 40 hour exposure to rosiglitazone, linoleic acid or vehicle, cells were 
harvested for luciferase assay. Cells were lysed in passive lysis buffer and assayed 
by the dual luciferase assay (Promega) according to manufacturer's instructions. 
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Luciferase assay was carried out in a Biorbit 1000 luminometer. Activity was 
normalized to internal control renilla luciferase activity and fold activation of each 
treatment calculated. 
3.2.6E Glucose Uptake. Following 21 days in differentiation medium containing 
either linoleic acid or Rosiglitazone, 2-deoxy-D-glucose uptake was determined as a 
measure of the glucose transport system in response to insulin. The assay was 
carried out as per the method of Hauner et al (Hauner et al 1998). Briefly, glucose 
concentration was reduced to 5mmolll, 24 hours prior to the assay, and both insulin 
and Hepes were completely removed from the medium. For assessment of the 
stimulatory effect of insulin, some dishes were incubated with human insulin at the 
concentrations indicated for 15 min immediately prior to the assay. eH)-labelled 2-
deoxy-D-glucose (lj.LCi/dish, concentration 4-5 j.lmol/1) was added to the medium 
which already contained 5mmolll unlabelled glucose. Hexose uptake was measured 
for 20 min at 37°C. Glucose uptake was terminated by transferring the dishes to an 
ice-bath. Cells were repeatedly washed with ice-cold PBS and incubated for 20 min 
with 0.1% SDS. The radioactivity of the cell material was counted in a liquid 
scintillation counter (Beckman, Munich, Germany). Some dishes were treated with 
cytochalasin B approximately 1 min before initiation of the assay and these values 
were used to correct for non-specific uptake. 
3.2. 7 Statistics. Statistical analysis was performed using Excel 5 Data Package. 
ANOV A was used to test for an effect of rosiglitazone and linoleic acid on glucose 
uptake in differentiated preadipocytes. The Student's t test was used to evaluate the 
significance of the difference in mean values between different treatments. Data are 
expressed as means ± SE. A P-value < 0.05 was considered statistically significant. 
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1. Human Preadipocytes 2. Human Skin Fibroblasts 
Figure 3.1: Photomicrographs of primary cultures of human subcutaneous adipocyte precursor cells 
and newly differentiated adipocytes (Panel 1), and human skin fibroblasts maintained under identical 
conditions to adipocyte precursor cells (Panel 2). Bar = 1 Oj..U11; magnification 1 00-fold. (A) 
Undifferentiated cells in serum-containing medium (SCM). Cells were subsequently exposed to 
differentiation-permissive medium for 21 days. (B) SFM alone. (C) SFM + 0.1 ~ Rosiglitazone. 
(D) SFM + 100~ Linoleic Acid (LA). (E) SFM + Rosiglitazone +LA. 
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3.3 RESULTS 
3.3.1 Triglyceride accumulation 
At day 21, cells maintained in serum-containing growth medium exhibited a 
fibroblast-like appearance with no intracellular lipid visible (Fig. 3.1A, Panel 1). 
After 21 days culture in chemically defined SFM alone (Fig. 3.1B, Panel I) or with 
added 0.1 !lM Rosiglitazone (Fig. 3.1 C, Panel 1 ), intracytoplasmic triglyceride was 
demonstrated in a small proportion of cells (Fig. 3.2A & 3.2C). After culture in the 
presence of 100!-lM linoleic acid (Fig. 3.1D, Panel 1), or linoleic acid + 
Rosiglitazone (Fig. 3.1E, Panel I), marked triglyceride accumulation was observed 
in the majority of cells (Fig. 3.2A & 3.2C). Cell count data (Figs. 3.2A & 3.2B) and 
Nile Red assay (Fig. 3.2C) showed no quantitative or qualitative difference between 
these two culture conditions. There was a non-significant trend indicating a greater 
number of triglyceride containing cells from the subcutaneous depot under all 
experimental conditions (Fig. 3.2A). 
Linoleic acid, in addition to increasing the number of cells containing lipid (Fig. 
3.2A) also increased the amount of lipid stored per cell, compared to Rosiglitazone 
(Fig. 3.2C, p<0.001). Linoleic acid-containing treatments had a higher proportion of 
cells in stages 2 to 4 of morphological differentiation (stages 3 & 4 indicate cells 
with large volumes of intracytoplasmic lipid) than did serum free medium +/-
Rosiglitazone (Fig. 3.2B). 
Human dermal fibroblasts cultured under identical conditions did not accumulate 
cytoplasmic lipid (Fig. 3.1, Panel2, A-E). 
3.3.2 Biochemical Differentiation 
In subcutaneous preadipocytes cultured for 21 days in linoleic acid no LPL or 
G3PDH expression was observed and minimalleptin expression was demonstrated 
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Figure 3.2: Triacylglycerol accumulation in human preadipocytes- assessing Rosiglitazone (Ros) 
and Linoleic acid (LA) effects. (A) Cell counts of subcutaneous and omental preadipocytes 
following 21 days in differentiation media (statistically different from SFM at* p < 0.01; n=5). (B) 
Percentage of cells at each stage of maturation within each treatment group. (Stage 0: 
undifferentiated fibroblastic cells with no lipid to stage 4: large lipid droplets fill cytoplasm; stages 
2-4 contain increasing amounts of lipid). (C) Triacylglycerol accumulation in subcutaneous 
preadipocytes treated for 21 days in LA (either alone or in combination with Ros) showed a marked 
increase in lipid accumulation over those treated with Ros alone (Statistically different from SFM at 
* p < 0.001; n=3). 
(Fig. 3.3 A&B). In contrast, Rosiglitazone treatment induced a marked increase in 
gene expression ofLPL (3.3 kb and 3.7 kb), G3PDH (3.55 kb) and leptin (4.5 kb) 
(Fig. 3.3 A&B). Omental preadipocytes were refractory to differentiation induction, 
as assessed by Northern blot analysis (Fig. 3.3 A&B), despite significant triglyceride 
accumulation in linoleic acid treated cultures. 
No expression of LPL, G3PDH, or leptin was detected in either subcutaneous or 
omental preadipocytes maintained in serum-containing medium throughout the 
experimental period (data not shown). 
Treatment of subcutaneous preadipocytes with combined linoleic acid + 
Rosiglitazone resulted in decreased expression of LPL and G3PDH over that seen 
with Rosiglitazone alone (Fig. 3.3 A&B). The effect of linoleic acid+ Rosiglitazone 
on leptin expression was inconsistent. In some experiments, combined treatment 
caused an increase in leptin expression (Fig. 3.3A) whereas in others there was a 
decrease. This gene expression pattern was observed despite marked differences in 
triglyceride accumulation in the two culture conditions. 
Analysis of total RNA from mature adipocytes showed that there was no difference 
in expression of LPL and G3PDH between depots whereas leptin expression was 
greater in S than in 0 (Fig. 3.3A). No expression of LPL, G3PDH, or leptin was 
detected in human dermal fibroblasts treated under identical conditions (results not 
shown). 
Ethidium bromide staining showed equal loading and quality of RNA on all gels 
(Fig 3.3A, bottom panel). 
In a limited number of experiments, the effects of culture in linoleic acid vs 
Rosiglitazone were compared with respect to G3PDH activity and leptin secretion. 
Analysis of G3PDH activity in preadipocytes following 21 days in differentiation 
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Figure 3.3 
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Figure 3.3A: Northern Blot Analysis for LPL(3.3 and 3.7 kb), G3PDH (3.55 kb) and leptin 
(4.5 kb) gene expression in human fat cell precursors. Subcutaneous and omental mature 
adipocytes and preadipocytes treated for 21 days in SFM, Ros, LA and LA+ Ros. Results 
shown are representative of at least 4 separate experimental procedures. (Lower panel 
shows ethidium bromide staining of28S rRNA band for comparison of lane loading.) 
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Fig. 3.3B: Gene expression of LPL, G3PDH and Leptin in both subcutaneous and 
omental preadipocytes, from 4 separate experimental procedures, was also assessed 
using densitometry. 
50 
medium demonstrated markedly increased activity in subcutaneous preadipocytes 
treated with Rosiglitazone over that observed in the same cells treated with linoleic 
acid (Fig. 3.4A; p<O.OOl, n=3). Similarly, subcutaneous preadipocytes secreted 
significantly more leptin into the media than cells treated with linoleic acid (Fig 
3.4B; p<0.05, n=2). 
Activation of PP ARy. The ability of the differentiation agents, Rosiglitazone and 
linoleic acid, to activate PP ARy transcriptional activity was determined by 
transfection of hPP ARy reporter constructs into human choriocarcinoma (JEG-3) 
cells. Exposure to Rosiglitazone at 0.1 and 1~-tM resulted in induction of PPARy 
activity (Fig. 3.5). This activity was abolished by treatment with 100~-tM 
Rosiglitazone which was toxic to the cells. Treatment of these JEG-3 cells with 
linoleic acid did not result in activation of the PP ARy reporter construct at any of the 
above concentrations (Fig. 3.5). 
Glucose Uptake. Glucose transport in response to insulin was measured in human 
subcutaneous preadipocytes that had previously been treated with either linoleic acid 
or Rosiglitazone. Figure 3.6 shows that both basal and insulin stimulated glucose 
uptake was increased in preadipocytes treated with Rosiglitazone over those 
maintained in SFM alone. In contrast, linoleic acid treated cells showed a marked 
decrease in insulin-stimulated glucose uptake compared to other treatments. This 
decrease was particularly marked compared to cells treated with SFM containing 
Rosiglitazone (p<0.002). Basal glucose uptake in linoleic acid treated cells was less 
than that seen following Rosiglitazone treatment but was raised compared to basal 
uptake in cells treated with SFM alone. 
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Figure 3.4: Biochemical analysis of subcutaneous preadipocyte differentiation. Cells exposed for 
21 days to differentiation medium containing Rosiglitazone (Ros) developed marked increases in 
both (A) G3PDH activity (p < 0.001 cf SCM; n=6) and (B) leptin secretion (p < 0.05 cf SCM; 
n=4) over cells differentiated in linoleic acid (LA) containing medium. 
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Figure 3.5: Activation of PPARy. JEG-3 cells were transfected with hPPARy reporter 
constructs and treated with Rosiglitazone and linoleic acid (LA) to detennine the ability of 
these agents to induce PPARy transcriptional activity. Induction of activity only occurred 
with exposure to 0.1 and lJ.LM Rosiglitazone (n=3). 
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Figure 3.6: Basal and insulin-stimulated (Ins, lOOnM) glucose uptake in subcutaneous 
preadipocytes treated for 21 days in either serum-free differentiation medium (SFM), 
Rosiglitazone (Ros), or linoleic acid (LA). Rosiglitazone treatment caused an increase in both 
basal and insulin-stimulated glucose uptake compared to controls (*p<0.05), however linoleic 
acid caused a marked decrease in insulin-stimulated uptake relative to both SFM and SFM + 
Ros (p < 0.002 cfRos; n=5). 
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3.4 DISCUSSION 
In this series of experiments the effects of Rosiglitazone and linoleic acid on human 
preadipocyte differentiation have been compared and contrasted. Both of these 
compounds have been reported to be ligands of the nuclear hormone receptor, 
PPARy (Forman et al 1995; Kliewer et al 1997). Rosiglitazone is a member of the 
thiazolidinedione class of insulin sensitizing drugs and linoleic acid is an essential 
dietary fatty acid which in humans makes up 85-90% of the total polyunsaturated 
fatty acid intake (Kris-Etherton et al 2000). This study showed that Rosiglitazone 
induced differentiation in subcutaneous preadipocytes as judged by all criteria 
assessed including intracellular triglyceride accumulation. As these were serum-free 
culture conditions the triglyceride must have been produced by de novo lipogenesis 
from glucose. In contrast, linoleic acid treatment of cells derived from both 
subcutaneous and omental adipose tissue caused marked triglyceride accumulation 
but no other markers of the adipocyte phenotype were detected. 
These results demonstrate that triglyceride accumulation can occur m human 
preadipocytes irrespective of their stage of differentiation. Further, these results 
suggest that lipid accumulation in preadipocytes may not correlate with biochemical 
differentiation, including leptin expression and secretion. This ability to store 
energy in the form of triglyceride would be expected to have survival advantage, 
allowing maximum utilization of consumed energy regardless of the energy storage 
capacity, which is limited, in 'mature' adipocytes. However, the failure of human 
skin fibroblasts to accumulate lipid or express markers of adipocyte differentiation 
when cultured under identical conditions to preadipocytes indicates that stroma-
vascular cells from adipose tissue ('preadipocytes') are indeed pre-determined to 
store energy as triglyceride plus carry out biochemical functions associated with the 
adipocyte phenotype. 
In this series of experiments Rosiglitazone had a modest, depot-specific effect on 
promotion of de novo lipogenesis in serum-free conditions. Furthermore, there was 
no observable increase in triglyceride storage in cells treated with Rosiglitazone plus 
linoleic acid compared with linoleic acid treatment alone. This indicates that free 
fatty acid esterification to triglyceride was not further promoted by Rosiglitazone. 
Thus, in vivo, the overall effect of Rosiglitazone to increase fat mass may be 
expected to be modest, and this has been found to be the case in clinical trials of 
thiazolidinediones (King 2000; Phillips et al 2001 ). This is of particular relevance 
when one considers that Rosiglitazone is a potent insulin sensitizer (Lebovitz et al 
2001) and thus might be expected also to promote lipid storage by this mechanism. 
Interestingly, in contrast to biochemical differentiation, no clear depot-specificity 
was observed in the potential of preadipocytes to accumulate triglyceride. This 
observation, plus the different effects of linoleic acid and Rosiglitazone in this 
experimental system, suggest that these compounds are mediating their effects via 
different biochemical pathways. Further, they suggest that linoleic acid is not itself, 
or metabolized to, a PP ARy ligand in human fat cells in vitro and this is supported 
by the hPP ARy reporter construct studies (Fig 3.5). It is interesting that 
triacylglycerol storage occurred in the cells treated with linoleic acid without any 
evidence of G3PDH expression or activity. It is possible that, despite non-detectable 
G3PDH rnRNA by Northern blot, sufficient activity is present in 'undifferentiated' 
preadipocytes to allow fatty acid esterification to occur. A further possibility is that 
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these cells are using an alternative pathway of fatty acid esterification that does not 
require activity of G3PDH. It has been reported previously that triacylglycerol 
synthesis in adipose tissue can occur by esterification of three different precursors -
glycerol phosphate, dihydroxyacetone phosphate and monoacylglycerols (Dodds et 
al 1976). In rat studies, dietary factors have been found to be important in the 
activity of the enzymes involved in these three pathways with the specific activity of 
dihydroxyacetone phosphate acyltransferase being highest in animals consuming a 
high-fat diet and glycerol phosphate acyltransferase and monoacylglycerol 
acyltransferase being higher in those fed a high carbohydrate diet. 
Consistent with previous reports (Adams et al1997), an intrinsic depot specificity in 
preadipocyte potential for biochemical differentiation was again observed. This 
depot specificity is present in preadipocytes differentiated soon after isolation from 
adipose tissue (data not shown) and is still present in cells differentiated after 2 or 3 
passages. Based on expression of molecular markers of the adipocyte phenotype, 
subcutaneous preadipocytes displayed a greater response than omental cells to 
differentiation induction by Rosiglitazone and, to a lesser extent, linoleic acid. 
Previous observations that leptin expression is higher in subcutaneous mature 
adipocytes than in omental adipocytes (Montague et al 1997), but that LPL and 
G3PDH expression are similar, are confirmed in this study (Fig. 3.3) (Montague et 
al 1998). Therefore, the finding that Rosiglitazone induces expression of all 3 genes 
in subcutaneous preadipocytes indicates that the entire differentiation program is 
promoted in a depot-specific manner, and that omental cells are refractory to this 
pro-differentiation effect. This depot-specificity of Rosiglitazone is not related to 
the level of PP ARy gene expression as this was found to be the same in cells from 
both subcutaneous and omental depots (data not shown). 
These different effects of linoleic acid and Rosiglitazone on leptin production have 
potential physiological significance. On the one hand, the minimal induction of 
leptin expression by linoleic acid, despite marked induction of triglyceride storage, 
is consistent with the observation that significant fat accumulation occurs on high fat 
diets with little induction of satiety (Astrup & Raben 1992). On the other hand, the 
promotion of biochemical differentiation - and importantly leptin expression - by 
Rosiglitazone without significant increase in triglyceride storage indicates that the 
possibility exists to manipulate leptin levels (and potentially appetite) without a 
concomitant major change in fat storage. 
Glucose utilization by fat cells has been suggested as the mechanism governing both 
leptin gene expression and leptin secretion (Havel et al 1999), while blockade of 
glucose transport has been shown to inhibit both of these processes in isolated 
adipocytes (Havel 2000). Consistent with these observations the present study 
shows that Rosiglitazone treatment of subcutaneous preadipocytes resulted in 
enhanced glucose uptake with increased leptin expression and secretion. 
Conversely, preadipocytes differentiated in the presence of linoleic acid developed 
significant intracytoplasmic triacylglycerol stores but no leptin expression or 
secretion was detected. These cells also showed marked reduction in insulin 
stimulated glucose uptake compared to both controls and TZD treated cells. These 
findings are in accordance with both in vivo and in vitro studies which have 
implicated linoleic acid in development of insulin resistance and decreased glucose 
uptake due to increased intracellular oxidative stress (Maziere et al 1999; 
57 
58 
Simopoulos 1994; Tirosh et al 2001). Oxidative stress in 3T3-L1 adipocytes has 
also been associated with increased GLUT -1 and reduced GLUT -4 protein and 
mRNA content compared to controls (Rudich et al 1997). An increase in GLUT-1 
due to oxidative stress in the human preadipocytes treated with linoleic acid could 
account for the result shown in Fig. 3.6 demonstrating a relatively high basal glucose 
uptake compared to the decreased insulin-stimulated uptake. In the present study 
Rosiglitazone treatment caused a 2-fold increase in basal glucose uptake with no 
further increase following insulin stimulation. These results are in agreement with 
findings in murine 3T3-Ll adipocytes treated with Troglitazone (Tafuri 1996). In 
these studies the enhanced basal transport was caused by both increased expression 
and synthesis of the Glutl glucose transporter. 
The present study demonstrates that preadipocytes treated with differentiation 
medium containing linoleic acid develop morphological evidence of adipose 
differentiation with intracytoplasmic lipid stores. These cells, however, do not 
express markers of biochemical differentiation, such as G3PDH; they are insulin 
resistant compared to controls, as measured by glucose uptake; and they do not 
express or secrete leptin. To our knowledge this is the first demonstration that, in 
adipose cells, triglyceride storage and biochemical features of the adipocyte 
phenotype may be independently regulated. 
These findings add significantly to our understanding of the biochemical pathways 
underlying adipocyte differentiation and leptin expression. The experimental system 
described will allow further assessment of the effects of dietary components 
including a range of fatty acids, and pharmacological agents on leptin expression 
and triglyceride storage in human adipose cells. 
It is also concluded from this work that in future studies aimed at identifying factors 
which enhance human adipogenesis, the serum-free differentiation medium 
described here which contains the thiazolidinedione, rosiglitazone, will form the 
basis on which comparisons will be made. 
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CHAPTER4 
Adipose-derived microvascular endothelial cells: 
isolation techniques and proliferative effects 
(The work presented in this chapter has been published in The American Journal of 
Physiology- Endocrinology and Metabolism, 2001 281 (5):E1 037-44) 
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4.1 INTRODUCTION 
During fetal development an established vascular network precedes adipogenesis 
(Crandall et al 1997) and adipose tissue, with its associated microvasculature, has the 
unique capacity to grow throughout adult life (Crandall et al 1997). This raises the 
possibility that microvascular endothelial cells secrete factors that play a role in 
regulation of adipose tissue growth, such as occurs in the development of obesity. 
Furthermore, adipose tissue functions as both the major site of energy storage in the 
body and as an endocrine organ synthesizing and secreting a number of important 
molecules involved in regulation of energy balance (Claffey et al 1992; Crandall et al 
1997). For optimum functioning therefore, adipose tissue requires extensive 
vascularization. 
There is evidence that endothelial cells secrete factors which are involved in regulation 
of growth and differentiation of a variety of mesenchymal cells, including adipose 
precursors (Davis et al 1997; Dodge et al 1993; Varzaneh et al 1994). Further, 
endothelial cells are as diverse in structural and biochemical characteristics as the 
organs and tissues in which they are found (Gerritsen 1987; Page et al1992). It has also 
been demonstrated that endothelial cells derived from the microvascular structures of 
specific tissues differ significantly from large-vessel endothelial cells (Folkman et al 
1979; Hull et al 1996; Kubota et al 1988). One very important difference between 
microvascular endothelial cells and large vessel endothelial cells, such as those derived 
from human umbilical vein (HUVEC), is that only microvascular endothelial cells are 
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involved in angiogenesis (Hewett et al1993). Therefore, it is important when studying 
the paracrine effects of these cells that the cells are isolated from vessels of the 
appropriate size and organ (Craig et al1998). 
Recently, techniques for immune-selection and subsequent culture of microvascular 
endothelium from various tissues have been described. Isolation techniques utilizing 
magnetic beads coated with a monoclonal antibody to platelet-endothelial cell adhesion 
molecule 1 (PECAM-1) have been reported by a number of groups (Dong et al 1997; 
Hara1dsen et al1995; Hewett & Murray 1993; Hull et al 1996; Marelli-Berg et al2000; 
Springhom et al 1995). However, the presence of initially small numbers of 
contaminating cells, such as fibroblasts and smooth muscle cells, which quickly 
outgrow the endothelial cells, has remained a major problem. 
This chapter describes the development of a simple technique that utilizes anti-
PECAM -1 coated magnetic beads and subsequent differential trypsinization steps which 
allows isolation and separate culture of both microvascular endothelial cells and 
preadipocytes derived from subcutaneous and omental adipose tissue depots. This 
isolation of both target cell types from one digest procedure allows optimization of the 
limited tissue available from any one individual. It also ensures that the microvascular 
endothelial cells are from the same tissue depot as the preadipocytes. 
As endothelial cells have common as well as specialized roles in different tissues and 
organs it is hypothesized that endothelial cells from human adipose tissue secrete a 
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factor(s) that influences preadipocyte proliferation and differentiation. A further 
hypothesis is that depot-specificity in these effects may exist. In these experiments the 
aim was to assess the effect of microvascular endothelial cell conditioned media on 
proliferation of human preadipocytes and to compare and contrast these effects in 
preadipocytes and endothelial cells from omental (intra-abdominal) and subcutaneous 
sites. 
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4.2 MATERIALS & METHODS 
(All chemicals obtained from Sigma-Aldrich unless otherwise stated.) 
4.2.1 Production of Anti-PECAM-1 Antibody-Coated Magnetic Beads. Dynabeads M-
450 with covalently bound sheep anti-Mouse IgG 1 (Dynal) were coated with purified 
mouse anti-human monoclonal antibody to PECAM-1 (CD31) (PharMingen) as per 
manufacturer's instructions. Dynabeads coated with anti-PECAM-1 antibody were 
resuspended and stored sterile at 4°C in deionised phosphate buffered saline (DPBS) + 
0.1% BSA (w/v) at a concentration of30 mg/mL. Prepared beads remained active for at 
least 4 months. 
4.2.2 Subjects. Paired omental (0) and abdominal subcutaneous (S) adipose tissue 
biopsies were obtained from 4 male (average age 69 years, range 66-70 yrs; average 
BMI 27, range 26-29) and 5 female (average age 55 years, range 39-67 yrs; average 
BMI 27, range 20-32) patients undergoing elective open-abdominal surgical procedures 
(either gynecological or vascular surgery). None of the patients had diabetes or severe 
systemic illness and none were taking medications known to affect adipose tissue mass 
or metabolism. The protocol was approved by the Research Ethics Committees of the 
Princess Alexandra Hospital and the Queensland University of Technology. All 
patients gave their written informed consent. 
4.2.3 Isolation of stromal-vascular cells. (Roman numerals refer to Figure 4.1). 
Biopsies were transported to the laboratory in Ringers solution (Baxter Healthcare, Old 
Toongabbie) (transport time 15 min.). Preadipocytes and microvessel endothelial cells 
were isolated from the same biopsies. (I) After removal of visible nerves, blood vessels 
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and fibrous tissue the fat was finely minced and incubated for 1 hr at 37°C in digest 
solution (25mM HEPES, 5mM glucose, 120 mM sodium chloride, 50mM potassium 
chloride, and 1mM calcium chloride) containing 3 mg/mL Type II collagenase and 
1.5% bovine serum albumin (w/v). The ratio of digest solution to adipose tissue was 
4:1. The resultant digest material was filtered through a 250J.lm mesh (Sigma) and 
adipocytes and free oil were separated from the stroma-vascular components by 
centrifugation at 250g for 5 min at 4°C. (II) The stroma-vascular pellet was 
resuspended, washed and centrifuged in DPBS + 10% BSA (w/v) (600g, 5min., 4°C). 
This was repeated and followed by a final wash in DPBS alone. (III) The resulting 
pellet was incubated in 0.25% trypsin containing 1 mM ethylenediamine tetraacetic acid 
(EDTA) (CSL, Brisbane) for 15 min at room temperature with occasional agitation. 
Trypsin was neutralized by addition of Hanks' balanced salt solution (HBSS) 
containing 5% fetal bovine serum (v/v) (ICN). (IV) Large fragments of connective 
tissue were removed by filtration through 100J.lm mesh (Sigma). (V) The filtrate was 
centrifuged (600g, 5min, 4°C) and the pellet resuspended and plated into 1% gelatin 
(w/v) coated 25cm2 culture flasks (Coming) in endothelial cell (EC) growth medium 
(M-199; ICN) containing 10% FBS (v/v); 100 IU penicillin; 100).lg/mL streptomycin, 
2mM L-glutamine (all ICN Biomedical Australasia); 90).lg/).lL Heparin; 30ng/mL ~­
endothelial cell growth factor (~-ECGF); 0.014M HEPES; 0.15% NaHC03 (w/v). 
This mixed cell population was cultured for 3-5 days at 37°C, 5%C02• 
Figure 4.1 
I 
II 
III 
IV 
v 
VI 
VII 
VIII 
Adipose Tissue 
Collagenase~igest, spin 
Resuspend pellet in DPBS+ 10% BSA 
Spin and wash x 3, final DPBS alone 
0.25% trypsin/EDT A digest 
.. 
15 mms at RT 
resusoend J HBSS+5%FCS 
Filter (100~-tm), wash, spin 
Plate cells in w Growth medium 
Culture 4 - 5 days 
Trypsinize, 5 mins. 
Resuspend t HBSS+5%FCS 
Anti-PECAM-1 beads. 4°C 15 mins. 
Selected cells 
(endothelial cells) 
+ Washed, reselected 
x3-5 
I' 
IX a Selected cells IXb \ 
X 
(MVEC) 
culre 
(EC Growth 
Medium) 
Contaminating cells 
removed by 
differential trypsinizations 
Non-se lected 
Is 
ocytes) 
eel 
(preadip 
Cult :Y ure 
(PA Growth 
Medium) 
66 
Figure 4.1: Method for isolation and separate culture of microvascular endothelial cells 
and preadipocytes from human adipose tissue. 
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4.2.4 Selection ofmicrovessel endothelial cells with anti-PECAM-1 Dynabeads. (See 
Figure 4.1) (VI) After a short culture period (approx. 3 days) the cells were incubated 
with 0.25% trypsin/1mM EDTA for 4-5 min., followed by neutralization of trypsin with 
Hank's buffered saline solution (HBSS) + 5% PBS (v/v) and centrifugation. (VII) The 
pelleted cells were resuspended in 1mL HBSS+5% PBS (v/v) and incubated with 50j..tL 
of anti-PECAM-1 coated dynabeads (15min., 4°C). (VIII) The cell/bead suspension 
was brought to a total volume of 1 OmL with HBSS+5%FBS and endothelial cells were 
selected using a magnetic particle concentrator for 3 min. at room temperature. With 
the tube still in the magnet non-selected cells (preadipocytes) in the wash were 
transferred to a fresh tube. Endothelial cells were then washed with a further 1 OmL 
HBSS+5%FBS and reselected using the magnetic particle concentrator (3 min.). This 
wash/selection procedure repeated x 5. (IXa) Selected cells (endothelial cells) were 
plated onto a 1% gelatin (w/v) coated culture flask in EC growth medium (as above). 
(IXb) Non-selected cells (preadipocytes - P A) were centrifuged and resuspended in 
DMEM/Ham's F12 1:1 (ICN Biomedical Australasia) containing 100 IU penicillin, 
1 OOj..tg/mL streptomycin, 2mM L-glutamine, and 10% PBS (P A growth medium). 
4.2. 5 Purification of endothelial cell cultures. (See Figure 4.1) (X) Separation of 
endothelial cells from contaminating fibroblastic cells was achieved by treating the 
cultures with 0.25% trypsin/1mM EDTA (TN) for 30-40 sec., neutralization of the 
TN with HBSS + 5% FCS and transferring the non-adherent endothelial cells to a 1% 
gelatin (w/v) coated flask with EC growth medium. This trypsinization and transfer 
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procedure was repeated 1 or 2 times over the first two weeks of culture until 
homogeneous endothelial cell cultures were obtained. 
4.2.6 Cell Culture. Cells were maintained at 37°C in an atmosphere of 5% C02• The 
medium was changed every 2 to 3 days and cells routinely passaged with 
trypsin/EDT A. Endothelial cells were maintained in gelatin-coated flasks in EC growth 
medium whilst preadipocytes were in uncoated culture flasks in P A growth medium. 
As endothelial cell numbers increased, the concentration of ~-ECGF in the EC growth 
medium was decreased from 30ng/mL to lOng/mL. Both endothelial cells and 
preadipocytes were used in experimental work between passages 2 and 4. 
4.2. 7 Culture of other cell types. The human dermal microvascular endothelial cell 
line, CADMEC (Cell Applications, Inc., San Diego) (cultured under the same 
conditions as adipose derived primary endothelial cells), and human skin fibroblasts 
(obtained by punch biopsy and cultured under identical conditions as the human 
preadipocytes) were used as positive and negative controls, respectively, for endothelial 
cell studies. 
4.2.8 Characterization of endothelial cells. Microvascular endothelial cells (MVEC) 
obtained from adipose tissue biopsies were characterized in a number of ways. 
4.2.8A Morphology. Cultures were examined by inverted phase-contrast microscopy 
for the characteristic cobblestone morphology of endothelial cells (Fig. 4.2A). 
4.2.8B Immunofluorescence. Cells were evaluated by immunofluorescence using 
specific monoclonal antibodies for expression of von Willebrand's Factor (vWF) (Clone 
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F8/86, DAKO) (Fig. 4.2B) and platelet endothelial cell adhesion molecule-1 (PECAM-
1; CD31) (Clone JC/70A, DAKO) (Fig. 4.2C). Cells were grown to confluence in 
individual wells of 24-well plates (1% gelatin (w/v) coated). Control cells (human 
dermal microvascular endothelial cells - CADMEC), primary cultures of human 
preadipocytes and human dermal fibroblasts) were processed in parallel. After removal 
of medium, cells were fixed in 2% paraformaldehyde (w/v) (BDH Laboratory Supplies, 
England), 2min. at room temperature (RT). Cells were permeabilized with 0.1% Triton 
X100 (v/v) (Ajax Chemicals, Australia), 30 sec at RT. Fixed and permeabilized cells 
were washed and blocked with 1% BSA (w/v) in PBS (x3) prior to incubation for 4 hrs 
at 4°C with primary antibodies applied after dilution in PBS + 1% BSA (w/v) (all 
antibodies used at 1:100 dilution). To preclude false positives produced by nonspecific 
binding of secondary antibodies, all cell types were also treated in a similar manner 
with either buffer substituting for primary antibody or with non-immune antibody (iso-
type control). The cells were washed with PBS (x3) then incubated at room 
temperature for 30 min with fluorescein isothiocyanate (FITC)-labelled secondary 
antibody (rabbit anti-mouse IgG FITC; DAKO) at 1:50 dilution in PBS + 1% BSA 
(w/v). Cells were washed (x 2) with PBS then nuclei were counter-stained with 
propidium iodide (stock: 5 mg propidium iodide in 100mL 0.1M trisodium citrate; 
working solution: 1 part stock to 3 parts 0.1M PBS) for 5 min at 4°C. Cells were 
washed a further 2 times with PBS before being examined and photographed using a 
Nikon Eclipse TE300 Inverted Microscope with a Nikon TE-FM Bpi-Fluorescence 
attachment and a Nikon F70 Camera with Kodak MAX 400 ASA film. The expression 
of E-selectin (CD62E) was also investigated, using a monoclonal antibody (Clone 
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BBIG-E4, R&D Systems, Inc) and immunofluorescence as above, in cells pretreated for 
4 hrs in growth medium containing 10 ng/mL tumor necrosis factor (TNF) a (Biosource 
International, USA). 
4.2.8C Gene expression. MVEC and CADMEC were examined for expression of 
endothelial nitric oxide synthase (eNOS) by the NOS3 gene. Total RNA was extracted 
from the cells using Tri-reagent (Sigma) according to the manufacturer's instructions. 
Two micrograms of RNA was converted into eDNA using Expand Reverse 
Transcriptase (Roche) with standard methodologies. PCR was performed in a total 
reaction volume of25JlL containing 1 x PCR buffer, 1flL of eDNA, 12.5 pmols of each 
primer, 1.5 mM MgCh, and 0.625 U of Taq DNA polymerase. Primer sequences and 
thermal cycling conditions were as previously described (Rockett et al 1998). PCR 
products were separated on 1.2% agarose gels (w/v) containing 1 Jlg of ethidium 
bromide per mL in 1 x TBE buffer and viewed and photographed under ultraviolet light. 
cpX174 markers were used. 
4.2.9 Characterization ofpreadipocytes: As previously described (Hauner et al1989), 
preadipocytes were characterized on the basis of morphology (phase contrast 
microscopy and cell counts) and differentiation capacity. The latter was assessed by 
G3PDH enzyme activity and triacylglycerol accumulation. 
4.2.9A G3PDH activity. Activity was assessed as previously described (Adams et al 
1997; Rutley et al2001b). 
Triacylglycerol accumulation. Cell counts and Nile Red assay were used to assess 
lipid accumulation. 
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4.2.9B Cell counts. After 14 days treatment in differentiation medium the number of 
lipid containing cells in each treatment was estimated under phase contrast microscopy 
using a 1 mm2 micrometer grid (Neubauer, West Germany) at 100-fold magnification. 
For each treatment 10 different areas were examined and both total number of cells and 
percentage oflipid-containing cells were evaluated (data not shown). 
4.2.9C Nile Red Assay. As previously described (Rutley et al 2001b) preadipocytes 
cultured in 6-well plates were washed 3 times in phosphate buffered saline (PBS) (pH 
7.4) and 150J.!L of trypsin-versene was added to each well. Cells were incubated at 
37°C for 10 minutes until cells detached from the culture plate. PBS containing Nile 
Red, at a final concentration of 1 J..Lg/mL, was added to each well and cells were further 
incubated at room temperature for 5 - 7 minutes. Fluorescence was measured at room 
temperature in a spectrofluorometer (Aminco.Bowman Series 2 Luminescence 
Spectrometer) at 488 nm excitation I 540 emission. Results were normalized to surface 
area (Fig. 4.5B). Each treatment was carried out in triplicate. 
4.2.1 0 Preparation of conditioned medium. Separate cultures of human adipose-derived 
microvascular endothelial cells (MVEC), human dermal microvascular endothelial cells 
(CADMEC), and human skin fibroblasts (HSF)- all at confluence on 1% gelatin (w/v) 
coated cultureware - were each exposed to EC growth medium (see above) containing 
10ng/mL ~-ECGF for 48 hrs at 37°C, 5%C02• This medium was then collected, filtered 
using a 0.22J.!low protein binding filter, and stored at -20°C prior to further use. EC 
growth medium + 10ng/mL ~-ECGF was also treated as above but in culture flasks 
minus cells (blank control). Just prior to use each medium was thawed and a further 5% 
FCS added to each. 
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4.2.11 Preadipocyte Proliferation Assays. Subcutaneous and omental preadipocytes 
and human skin fibroblasts were plated separately at about lxl03 cells/well 
(subconfluent) in 96-well plates in DMEM/Ham's F12 1:1 plus 10% FCS (vlv) (PA 
growth medium) and allowed to adhere at 37°C, 5%C02 for 16-20 hrs. The medium 
was then changed to EC growth medium which had been conditioned (see above) by 
exposure to either confluent subcutaneous or omental MVEC, human skin fibroblasts 
(HSF), or wells containing no cells (blank control) (each treatment was done in 
quadruplicate). In separate experiments subcutaneous and omental PAs were plated as 
above and subsequently treated with either S MVEC, 0 MVEC, human dermal EC 
(CADMEC) conditioned media, fresh EC growth medium, or blank control. After 48 
hrs, preadipocyte cell number was assessed using a formazan colorimetric assay 
(Promega). The water soluble tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was added to each 
well at a concentration of 200!J.g/mL. After incubation at 37°C for 4 hrs, absorbance at 
490nm was measured using a Bio-Rad 3550 microplate reader. Results are presented as 
an increase/decrease in absorbance units relative to absorbance at 490nm obtained from 
preadipocytes growing in the 'blank' conditioned medium control. The validity of this 
assay was tested in two ways; 1) preadipocytes were plated at 250; 500; 1 000; 2000; 
4000 cells per well (in quadruplicate) and absorbance was measured at 490nm; 2) after 
measurement at A490nm the cells were subsequently stained with propidium iodide and 
direct cell counts carried out using fluorescence microscopy. A total of 4 fields per well 
were counted and these results compared with those obtained with formazan absorbance 
at490nm. 
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4.2.12 Statistics. Statistical analysis was performed using ExcelS Data Package. Data 
are expressed as means ± SE. The correlation between cell number and optical density 
was estimated by means of Pearson's correlation coefficient. Proliferation data were 
evaluated by one-way analysis of variance for repeated measures. Post hoc comparison 
for the within condition effect was handled with paired-t tests at alpha= 0.005. 
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4.3 RESULTS 
4.3.1 Isolation of adipose derived MVEC: Following selection for MVEC using anti-
PECAM-1 coated Dynabeads individual cells coated with numerous beads could be 
seen using phase contrast microscopy. These cells grew quite rapidly in distinctive 
cobblestone patches and the number of beads on each cell decreased with mitosis. The 
presence of beads on the cells was not found to have any adverse affects. 
Contaminating fibroblastic cells, characterized by morphology and absence of beads, 
were also found in the MVEC cultures following initial selection with Dynabeads. It 
was determined that following trypsin-EDT A treatment, rapidly growing MVEC lift off 
culture-ware within 1 to 2 min while contaminating fibroblastic cells remain adherent 
for a much greater time. This allowed separation of the MVEC from other cell types 
present in the culture and homogeneous cultures of adipose derived MVEC were 
achieved. These MVEC displayed typical cobblestone morphology and formed contact-
inhibited monolayers (Fig. 4.2A). These cells were successfully grown to passage 6 
with no changes in morphology. Cells between passages 2 to 4 were used in 
experimental work. 
4.3.2 Isolation of preadipocytes: Preadipocytes (P A) negatively selected during 
Dynabead selection for MVEC displayed typical fibroblastic morphology that 
contrasted markedly with the cobblestone morphology of the MVEC. These cells were 
also used between passages 2 to 4. 
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Figure 4.2 
Figure 4.2: Characterization of adipose tissue-derived microvascular 
endothelial cells. (A) Phase contrast photomicrograph of MVEC isolated from 
human adipose tissue. Note the typical cobblestone morphology and the prominent, 
centrally located nuclei. (B) Immunocytochemical staining for vWF shows 
prominent perinuclear cytoplasmic staining (arrows show examples). 
(C) Immunocytochemical staining for PECAM-1 shows junctional staining 
consistent with plasma membrane expression (arrows show examples). In (B) and 
(C) nuclei counterstained with propidium iodide. (Bar = 1 O!lm; original 
magnification 200x). 
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4.3.3 Characterization of MVEC: Table 4.1 summarizes the results of characterization 
studies. Confluent monolayers of adipose-derived MVEC were examined by phase-
contrast microscopy and showed a homogeneous monolayer of cells with morphology 
typical of endothelial cells (Fig. 4.2A). The endothelial nature of these cells was 
confirmed by immunofluorescence studies demonstrating expression of von Willebrand 
Factor (vWF), PECAM-1 (CD31), and E-selectin all of which are endothelial cell 
specific markers (Hewett et al 1993; Hull et al 1996; Potzsch et al 1990). 
Immunofluorescence microscopy showed that vWF is expressed throughout the 
cytoplasm ofMVEC, particularly in the peri-nuclear region (Fig. 4.2B), while PECAM-
1 is expressed on the cell membrane particularly at points of cell-cell contact (Fig. 
4.2C). The human dermal MVEC line (CADMEC) showed the same pattern of 
expression ofvWF and PECAM-1 as adipose derived MVEC (not shown). Incubation 
with 1 Ong/mL TNF -a for 4 hours induced E-selectin expression in the adipose derived 
MVEC (Fig. 4.3A) with immunostaining being characteristically perinuclear 
cytoplasmic. This staining was absent in unstimulated controls (Fig. 4.3B). Human 
skin fibroblasts and preadipocytes did not express any of the markers. In all cases there 
was no non-specific binding with either secondary antibody or with the isotype control 
(not shown). RT-PCR studies demonstrated that both MVEC and CADMEC strongly 
express the NOS3 gene (Fig. 4.4), which codes for endothelial nitric oxide synthase, a 
marker of functional endothelium (Thurn et al 2000). MVEC isolated using the 
described method were shown to express vWF, PECAM-1, and E-selectin from passage 
1 to passage 6 and eNOS expression was present even after recovery from 
cryopreservation. 
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Table 4.1 
Cell Type vWF PECAM-1 E-selectin eNOS Adipocyte Morphology 
(after Differentiation 
TNF-ct 
MVEC v v 
stimulation) 
v v X Cobblestone 
CADMEC v v ND v X Cobblestone 
Preadipocytes X X X ND v Fibroblastic 
Human Skin Fibroblasts X X ND ND X Fibroblastic 
Table 4.1: Characteristics of cell types. 
Morphological features and immunohistochemical staining of microvascular endothelial cells (MVEC) 
and preadipocytes obtained from human adipose tissue. CADMEC (a human dermal MVEC line) and 
human skin fibroblasts are used as control cell types. 
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Figure 4.3 
Figure 4.3: E-selectin expression by adipose derived MVEC. (A) Following 4 hrs 
stimulation with TNF-a (lOng/mL) immunostaining for E-selectin was diffusely 
cytoplasmic. (B) The control for (A) was adipose-derived MVEC that were maintained 
in normal medium without TNF-a for 4 hrs (Bar= lOf.!m; approximate magnification 
200x). 
Figure 4.4 
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Figure 4.4: eNOS gene expression in adipose-derived microvascular endothelial cells 
(MVEC) and in a dermal endothelial cell line (CADMEC). 
79 
4.3.4 Characterization of preadipocytes. When exposed to differentiation permissive 
medium, preadipocytes started to accumulate intracytoplasmic lipid after 5 to 6 days. 
By 21 days in this medium, cell counts demonstrated that 25% to 40% of cells 
contained lipid (results not shown). G3PDH activity and triacylglycerol accumulation 
were also measured at 21 days and both were found to be markedly increased over the 
negligible levels in preadipocytes maintained during this period in non-differentiating 
P A growth medium (Fig 4.5). Human skin fibroblasts cultured under the same 
conditions as the preadipocytes did not accumulate lipid and no G3PDH activity was 
demonstrated (data not shown). MVEC obtained from adipose tissue did not survive in 
the above serum-free differentiation medium. Preadipocytes isolated using this 
procedure were morphologically and biochemically indistinguishable from those 
isolated using standard techniques (Hauner et al 1989). This was demonstrated on the 
basis of G3PDH activity and triacylglycerol accumulation (Fig 4.5). 
4.3.5 Effect of MVEC conditioned media on PA proliferation. To determine if any 
soluble factors affecting preadipocyte proliferation were secreted by MVEC the human 
preadipocytes were exposed to 48hr treatment with MVEC conditioned medium. 
Results demonstrated a significant increase in the rate of proliferation of preadipocytes 
(both subcutaneous and omental) compared to the blank control (Fig. 4.6) (p = <0.001). 
This result was similar for preadipocytes treated with MVEC conditioned media from 
both subcutaneous (S) and omental (0) adipose tissue sites. However, preadipocytes 
treated with 'S' MVEC showed a slightly higher trend in proliferation rate than those 
treated with '0' MVEC (Fig. 4.6). Figure 4.6 demonstrates that the mitogenic effect of 
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Figure 4.5: Characterization of human preadipocytes and comparison of preadipocyte 
isolation techniques. Preadipocytes exposed to differentiation medium for 21 days 
developed marked increases in both (A) G3PDH activity and, (B) triacylglycerol 
accumulation consistent with adipose conversion. There was no difference in either of these 
parameters between preadipocytes isolated using a standard technique (Isolation 1, n=7) or 
co-isolation with MVEC (Isolation 2, n=5) (p > 0.5 for both). 
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Figure 4.6: Effect of MVEC conditioned media on human preadipocyte proliferation. 
Subcutaneous (S) and omental (0) preadipocytes (PA) and (in some experiments) human skin 
fibroblasts (HSF) were exposed for 48hrs to growth medium pre-conditioned by exposure to either 
'S' MVEC, '0' MVEC, human skin fibroblasts (HSF) (all n=24), or a dermal MVEC line 
(CADMEC) (n=16). Growth in conditioned media was compared to growth in non-conditioned 
control medium (see method section 4.2.11). A significant increase in proliferation (over basal) 
was seen in both MVEC and CADMEC groups . Additionally S + 0 MVEC groups were 
significantly greater than CADMEC (p = 0.001). Medium conditioned by exposure to human skin 
fibroblasts (HSF) had no increased Proliferative effect on oreadioocvtes above control. 
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factors produced by adipose derived MVEC on preadipocytes shows some specificity as 
proliferation induced by human dermal MVEC (CADMEC) was not as great as that 
induced by adipose derived MVEC (p = 0.001). Conditioned medium from human skin 
fibroblasts had no increased proliferative effect on preadipocytes over controls. The 
proliferation assay used in these studies was validated using known numbers of 
preadipocytes and results demonstrated a linear relationship between cell number and 
absorbance at 490nm (r2 = 0.9). In a limited number of experiments direct cell count 
was also used to validate the results and showed a positive correlation (Pearson 
correlation coefficient = 0.97) with formazan absorbance at 490nm in both test and 
experimental assays. 
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4.4 DISCUSSION 
This chapter describes a method for isolation and culture of microvascular endothelial 
cells (MVEC) and preadipocytes from the same human adipose tissue sections. A 
paracrine effect of the MVEC from both subcutaneous and omental sites on the 
proliferation of preadipocytes is also demonstrated. 
Isolation and culture of microvascular endothelial cells has been difficult due mainly to 
small initial yields and overgrowth of contaminating cells (Hull et al 1996). However, 
recently described techniques utilizing magnetic beads (Dynabeads) coated with either 
Ulex europaeus agglutinin 1 (UEA-1) or a monoclonal antibody to platelet-endothelial 
cell adhesion molecule 1 (PECAM-1) have alleviated some of the earlier problems 
associated with the isolation of MVEC from a number of different tissues (Conrad-
Lapostolle & Baquey 1996; Hewett & Murray 1993; Hull et al 1996; Jackson et al 
1990). 
In the present series of experiments a modification of this method has been developed 
and the magnetic beads have been coated with anti-PECAM-1 as it has been reported to 
be very specific for MVEC in adipose tissue (Hewett & Murray 1993). This is 
particularly important in adipose tissue from omental sites which also contains 
mesothelial cells (Hewett et al1993; Potzsch et al 1990). This cell type shares several 
morphological and functional features with endothelial cells, but does not express 
PECAM-1 (Hull et al 1996). PECAM-1 was also chosen as the selection antigen 
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because it is one of the few endothelial cell surface molecules that shows trypsin 
resistance and persists in culture over several passages (Haraldsen et al 1995). 
In these experiments the use of Dynabeads coated with anti-PECAM-1 proved 
successful in the initial selection ofMVEC from adipose tissue but non-endothelial cells 
contaminating the culture were still a problem. While working with these cells it was 
observed that MVEC, when treated with trypsin-EDTA, lifted off the culture-ware 
surface much faster than the non-endothelial cells. Using this differential sensitivity to 
trypsin-EDTA a simple technique for separating rapidly growing MVEC from 
contaminating cells was developed and this made it possible to obtain homogenous 
cultures of MVEC from adipose tissue biopsies (see Fig. 4.2A). These cells were 
characterized as endothelial by their distinctive cobblestone morphology and the 
expression of vWF (Fig. 4.2B), PECAM-1 (Fig. 4.2C), and E-selectin (following TNF-
a stimulation) (Fig. 4.3A). These markers are specific for MVEC from adipose tissue 
as vWF is not found in any other cell type present in adipose tissue (Potzsch et al 1990) 
and apart from endothelial cells, PECAM-1 is only found in myeloid cells and platelets 
none of which are viable in the culture conditions used (Springhom et al 1995). 
Contamination by mesothelial cells of endothelial cell cultures obtained from omental 
sites can occur, however this possibility was ruled out in the present experiments as 
mesothelial cells do not express vWF, PECAM-1, or E-selectin (Hull et al 1996). The 
use of PECAM -1 in both the selection and characterization of adipose derived MVEC 
demonstrates that expression of this surface protein is present at the time of isolation 
and persists over several passages. MVEC were also shown to strongly express eNOS 
which has been shown to be both a marker of endothelial cell identity (MacEachern et 
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a11997; Ratcliffe et al1999) and also endothelial cell function (Thurn et al 2000). All 
markers of endothelial cell identity were present in both CADMEC and in MVEC 
derived from adipose tissue (passage 1 through 6). This would indicate that these 
markers are not affected by the MVEC isolation procedure and persisted over several 
subcultures. The presence of eNOS, and PECAM-1 gene expression gives strong 
indication that these cells are functional MVEC (Thurn et al 2000) and expression of E-
selectin following cytokine stimulation is further evidence that these cells are MVEC in 
which the integrity of functional properties has been preserved. MVEC were used in 
experimental procedures between passage 2 and 4. 
Preadipocytes negatively selected usmg this isolation technique had the same 
morphological appearance as those isolated using standard procedures. These cells 
developed the same degree of G3PDH activity following 21 days in differentiation 
medium containing TZD as did those obtained by standard procedure (p = >0.5) (see 
Fig 4.5). Overall, no cell loss, morphological changes, changes in growth 
characteristics or degree of differentiation were detected between preadipocytes 
obtained using standard isolation procedures or those obtained using the present 
technique. 
In this series of experiments MVEC isolated as above have been used to study their 
paracrine interactions with human preadipocytes. The MVEC and preadipocytes were 
isolated from the same adipose tissue biopsies and cultured separately. Results 
demonstrated a significant mitogenic effect of the MVEC conditioned medium (Fig. 
4.6). Overall there was no significant site-specific difference in proliferation of human 
preadipocytes treated with conditioned medium from MVEC derived from either 
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subcutaneous or omental sites but subcutaneous preadipocytes treated with 
subcutaneous MVEC conditioned media showed a slightly higher trend. The greater 
proliferative response of preadipocytes to conditioned medium from adipose-derived 
MVEC over the response to CADMEC indicates some specificity of effect. This is 
consistent with the organ-specific characteristics of endothelial cells (Garlanda & 
Dejana 1997). Human skin fibroblasts also responded to the mitogenic effect of adipose 
derived MVEC to the same degree as did the preadipocytes. This is not altogether 
surprising as microvascular endothelial cells have been shown to secrete a number of 
mitogens including IGF-1 (Ramsay et al 1992) and members of the heparin-binding 
fibroblast growth factor family (Crandall et al 1997) all of which would have a 
proliferative effect on a number of cell types. 
These findings demonstrate paracrine interactions between microvascular endothelial 
cells and preadipocytes present within each adipose tissue depot. As the hyperplastic 
capacity of adipose tissue resides in the fibroblast-like preadipocyte pool these results 
show that factors produced by microvascular endothelial cells may play an important 
role in the development of human obesity (Prins & O'Rahilly 1997). The factor/s 
produced by MVEC responsible for the demonstrated increase of human preadipocyte 
proliferation remain to be determined. MVEC are known to produce several growth 
factors and we are currently investigating a number of candidate molecules to determine 
if these may be responsible for the observed effects. 
Growth of adipose tissue also depends on the adipose conversion of the preadipocytes 
contained within fat tissue. Future studies will investigate the role that MVEC may 
87 
play in development of adipose tissue stores concentrating specifically on the 
differentiation of human preadipocytes. 
CHAPTERS 
Adipogenic effects of adipose-derived 
microvascular endothelial cells 
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5.1 INTRODUCTION 
Expansion of adipose tissue in obesity is preceded by the development of new 
capillaries (Varzaneh et al 1994). These new capillaries are formed by the migration 
and replication of microvascular endothelial cells from established blood vessels 
(Hewett et al 1993). Studies in foetal adipose tissue suggests both spatial and temporal 
relationships between adipogenesis and angiogenesis (Crandall et al 1997). Therefore 
paracrine interaction between microvascular endothelial cells (MVEC) in the 
developing capillary network and preadipocytes resident in the adipose tissue depots 
may play a role in the regulation of adipose tissue growth. Indeed, results obtained in 
the series of experiments described in Chapter 4 of this thesis demonstrate that MVEC 
derived from human adipose tissue secrete a factor(s), which stimulates the proliferation 
of human subcutaneous, and omental (intra-abdominal) preadipocytes (Rutley et al 
2001a). 
For significant increases in adipose tissue mass to occur, preadipocytes present in 
adipose tissue need to undergo differentiation to the mature adipocyte phenotype (Prins 
& O'Rahilly 1997). This is an energy-requiring, regulated process characterized in vitro 
by the sequential acquisition of protein expression patterns and morphological features 
(Hauner 1990). Intrinsic to the process is the development of the potential to store 
energy in the form of triglyceride, development of the capacity for insulin-stimulated 
glucose uptake and the production of characteristic proteins such as leptin (Hwang et al 
1997; Spiegelman & Flier 1996). While the transcription factors, PPARy and C/EBPa 
are known to be master regulators of this differentiation process, factors affecting the 
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earliest stages of adipocyte differentiation are yet to be defined. Further, elucidation is 
needed of the factors regulating the mechanisms involved in cellular, metabolic, and 
regional differences between adipose tissue depots and how these factors may impact on 
the adipocyte hyperplasia characteristic of massive obesity. 
In vitro studies show that subcultured human preadipocytes lose the ability to 
differentiate following exposure to serum (Hauner 1990). It has been suggested that 
serum treatment of these cells leads to an over-proliferation due to the mitogenic 
activity of serum and this proliferation is followed by a decommitment of susceptible 
cells (Hauner 1990). However, in vivo, both proliferative and differentiating factors 
must act together to promote the expansion of adipose tissue. 
Based on the observation that angiogenesis and adipose tissue growth are integrated 
events, and that previous findings from the present study indicate that factors produced 
by human endothelial cells promote preadipocyte proliferation, the hypothesis that 
microvascular endothelial cells also play a role in preadipocyte differentiation has been 
pursued. A further aim was to show that co-culture of human preadipocytes with 
endothelial cells can overcome the inhibition of differentiation previously observed in 
subcultured preadipocytes. 
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5.2 MATERIALS & METHODS 
All chemicals were obtained from Sigma-Aldrich, Castle Hill, Australia unless 
otherwise stated. 
5.2.1 Subjects 
Paired omental (0) (intra-abdominal) and subcutaneous (S) adipose tissue biopsies were 
obtained from 4 male (average age 68 yrs, range 62-75 yrs; average BMI 26.9, range 
24-30) and 5 female (average age 43 yrs, range 32-52 yrs; average BMI 32.5, range 23-
45.9) patients undergoing elective open-abdominal surgery. None of the patients had 
diabetes or severe systemic illness and none were taking medications known to affect 
adipose tissue mass or metabolism. The protocol was approved by the Research Ethics 
Committees of the Princess Alexandra Hospital and the Queensland University of 
Technology. All patients gave their written informed consent. 
5.2.2 Isolation of stromal-vascular cells. 
Biopsies were transported to the laboratory in Ringers solution (Baxter Healthcare, Old 
Toongabbie) (transport time 15 min.), and preadipocytes and adipocytes were obtained 
by collagenase digestion and centrifugation as previously reported (see section 3.2.2) 
(Rutley et al 2001a; Rutley et al 2001b; Prins et al 1994). For co-culture experiments 
both microvascular endothelial cells and preadipocytes were obtained simultaneously 
from the same biopsies using the technique described in Chapter 4 which utilizes anti-
PECAM-1 coated dynabeads (sections 4.2.1, 4.2.3 and 4.2.4) (Rutley et al2001a). 
5.2.3 Culture of stromal-vascular cells 
Preadipocytes (P A): Isolated cells were suspended in P A Growth medium consisting of 
DMEM!Ham's F-12 1:1 containing 100 IU penicillin, 100j..Lg/mL streptomycin, 2mM L-
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glutamine (all ICN Biomedical Australasia Pty Ltd) and 10% foetal bovine serum (v/v) 
(FBS) (Commonwealth Serum Laboratories, Brisbane) in uncoated culture flasks 
(Coming). Cultures were grown for up to 8 weeks and maintained at 37°C with 5% 
C02. Cells were used in experimental work at passage 2 and 3. Prior to treatment with 
differentiation medium PA-only cultures were grown for 2 weeks in EC growth medium 
containing heparin and 10ng/mL B-ECGF (see below) as a control for PA + MVEC co-
culture differentiation. 
Microvascular endothelial cells (MVEC): Following anti-PECAM-1 coated dynabead 
isolation and subsequent differential trypsinization steps to obtain homogeneous 
cultures as previously described (section 4.2.5) (Hutley et al2001a), the isolated MVEC 
were maintained in 0.5% gelatin-coated (w/v) flasks (Coming) in endothelial cell (EC) 
growth medium (M-199; ICN) containing 10% FBS (v/v), 100 IU penicillin, lOOJ.Lg/mL 
streptomycin, 2mM L-glutamine (all ICN Biomedical Australasia), 90J.Lg/J.LL Heparin, 
30ng/mL B-endothelial cell growth factor CB-ECGF), 0.014 M HEPES, and 0.15% 
NaHC03 (w/v). As MVEC numbers increased and the cells were growing rapidly the 
concentration of B-ECGF in the medium was reduced from 30ng/mL to 10ng/mL. 
MVEC were used in experimental work between passage 2 and 4. 
MVEC + PA: For co-culture experiments PAs were seeded at low cell density with 
homogeneous MVEC and the mixed cultures allowed to grow together for 2 - 6 weeks 
in EC growth medium containing heparin and 10ng/mL B-ECGF. 
5.2.4 Culture of other cell types 
Human skin fibroblasts (obtained by punch biopsy and cultured under identical 
conditions as the human preadipocytes, either alone or in co-culture with MVEC) were 
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used as controls for the MVEC + PA studies. For donor details see section 3.2.3 
Chapter 3. 
5.2.5 Characterization of endothelial cells 
MVEC obtained from adipose tissue biopsies were characterized as previously 
described (section 4.2.8) (Hutley et al 2001a) on the basis of morphology, 
immunofluorescence staining for von Willebrand's Factor (vWF), platelet endothelial 
cell adhesion molecule-1 (PECAM-1; CD31), E-selectin (CD62E) (following 
stimulation of cells by 10ng/mL tumor necrosis factor (TNF)-a), and RT-PCR for 
expression of endothelial nitric oxide synthase (eNOS). 
5.2.6 Characterization ofpreadipocytes 
PAs were characterized on the basis of their ability to acquire an adipocyte phenotype 
(measured by triacylglycerol accumulation and increased glycerol-3-phosphate 
dehydrogenase (G3PDH) activity) when maintained in differentiation permissive 
medium. 
5.2. 7 Adipose differentiation protocol 
Following approximately 2 months in culture, to gam sufficient cell numbers for 
experimental work, confluent preadipocytes were changed from serum-containing 
growth medium to a chemically defined serum-free medium containing insulin, T3, 
cortisol, the thiazolidinedione, Rosiglitazone, and other inducers of adipose 
differentiation as previously described (section 3.2.4) (Hutley et al 2001a; Hutley et al 
2001b). 
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5.2.8 Assessment of adipose differentiation 
After 21 days in serum-free differentiation medium adipogenesis was assessed using a 
Nile Red assay for triacylglycerol accumulation and an enzyme assay measuring 
G3PDH activity (for details see sections 3.2.5B and 3.2.6B respectively) (Rutley et al 
2001a; Rutley et al2001b). 
5.2.9 Preadipocyte proliferation assay 
Human subcutaneous preadipocytes were plated at approximately 500 cells per well in 
96 well plates and maintained in serum-containing medium (P A growth medium) at 
37°C, 5%C02 for 16-20 hrs (to adhere to plate). Following this period the medium was 
changed and different proliferation treatments applied to each cell type (in 
quadruplicate). The different treatments were conditioned media from MVEC from 
both subcutaneous (S MVEC) and omental (0 MVEC) adipose tissue, and the same 
medium either fresh or conditioned in the same way as above but in the absence of cells 
(blank). All media contained 10ng/mL ~-ECGF either added just prior to use (fresh) or 
added prior to conditioning period (for details of conditioned media preparation see 
section 4.2.10) (Rutley et al 2001a). Control cells were maintained in non-conditioned 
PA growth medium (minus ~-ECGF). Cultures were maintained in these different 
treatments for a period of 48 hrs after which time P A growth was assessed using an 
MTS proliferation assay (Promega) as per manufacturers instructions as previously 
described (section 4.2.11) (Rutley et al2001a). Results are presented as an increase in 
absorbance units ( 490nm) over P A growth medium control. 
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5.2.1 0 Statistics 
Statistical analysis was performed using the Excel 5 Data Package. Data are expressed 
as means ± SE. The Student's t test was used to evaluate the significance of the 
difference in mean values between different treatments. For the proliferation assay 
validation of the correlation between cell number and optical density was estimated by 
means ofPearson's correlation coefficient. 
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5.3 RESULTS 
5.3.1 Characterization of preadipocytes and endothelial cells 
As shown previously both cell types isolated from human adipose tissue proved positive 
for their specific phenotype markers including morphology and biochemical 
characteristics (see Figures 4.2 to 4.5). 
5.3.2 Endothelial cell and preadipocyte co-culture 
In mixed cultures of PAs and MVECs both cell types were readily distinguishable 
during the 4 - 6 weeks of co-culture. MVEC grew in confluent patches while PAs grew 
in the areas between these patches. PAs in culture with MVEC grew rapidly and P A 
growth became very dense particularly in areas bordering MVEC patches. This was in 
contrast to PAs grown alone where the cell population was evenly distributed 
throughout the culture vessel. The photomicrographs in figure 5.1 show the 
morphology of MVECs and PAs both alone and in co-culture. During the course of the 
co-culture period P A numbers increased and there was a concurrent decrease in the 
' number of identifiable MVECs. However, prior to treatment with differentiation 
medium, distinct areas of MVEC growth were still present. MVECs require the 
presence of a growth factor (P-ECGF) for long-term culture thus PAs in co-culture with 
I 
the MVECs were also exposed to this growth factor. The P A -only cultures therefore, 
were subsequently cultured under the same conditions as the MVEC/P A co-cultures, 
including growth factor (P-ECGF) for a period of 2 weeks prior to induction of 
differentiation. During this period there was no change in morphology or growth 
characteristics of the cells in the P A-only cultures. 
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Figure 5.1 
Figure 5.1: Morphology of adipose-derived microvascular endothelial cells and 
preadipocytes both alone and in co-culture. (A) Confluent endothelial cells; (B) Confluent 
preadipocytes. Cells in both (A) and (B) are homogeneous cultures; (C) Co-culture of the 
two cell types, note the island of endothelial cells in the center of the photomicrograph with 
fibroblastic preadipocytes growing around this area; (D) Area of confluent preadipocytes 
co-cultured with endothelial cells, note the very high cell density; cf (B). (Bar = lOJ.lm; 
Original magnificaion 1 OOx). 
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5.3.3 Adipocyte Differentiation 
At confluence following passage 2 all cultures were changed to serum-free medium 
containing known inducers of adipocyte differentiation plus or minus the PP ARy ligand, 
Rosiglitazone. After 2- 5 days in this serum-free medium all MVEC had lifted from 
the surface of the culture vessel leaving obvious spaces around which PAs were still 
densely packed. In MVEC-only cultures all cells had lifted from the dish and the 
medium contained a large amount of cell debris after this same period. In PA-only 
cultures the change from serum-containing to serum-free conditions had no detrimental 
effects. PAs from both culture conditions changed morphology from the fibroblastic 
appearance of cells in serum-containing medium to a more rounded appearance when in 
the differentiation medium. PAs in the co-culture flasks started to show signs of 
triacylglycerol accumulation after 3-5 days in this differentiation medium whereas those 
from the P A -only cultures did not begin to accumulate lipid until 7-10 days in this 
medium. In the co-culture flasks the PAs that had previously been densely clustered 
around the MVEC patches were the first to accumulate lipid and this accumulation 
increased rapidly, with cells in these dense clusters being lipid-laden by 7-10 days in 
differentiation medium. By 21 days in differentiation medium between 70-95% of PAs 
from the co-culture condition contained large amounts oftriacylglycerol (Fig.5.2A). In 
contrast, PAs cultured alone accumulated lipid stores in isolated cells throughout the 
culture and by day 21 of differentiation only 5-25% of cells contained triacylglycerol 
(Fig.5.2B). Human skin fibroblasts either cultured alone or in co-culture with MVEC 
did not accumulate lipid when treated with differentiation medium (data not shown). 
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Figure 5.2 
Figure 5.2: Morphology of preadipocytes following 21 days in differentiation 
medium. (A) Following co-culture with endothelial cells; (B) cultured alone. 
(Bar = 1 0!ll11; Original magnification 1 OOx). 
5.3.4 Assessment of adipocyte differentiation 
5.3.4A Glycerol-3-phosphate dehydrogenase activity 
100 
PAs from the MVEC+PA co-culture conditions had a significantly increased G3PDH 
activity following 21 days in differentiation medium over PAs cultured alone. This was 
the case for PAs from both subcutaneous (p=O.OOl) and omental (p=0.003) adipose 
tissue depots. However, the rise in activity in subcutaneous PAs was much greater (Fig. 
5.3A) than that seen in cells from omental adipose tissue (Fig. 5.3B). This dramatic rise 
in G3PDH activity was only seen when cells were differentiated in the presence of the 
PP ARy ligand, Rosiglitazone (data not shown). 
5.3.4B Triacylglycerol accumulation 
A Nile Red assay for non-polar intracytoplasmic lipid demonstrated that triacylglycerol 
accumulation positively correlated with the results for G3PDH activity. Both 
subcutaneous (Fig. 5.4A) and omental (Fig. 5.4B) PAs that had been co-cultured with 
MVEC showed far greater accumulation of lipid than PAs cultured alone (for 
subcutaneous PAs p=0.006 and for omental PAs p=O.OOl). 
5.3.5 P A proliferation 
P A proliferation was again shown to be enhanced in response to medium that had been 
conditioned by 48hr pre-treatment on adipose-derived MVEC (Fig. 5.5). This 
proliferative effect is absent in the same P-ECGF containing medium that has been 
'blank' conditioned (i.e. treated under identical conditions, including culture-vessel, 
time and temperature, but in the absence ofMVEC). Figure 5.5 shows that the same P-
ECGF containing medium when used fresh (no conditioning period) has the same 
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Figure 5.3 
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Figure 5.3: G3PDH activity in both (A) subcutaneous and (B) omental preadipocytes 
either alone (P A) or following co-culture with endothelial cells (PA +EC). Preadipocytes 
from both treatment groups were differentiated in the presence of the thiazolidinedione, 
Rosiglitazone (Ros). (Note the scale difference on they axis between (A) subcutaneous 
and B omental.) 
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Figure 5.4: A Nile Red assay for intracytoplasmic lipid accumulation showed that 
differentiated preadipocytes, from both subcutaneous (A) and omental (B) depots, that 
had previously been co-cultured with endothelial cells (PA+EC) contained more 
triglyceride than preadipocytes which had been cultured alone (PA). (Note the scale 
difference on they axis between (A) subcutaneous and B omental.) 
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Figure 5.5: Medium conditioned by exposure to microvascular endothelial cells derived 
from subcutaneous (S MVEC) and omental (0 MVEC) adipose tissue has a mitogenic 
effect on human preadipocytes from both subcutaneous and omental sites. This 
proliferative effect is completely absent in the same growth factor containing medium that 
has been 'blank' conditioned (i.e. exposed to the same conditions of time and temperature 
as the conditioned medium but in the absence of endothelial cells) (Blank). Medium that 
has fresh growth factor added just prior to treatment of preadipocytes (Fresh) has a similar 
proliferative effect on human preadipocytes as does the medium conditioned by exposure 
to endothelial cells. 
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stimulatory effect on human P A proliferation as does media conditioned by 2 days prior 
exposure to MVEC. 
5.3.6 G3PDH activity following /3-ECGF treatment ofpreadipocytes 
In a limited number of experiments PA-only cultures were maintained in EC growth 
medium containing heparin and 10ng/mL B-ECGF for the entire growth period (4-6 
weeks). Figure 5.6A shows that the effect of extended treatment of PA-only cultures 
with B-ECGF at 10ng/mL is similar to that induced by co-culture with MVEC, in 
medium containing B-ECGF at 1 Ong/mL. When the preadipocyte cultures, both alone 
and in co-culture with MVEC, are all maintained in growth medium containing B-
ECGF at 1 Ong/mL for a shorter time period (2 weeks) prior to induction of 
differentiation the level of G3PDH is decreased in the PA+EC co-cultures (relative to 
the results following a longer exposure to growth factor) but is still greater than that 
seen in preadipocyte only cultures (Fig. 5.6B). It can also be seen in Figure 5.6B that, 
following treatment with the same differentiation medium as human preadipocytes, 
G3PDH activity is negligible in human skin fibroblasts (HSF) co-cultured with adipose-
derived MVEC. 
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Figure 5.6 
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Figure 5.6: (A) Treatment of subcutaneous (S) and omental (0) human preadipocytes with~­
ECGF (1 Ong/mL) during the entire proliferative phase ( 4-6 weeks) of culture leads to the same 
degree of G3PDH activity in cells subsequently induced to differentiate (in SFM+Ros) as that 
seen following co-culture with endothelial cells in ~-ECGF containing medium. (B) 
Treatment of preadipocytes (PA) with this growth factor for only 2 weeks prior to induction of 
differentiation does not have as great an effect on preadipocyte differentiation as does 
treatment for a more extended period (cf 5.6A). Two weeks in co-culture with endothelial 
cells however, which also includes exposure to the growth factor, causes a marked increase in 
G3PDH activity over that seen in preadipocytes exposed to growth factor but cultured alone 
for the same period. No significant G3PDH activity was measured in human skin fibroblasts 
(HSF) cultured in the presence of endothelial cells and j3-ECGF and treated the same way as 
preadipocytes. 
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5.4 DISCUSSION 
In this study it is demonstrated that co-culture of human preadipocytes with adipose-
derived microvascular endothelial cells prior to induction of adipose differentiation 
leads to a dramatic increase in triacylglycerol accumulation and G3PDH enzyme 
activity over preadipocytes cultured alone. The effect of endothelial cell co-culture on 
preadipocyte differentiation seems to have occurred very early in the differentiation 
period or even during the proliferative phase of co-culture as the endothelial cells did 
not survive long into the differentiation period. Indeed, in these studies, proliferation 
assays show that conditions which increase proliferation of preadipocytes also increase 
the differentiation capacity of these cells. These results were surprising as the current 
body of evidence suggests that factors which have a mitogenic effect on cultured human 
preadipocytes have an inhibitory effect on subsequent differentiation (Gregoire et al 
1998). 
In subsequent experiments treatment ofpreadipocytes with P-ECGF, in the absence of 
MVEC, during the entire growth period also caused a dramatic increase in adipose 
differentiation (Fig. 5.6A). This increased differentiative capacity was not observed in 
'preadipocyte only' cultures treated with P-ECGF for only 2 weeks prior to induction of 
differentiation. This same time period, however, was enough to demonstrate enhanced 
differentiation in preadipocytes previously maintained in co-culture with MVEC in the 
presence of P-ECGF (see Fig. 5.6B). 
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It was demonstrated in earlier experiments that adipose-derived MVEC produce a 
factor/s which acts as a mitogen on human preadipocytes (see section 4.3.5 and Fig. 4.6) 
(Rutley et al200la), this is shown again in this set of experiments and results also show 
that this mitogenic effect of MVEC is equal in magnitude to that seen in preadipocytes 
treated with freshly added ~-ECGF (see Fig. 5.5). This growth factor was also present 
in the MVEC conditioned medium but had been subjected to 2 days conditioning at 
37°C prior to treatment ofpreadipocytes. Figure 5.5 shows that this conditioning period 
abrogates the mitogenic effect of ~-ECGF in medium conditioned in empty wells (GF 
Blank). The fact that conditioned medium from subcutaneous and omental MVECs 
contains high mitogenic activity even after this conditioning period suggests that 
MVEC are either producing endogenous mitogenic factors, or factors that enhance or 
prolong the effects of exogenous ~-ECGF. It has been shown previously that 
endothelial cells produce members of the fibroblast growth factor family, to which ~­
ECGF belongs (Burgess et al 1986), and that exogenous treatment of these cells with 
growth factor has a paracrine effect resulting in endogenous expression of these same 
factors by the endothelial cells (Dusterhoft & Pette 1999). 
Taken together, the data presented here demonstrate that co-culture of preadipocytes 
with adipose-derived microvascular endothelial cells promotes two aspects of adipose 
tissue growth, the proliferation and differentiation of human preadipocytes. Further, 
these adipogenic properties of endothelial cells can be mimicked by treatment with the 
growth factor, ~-ECGF. However, the differentiative effects of ~-ECGF require a 
period of preadipocyte growth of at least 4 weeks in the presence of growth factor. 
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Enhanced differentiation of preadipocytes maintained in the presence of endothelial 
cells, however, can be demonstrated after 2 weeks co-culture followed by induction of 
differentiation. When preadipocytes are maintained either alone or in co-culture with 
endothelial cells, in the presence of ~-ECGF for a period of 4 weeks or more prior to 
induction of differentiation, the subsequent level of G3PDH activity, as a marker of 
differentiation, is of equal magnitude in both treatment groups. This is the case for 
preadipocytes from both subcutaneous and omental adipose tissue (see Fig 5.6A). The 
results for both treatment groups were quantitatively the same however there were 
qualitative differences in the appearance of both culture types. In the preadipocyte-only 
cultures the cells were evenly distributed throughout the culture vessel and had a 
uniform distribution of cytoplasmic lipid accumulation across the entire culture. In 
contrast, the preadipocytes in the co-culture vessels were very densely clustered in the 
areas around the endothelial cell growth areas. The lipid accumulation in the cells in 
these densely packed areas was quite dramatic with 100% of cells being fully laden with 
large lipid droplets. In the areas more distant from these patches the preadipocytes 
contained less lipid and were less densely packed. This suggests that the adipogenic 
factors produced by endothelial cells may have been sequestered and concentrated in 
the extracellular matrix adjacent to their area of growth. There is evidence suggesting 
that endothelial cells do indeed produce extracellular matrix components which 
modulate and co-ordinate adipogenic regulatory signals in rats (Lau et al 1996; 
Varzaneh et all994). The data obtained in this current series of experiments suggests 
that this may also be an important mechanism in the control of human adipogenesis. 
Overall, these data suggest that a growth factor or factors, possibly a member of the 
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fibroblast growth factor family, is responsible for a significant proportion of the 
adipogenic effect of endothelial cells. Furthermore, the timecourse of action of this 
growth factor suggests that its effect is to prime preadipocytes for subsequent 
differentiation rather than to act as a direct inducer of differentiation. 
As these studies continue the mm is to better identify the factors produced by 
endothelial cells that promote fat cell growth, and thus gain a better understanding of 
the regulation of adipocyte hyperplasia in obesity. Unraveling the complex 
paracrine/autocrine modes of communication between constituent cells in given adipose 
tissue depots will provide new insight into the control of regional adiposity. 
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CHAPTER6 
The role of FGF -1 in human adipogenesis 
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6.1 INTRODUCTION 
In previous work described in this thesis it has been demonstrated that endothelial cells 
derived from human adipose tissue promote both proliferation and differentiation of 
human preadipocytes thus overcoming the inhibition of differentiation previously seen 
in subcultured preadipocytes (see chapters 4 and 5). This adipogenic effect occurs in 
preadipocytes from both subcutaneous and omental adipose tissue depots with effects 
on subcutaneous preadipocytes being greatest (see Figs. 5.3 and 5.4). It was also found 
that these adipogenic effects also occur following treatment of human preadipocytes 
with !)-endothelial cell growth factor (!3-ECGF) during the proliferative phase, prior to 
induction of differentiation. This effect of a growth factor on human adipogenesis has 
not been demonstrated before and indeed it is surprising as factors having a mitogenic 
effect on preadipocytes have been reported to inhibit subsequent differentiation of these 
cells (Gregoire et al1998; Hauner 1990). 
!3-ECGF is a member of the fibroblast growth factor (FGF) family which to date 
consists of 22 members (Kato & Sekine 1999). This growth factor was originally 
purified from bovine brain (Gimenez-Gallego et al1985) and has been shown to be a 14 
amino terminal extension of one of the prototype members of the FGF family, FGF-1 
(or acidic FGF) (Burgess et al1986). This data indicates that FGF-1 is derived from 13-
ECGF by post-translational modification (Burgess et al1986). The biological activities 
of !3-ECGF and FGF -1 have been found to be similar to one another but in several ways 
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to be distinct from those of another well characterized member of this family, FGF-2 
(basic FGF) (Schreiber et al1985). 
All FGFs are potent mitogens, but varying members of the family have different effects 
on differentiation. Both FGF-1 and FGF-2 have been shown to stimulate chicken 
preadipocyte replication (Butterwith et al1993). In murine 3T3-L1 preadipocyte cells, 
FGF-2 suppresses adipose conversion but FGF-1 accelerates the same process (Krieger-
Brauer & Kather 1995). Similarly, in human preadipocytes, FGF-2 has been reported to 
stimulate replication and inhibit differentiation (Teichert-Kuliszewska & Hamilton 
1993), but FGF-1 effects have not been reported in this system. Interestingly, a role for 
FGFs in human adipose tissue metabolism in vivo is suggested by the observation that 
preadipocytes from massively obese individuals over-express FGF-2 (Teichert-
Kuliszewska et al1992). 
The present study examines the role of FGF-1 in human preadipocyte proliferation and 
differentiation in vitro and compares these effects with those previously demonstrated 
for f3-ECGF. A further aim was to investigate whether the observed effects on human 
preadipocytes are mediated via PP ARy, a known adipogenic transcription factor. 
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6.2 MATERIALS & METHODS 
All chemicals were obtained from Sigma-Aldrich, Castle Hill, Australia unless 
otherwise stated. 
6.2.1 Subjects 
Paired omental (0) (intra-abdominal) and abdominal subcutaneous (S) adipose tissue 
biopsies were obtained from 2 male (average age 70.5 yrs, range 70-71 yrs; average 
BMI 24.8, range 22.6- 27) and 8 females (average age 50 yrs, range 31-69 yrs; average 
BMI 29, range 21 - 40.6) patients undergoing elective open-abdominal surgery. None 
of the patients had diabetes or severe systemic illness and none were taking medications 
known to affect adipose tissue mass or metabolism. The protocol was approved by the 
Research Ethics Committees of the Princess Alexandra Hospital and the Queensland 
University of Technology. All patients gave their written informed consent. 
6.2.2 Preadipocyte isolation and culture 
Biopsies were transported to the laboratory and preadipocytes isolated as per the 
reported method in Chapter 3. The stromovascular pellet was suspended in growth 
medium consisting ofDMEM!Ham's F-12 1:1 (ICN Biomedical Australasia) containing 
10% FBS (CSL, Brisbane), 100 IU penicillin, lOOf..lg/mL streptomycin, 2mM L-
glutamine (all ICN Biomedical Australasia), or in this same medium with the further 
addition of 90f..lg/f..lL Heparin, 0.014 M HEPES, 0.15% NaHC03 (w/v), and plus or 
minus either [)-endothelial cell growth factor ([3-ECGF) or FGF-1 (R&D Systems, 
Minneapolis USA). Cultures were grown for 2-3 months and maintained at 37°C with 
5% C02• Cells were used in experimental work at passage 2 and 3. In some 
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experiments a neutralizing antibody to FGF-1 (R&D Systems, Minneapolis USA) was 
also included in the growth medium. 
6.2.3 Preadipocyte Proliferation Assays 
Subcutaneous and omental preadipocytes and on some occasions, human skin 
fibroblasts, were each plated at approximately 500 cells per well (subconfluent) in 96-
well plates in serum-containing growth medium and allowed to adhere at 37°C, 5% C02 
for 16-20 hrs. The cells were then subjected to various proliferation treatments for 48 
hrs and an MTS proliferation assay (Promega) was carried out according to 
manufacturer's instructions (for detailed protocol and validation of procedure see 
sections 4.2.11 and 4.3.5 (Rutley et al2001a). Results are presented as an increase or 
decrease in absorbance units compared to the 'blank' conditioned control medium (see 
Chapter 4 for preparation of conditioned medium). 
6.2.4 Induction of adipose differentiation 
At confluence, following the final passage, cells from all treatment groups were 
changed to serum-free medium containing known inducers of differentiation plus or 
minus the thiazolidinedione, Rosiglitazone (for full details of methodology see section 
3.2.4). 
6.2.5 G3PDH assay 
Following 21 days in serum-free differentiation medium adipogenesis was assessed 
usmg an enzyme assay for G3PDH activity as per previously described protocol 
(section 3.2.6B). 
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6.2. 6 Electrophoretic mobility shift assay 
The following pair of single-stranded oligonucleotides, based on the peroxisome 
proliferator response element (PPRE) in the promoter region of the human acyl-CoA 
oxidase (ACO) gene, were synthesized for use in the electrophoretic mobility shift 
assay: sense PPRE, 5'-AGGGGACCAGGACAAAGGTCACGTTCGGG-3' and 
antisense PPRE, 5 '-CCCGAACGTGACCTTTGTCCTGGTCCCCT -3'. Nuclear 
extracts were isolated from cells grown to confluence either in the presence or absence 
of FGF -1. Complementary strands of oligonucleotides, shown above, were annealed by 
combining equal amounts of each oligonucleotide in buffer (50 mM Tris pH 7.5, 50 
mM KCl, and 10 mM MgCh), heating to 70°C for 10 min, and cooling to room 
temperature. The annealed oligonucleotides were 3'-end-labeled with the non-
radioactive label, digoxigenin (DIG) (Roche Diagnostics, Australia). Three micrograms 
(3 Jlg) of nuclear extract from preadipocytes were incubated for 20 minutes at room 
temperature with DIG labeled probe and resolved on a non-denaturing polyacrylamide 
gel. For competition experiments, unlabeled competitor DNA was added to the reaction 
mixture. Oligonucleotide-protein complexes were transferred to nylon membrane by 
electroblotting. DIG labeled probes were detected by an enzyme immunoassay (Roche 
Diagnostics, Australia) using anti-digoxigenin-AP and the chemiluminescent substrate 
CSPD. 
6.2. 7 PPARyactivation 
Transcriptional activation by FGF-1 and Rosiglitazone was compared using a chimeric 
receptor containing GAL4 DNA-binding domain linked to the hPP ARy hormone-
116 
binding domain co-transfected with UASTKLUC luciferase reporter. This assay was 
carried out as previously described (see section 3.2.6D). 
6.2.8 Statistics 
Excel 5 Data package was used to perform statistical analysis. Data was analysed using 
the repeat measures analysis of variance for differences across experimental groups. 
The Student's t test was used to evaluate the significance of the difference in mean 
values between different treatments. Data are expressed as means ± standard error. 
6.3 RESULTS 
6.3.1 Growth Factor Effects 
6.3.1A Proliferation 
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The proliferation of preadipocytes m response to both ~-ECGF and FGF-1 was 
compared and Fig. 6.1 shows that FGF-1 at a concentration of lng/mL is a more 
effective mitogen towards human preadipocytes than ~-ECGF at lOng/mL. This is true 
for both subcutaneous and omental preadipocytes. This mitogenic effect of FGF-1 is 
decreased in both cell types at a concentration of 10ng/mL (Fig. 6.1) (p=<0.05 for both 
S and 0). In previous work using ~-ECGF at both 1 and 10 ng/mL (data not shown) it 
was found that treatments inducing the greatest proliferative response were positively 
correlated with the subsequent degree of differentiation achieved in these cells, 
therefore, as FGF-1 had the greatest proliferative effect at 1ng/mL it was decided that in 
later experimental work this growth factor would be used at a concentration of 1ng/mL. 
The photomicrographs in Fig. 6.2 show the difference in appearance of preadipocytes 
grown in serum-containing medium without FGF-1 (6.2A) and those grown in the same 
medium with the addition of FGF-1 (6.2B). The greater proliferative capacity of 
preadipocytes exposed to FGF-1 at 1ng/mL is clearly demonstrated and cells do not 
display the same degree of contact inhibition of growth as those grown in the absence of 
the growth factor. 
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l'Igure 6.1: Proliferation assays show that FGF-1 at 1ng/mL has greater mitogenic 
effects on human preadipocytes than either FGF-1 at 10ng/mL or ~-ECGF (b-ECGF) 
at both 1ng/mL and 10ng/mL (*p < 0.05 for both S & 0 cf ~-ECGF 10ng/mL). 
Figure 6.2 
Figure 6.2: The photomicrographs 
show differences in morphology 
between human preadipocytes either 
grown (A) in the absence of FGF-1 or 
(B) in the presence ofFGF-1. Note the 
greater cell density of confluent 
preadipocytes exposed to FGF-1 
during proliferation (B). (Bar= lOJ..Lm; 
Original magnification 1 OOx.) 
6.3.1B Adipose differentiation 
P-ECGF vs FGF-1 
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To ascertain if FGF-1 has the same adipogenic effects on human preadipocytes as 
previously demonstrated for P-ECGF (see Chapter 5) a G3PDH enzyme activity assay 
was performed after growth of the cells in the presence ofFGF-1 (1ng/mL) (approx. 4 
weeks) and subsequent exposure of cells to differentiation medium (21 days). In Fig. 
6.3 it can be seen that FGF-1 does induce differentiation to the same degree as P-ECGF. 
This effect is specific for preadipocytes as human skin fibroblasts treated in the same 
way did not accumulate intracytoplasmic lipid and no G3PDH activity was measured 
(data not shown). The photomicrographs in Fig. 6.4 show that FGF-1 treatment during 
growth ofpreadipocytes has a marked effect on the subsequent degree oftriacylglycerol 
accumulation in the same cells following 21 days in differentiation medium. 
6.3.2 Time of FGF-1 treatment 
To characterize the effect of these growth factors on differentiation of preadipocytes, 
cells were initially grown in medium without growth factor and subsequently exposed 
to P-ECGF or FGF-1 either from passage 1 to differentiation (approx. 6 weeks) or from 
passage 2 (approx. 3 weeks). In other experiments cells were grown in FGF-1 
containing medium from the time of isolation to passage 2 ( approx. 4 weeks) and then 
treated for 2 weeks in the absence of growth factor. Fig. 6.5A shows that the longer 
cells are exposed to either P-ECGF or FGF-1 the greater the level of G3PDH activity 
present. In Fig. 6.5B it can be seen that when FGF-1 is removed from post-confluent 
preadipocytes for the final 2 weeks prior to induction of differentiation then the G3PDH 
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Figure 6.3 
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Figure 6.3: A G3PDH activity assay showed that treatment of human preadipocytes 
with either (3-ECGF (b-ECGF) or FGF-1 prior to induction of differentiation 
markedly enhanced the differentiative capacity of these cells over cells not exposed 
to growth factor (GF) (*P<0.002 cf control). The level of enzyme activity reached 
subsequent to differentiation was the same for both growth factor treatments. 
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Figure 6.4 
Figure 6.4: Photomicrographs (Bar = 1 Ojlm; original magnification 1 OOx) of (A) preadipocytes 
grown in the absence of FGF-1 and (B) subsequent differentiation of the same cells; (C) 
preadipocytes grown in the presence ofFGF-1 (lng/mL); (D) subsequent differentiation. 
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Figure 6.5: G3PDH activity in differentiated preadipocytes following exposure to growth factors for 
different periods of time; (A) from either commencement of passage 1 (P1) or passage 2 (P2) to 
induction of differentiation (*P=0.01 ~-ECGF P1 vsP2; #P=0.05 FGF-1 P1 vsP2), and (B) removal of 
FGF-1 from proliferation medium for a period of time prior to induction of differentiation causes a 
decrease in the subsequent level of G3PDH activity over that seen in cells maintained in the presence 
of growth factor for the entire period prior to induction of differentiation (*p = < 0.001 ); the insert in 
(B) shows that removal of FGF-1 for 2 weeks prior to differentiation did not alter the amount of 
whole cell protein obtained from these cultures. 
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activity is markedly decreased over that seen in cells maintained in FGF-1 for the entire 
period from isolation to differentiation (p=<0.001). The insert in Fig. 6.5B shows that 
the amount of protein in whole cell lysates obtained from both treatments, was not 
significantly different. 
To further investigate the timing of FGF-1 treatment of preadipocytes for optimal 
differentiation, preadipocytes were grown for 4 to 6 weeks either in the presence or 
absence of FGF-1. These cells were subsequently differentiated for 3 weeks in the 
presence or absence of the growth factor. Fig. 6.6 shows the greatest level of G3PDH 
activity in preadipocytes grown in the presence of FGF-1 but differentiated in the 
absence of this growth factor (p=0.01 cf other treatments). Treatment of preadipocytes 
with FGF-1 only during the differentiation period causes no increase in G3PDH activity 
over that seen in control cells (i.e. cells grown and differentiated in the absence ofFGF-
1). 
6.3.3 PPARyinvolvement 
6.3.3A G3PDH assay 
In all of the above work preadipocytes have been differentiated in the presence of the 
thiazolidinedione (TZD), rosiglitazone (Ros) - a potent PP ARy ligand (Forman et al 
1995). To determine if FGF-1 is acting as a PPARy ligand and thus promoting 
adipogenesis, preadipocytes were grown plus or minus FGF-1 and then differentiated 
plus or minus Ros. Results show that when exposed to FGF-1 during proliferation and 
differentiated without Ros the G3PDH activity is raised marginally over controls and 
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Figure 6.6: Exposure of human subcutaneous preadipocytes to FGF-1 (GF) 
(1ng/mL) during proliferation, prior to induction of differentiation, is associated 
with a marked increase in G3PDH activity over cells not exposed to this growth 
factor during the growth period. Exposure to FGF-1 (1ng/mL) only during the 
differentiation period has no effect on subsequent G3PDH activity (*p = 0.01 cf 
other treatments)_ 
Figure 6.7 
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Figure 6.7: The marked increases in G3PDH activity seen in differentiated human 
subcutaneous (S) and omental (0) preadipocytes previously exposed to FGF-1 (GF) 
(1 ng/mL) during proliferation require the presence of a thiazolidinedione (Ros) in 
the differentiation medium. 
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the level is similar for both subcutaneous and omental preadipocytes (Fig. 6.7). 
However, for the full effect of prior FGF-1 treatment to be achieved Ros needs to be 
included in the differentiation medium. Once again Fig. 6. 7 shows that the greatest 
degree of G3PDH activity occurs in preadipocytes from subcutaneous sites but omental 
preadipocytes also respond to this effect ofFGF-1. 
6.3.3B Endogenous PPRE binding activity 
DNA binding activity is demonstrated in nuclear lysates from both treatment groups 
(Fig. 6.8). The treatment groups being subcutaneous preadipocytes grown to 
confluence either in the presence or absence ofFGF-1 and subsequently differentiated. 
Specificity of the binding was verified by competition with unlabelled PPRE 
oligonucleotides. There is no difference in the binding patterns between the two 
treatment groups. 
6.3.3C PP ARy activation 
FGF-1 does not induce PPARy activity in transfected JEG-3 cells (Fig. 6.9A) and 
neither does it increase the activity seen in cells treated with the TZD (Ros) (Fig. 6.9B). 
6.3.4 Effects of a neutralizing antibody to FGF-1 
6.3.4A Proliferation 
To determine if the adipogenic effects seen in the above work are indeed mediated by 
FGF -1 the effects of a neutralizing antibody specific for this growth factor were 
investigated. Fig. 6.1 OA shows that inclusion of this antibody at increasing 
concentrations in growth medium containing 1ng/mL FGF-1 caused a marked decrease 
in the level of proliferation over that seen in cells treated with FGF-1 alone. 
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Figure 6.8 
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Figure 6.8: Electrophoretic mobility shift assay shows no difference in PPARy 
binding activity between nuclear lysates prepared from human subcutaneous (S) 
preadipocytes grown either in the absence (SPA) or presence (S PA+GF) ofFGF-1 
(lng/mL). 
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Figure 6.9: Activation of PP ARy. JEG-3 cells were transfected with hPP ARy reporter 
constructs and maintained either in the presence or absence ofFGF-1 (GF) (1ng/mL) for a 
period of 40hrs. The cells were then treated either with (A) FGF-1 alone (at the indicated 
concentrations) or (B) Rosiglitazone (0.1).!M) (Ros) + FGF-1 (10ng/mL) to determine the 
ability of these agents to induce PP ARy transcriptional activity. FGF-1 did not induce 
PP ARy activity in these cells and neither did it enhance Rosiglitazone induced activity. 
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Figure 6.10: Effects of FGF-1 neutralizing antibody. (A) Addition of a neutralizing 
antibody (10J.Lg/mL) specific to FGF-1 to the treatment conditions ofhuman subcutaneous 
(S) and omental (0) preadipocytes grown in the presence of FGF-1 (1ng/mL) leads to a 
decrease in their rate of proliferation over a 2 day period (P<0.05 for both * and#). (B) 
G3PDH assay following differentiation of human subcutaneous preadipocytes previously 
grown in the presence of FGF-1 (lng/mL) +/- anti-FGF-1(10J.Lg/mL) demonstrated no 
effect of the neutralizing antibody on the level of enzyme activity detected in 
differentiated cells (P=0.2 cfFGF-1 alone). 
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6.3.4B G3PDH activity 
Fig. 6.1 OB demonstrates no effect of the neutralizing antibody on the level of G3PDH 
activity seen in differentiated preadipocytes treated with FGF-1 plus or minus anti-FGF-
1 during the proliferative phase of growth (p=0.2). 
6.3.5 Proliferation in endothelial cell conditioned media+/- anti-FGF-1 
In a limited number of experiments the proliferation of preadipocytes in conditioned 
medium from adipose-derived microvascular endothelial cells (MVEC), plus or minus 
antibody to FGF -1, was investigated. Results are presented as an increase or decrease 
in absorbance at 490nm relative to a 'blank' conditioned (i.e. the same medium 
conditioned in the absence of cells) control). Fig. 6.11 demonstrates a decrease in 
MVEC induced preadipocyte proliferation in the presence of anti-FGF-1 (p<O.OS for 
both S and 0). 
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Figure 6.11: The proliferative capacity of human subcutaneous preadipocytes in 
response to a factor/s present in medium conditioned by exposure to subcutaneous (S 
MVEC) and omental (0 MVEC) adipose-derived microvascular endothelial cells can 
be abrogated by addition of a neutralizing antibody (Ab) (lO!lg/mL) specific to FGF-1 
(p = < 0.05 MVEC conditioned medium vs MVEC conditioned medium+ antibody-
for both * and#). 
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6.4 DISCUSSION 
Knowledge of the cellular mechanisms implicated in the over-development of adipose 
tissue is a critical issue in the design of pharmaceutical strategies aimed at lessening 
nutritional obesity. This study demonstrates that FGF-1 is an adipogenic molecule 
which promotes human preadipocyte proliferation and which 'primes' human 
preadipocytes for TZD-induced differentiation. Treatment of human preadipocytes with 
FGF-1 during their proliferative growth also overcomes the inhibition of differentiation 
previously observed in subcultured cells. These results also indicate that FGF-1 is not 
acting as, or inducing expression of, a ligand for PP ARy in this system as the full 
adipogenic effects were only observed when the PP ARy ligand, rosiglitazone, was 
included in the differentiation medium (see Figs. 6.7, 6.8 and 6.9). 
The proliferative effect of FGF-1 on human preadipocytes was the same in cells from 
subcutaneous and intra-abdominal sites (see Fig. 6.1). There was depot specificity 
however in TZD-induced differentiation which was greater in subcutaneous than in 
omental preadipocytes (Fig. 6.7). Interestingly, these are the only culture conditions 
ever used in our lab, or reported (Adams et al 1997), in which omental preadipocyte 
differentiation can be reliably and reproducibly observed, albeit at a lesser rate than 
similarly treated subcutaneous cells. The level of G3PDH activity and triacylglycerol 
accumulation seen in both cell types was far greater than seen in any previously 
reported studies in subcultured human preadipocytes. 
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These adipogenic effects of FGF -1 were specific for cells obtained from the stromal-
vascular compartment of adipose tissue as human skin fibroblasts maintained under 
identical conditions did not accumulate cytoplasmic lipid and no G3PDH activity was 
measured in these cells (data not shown). This is consistent with the premise that 
preadipocytes are a unique type of mesenchymal cell, distinctly different from dermal 
fibroblasts, and capable of expressing a developmental commitment which at terminal 
differentiation may result in a typical mature fat cell. 
In these studies the mitogenic effect of FGF-1 towards preadipocytes could be 
abrogated by addition of a specific FGF-1 neutralizing antibody to the growth medium 
(Fig. 6.1 OA) but this antibody, at the concentration used, had no effect on the 
differentiation capacity of preadipocytes (Fig. 6.1 OB). For the proliferation assays, 
preadipocytes were grown for a period of 48 hrs in treatment media and after this time 
the effect of the antibody was clearly demonstrated (Fig. 6.10A). However, for the 
differentiation studies cells were grown for a period of 4 weeks in the presence of FGF-
1 plus or minus anti-FGF-1 and were then maintained for a further 3 weeks in 
differentiation medium in the absence of either growth factor or antibody. It is possible 
that the concentration of antibody used during the growth period, prior to induction of 
differentiation, was not high enough to completely block the adipogenic effects ofFGF-
1 over this period of time. FGF -1 is sequestered in the extracellular matrix and this has 
been reported to form a store of growth factor (Baird et al 1987; Powers et al 2000). 
Possibly the antibody was at a high enough concentration to block the FGF-1 added 
over a 2 day period, for the proliferation studies, but over longer periods the addition of 
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fresh antibody with each change of medium was not sufficient to block both the FGF -1 
also added in the medium as well as that available to the cells in the matrix. Certainly, 
the cells grown in the presence ofFGF-1 plus antibody grew more slowly than those in 
FGF-1 alone, however this growth was still enhanced over that seen in cells that had no 
exposure to FGF-1 (data not shown). This suggests that the activity ofFGF-1 was not 
completely blocked by the antibody in these studies. 
FGF-1 is a member of a large family of related growth factors that have been 
characterized by their high affinity for heparin and their capacity to stimulate 
angiogenesis in vivo (Baird et al 1987). These growth factors have a wide distribution 
which is in part attributable to their production by endothelial cells and their storage in 
the extracellular matrix (Baird et al 1987). The FGFs are polypeptides with multiple 
biological activities including angiogenesis, mitogenesis, cellular differentiation and 
repair of tissue injury (Konishi et al 2000). The stimulation of cellular metabolism by 
FGFs is mediated via a dual receptor system comprising four high affinity tyrosine 
kinase receptors (FGFR 1-4), and a class of low affinity receptors, the heparan sulphate 
proteoglycans (HSPGs) (Steger et al 1998). Multiple layers of complexity exist in the 
regulation of FGF actions including tissue-specific spatial and temporal expression of 
ligands and receptors, modulation of binding specificity by alternative splicing of 
FGFRs, and modulation of binding affinity and specificity by HSPG molecules with 
specific patterns of sulfation (Choi et al 2000; Ornitz 2000; Pye et al 2000; Steger et al 
1998). 
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FGF-1 is synthesized as a 155 aa protein (Powers et al2000) and is unique amongst the 
FGF family as it binds with high affinity to all known receptor isoforms (Miller et al 
2000). FGF-1 also requires either endogenous or exogenous heparan sulfate/heparin 
moieties in order to establish receptor binding and mitogen action and this raises the 
possibility that FGF-1 can have different effects in different cell types according to the 
nature and/or quantity of cell surface heparan sulfate moieties in vivo (Spivak-Kroizman 
et al 1994). FGF-1 has no definitive signal sequence and therefore is not secreted 
through classical pathways (Ananyeva et al 1997; Jaye et al 1986). The mechanism of 
FGF-1 release from cells is yet to be fully elucidated but evidence suggests that it 
associates with synaptotagmin-1 (Syn-1) on the cytosolic face of conventional 
exocytotic vesicles (Carreira et al 2001) and in this complex is trafficked to the inner 
surface of the plasma membrane and gains access to the extracellular compartment 
(Tarantini et all998). There is also evidence that FGF-1 may act at intracellular sites-
both cytoplasm and nucleus - and an FGF -1 intracellular binding protein (FIBP) has 
been identified (Kolpakova et al 2000). 
Thus, the current model of FGF-1 action is that FGF-1 is secreted from producer cells 
via non-classical mechanisms, and acts locally to bind ubiquitously expressed FGF 
receptors in a complex with heparinlheparan sulphate. Upon receptor ligation and 
subsequent phosphorylation a number of downstream signaling pathways are activated, 
subserving differing biological actions. Additionally, a proportion of receptor-bound 
FGF-1 is translocated intra-cellularly to both the cytoplasm and nucleus, probably 
bound to intracellular binding proteins. 
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In this study we have identified FGF-1 as a factor having profound effects on human 
preadipocyte proliferation and differentiation in vitro. Culture in the presence ofFGF-1 
from the time of preadipocyte isolation appears to prime the cells for differentiation. 
This priming effect is made much more apparent if the cells are subsequently 
differentiated in the presence of theTZD, Rosiglitazone. We have previously shown 
that microvascular endothelial cells from adipose tissue secrete a factor/s that enhances 
preadipocyte proliferation (see section 4.3.5 and Fig. 4.6) (Rutley et al 2001a). We 
have now demonstrated that this proliferative effect of conditioned medium from 
endothelial cells can be blocked by the addition of a neutralizing antibody specific for 
FGF-1 (Fig. 11). FGF-1 has been found in the extracellular matrix produced by 
endothelial cells (Baird & Ling 1987) and soluble matrix components released by 
endothelial cells have been found to promote rat preadipocyte differentiation (Varzaneh 
et al 1994). Taken together this evidence suggests that FGF-1 may be produced by 
endothelial cells in adipose tissue and it is possible, therefore, that this factor may play a 
role in the regulation ofhuman adipose tissue growth in vivo. 
Further work will be aimed at determining if FGF -1 is produced by endothelial cells, or 
other cell types, in adipose tissue and if expression of this growth factor is regulated by 
signals from mature adipocytes. Also it is important to identify the particular FGF 
receptor isoform(s) present on or within preadipocytes at various stages of growth and 
which are responsible for the observed effects ofFGF-1 in this tissue. Finally, the role 
of various growth factors in human adipogenesis needs to be investigated under the 
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same conditions as those used in the present study to determine if the actions ofFGF-1 
in this system are specific or if a range of growth factors can mediate the same effects. 
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CHAPTER 7 
DISCUSSION & CONCLUSIONS 
7.1 Fatty acids and thiazolidinediones in human preadipocyte 
differentiation 
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The first aim of this research was to further develop a system of human preadipocyte 
differentiation which could be used as the standard against which future studies of 
putative adipogenic agents could be compared. Much of the progress that has been 
made in our understanding of adipocyte differentiation at the cellular and molecular 
levels comes from studies using rodent-derived cell lines. While studies utilizing these 
cell lines have yielded valuable information about the molecular events involved in 
preadipocyte differentiation care must be taken when extrapolating results to the human 
situation. To clarify questions pertaining to growth of human adipose tissue, studies 
need to be carried out using primary cultures of human preadipocytes and, whilst this 
work is more difficult and time-consuming compared to murine equivalents, 
observations made will more directly reflect the human in vivo context. 
Unlike most of the murine adipose cell lines, human preadipocytes do not differentiate 
in the presence of serum (Hauner et al1989). Therefore the development of serum-free 
strategies for induction of differentiation has made possible the in vitro study of the 
biochemical and molecular characteristics of the human adipogenic program (Des lex et 
al1987b). The principle components for differentiation in this protocol include insulin, 
glucocorticoid, and methylisobutylxanthine (MIX), a phosphodiesterase inhibitor which 
raises intracellular cAMP levels (Hauner et al 1987). Relatively recently it has been 
demonstrated that addition of activators of the transcription factor PP ARy, a central 
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regulator of the differentiation program, markedly enhances the differentiation capacity 
ofhuman preadipocytes (Adams et al1997). 
In initial studies we aimed to further develop the methods currently in use for the 
induction of differentiation in human preadipocytes. This involved the comparison of 
two compounds, one a synthetic agent, rosiglitazone - a member of the 
thiazolidinedione (TZD) class of drugs, and the other a naturally occurring fatty acid, 
linoleic acid. Both of these compounds have been reported to be activators of PP ARy 
(Adams et al 1997; Klaus 1997) although the relative potency of each has not 
previously been investigated in human preadipocytes. These studies were carried out to 
determine the most efficient and reliable method of induction of differentiation in 
subcultured human preadipocytes and this method would then be used as the basis for 
comparison in future studies of putative adipogenic factors. 
·Results were surprising with initial observations suggesting that linoleic acid was a far 
more potent adipogenic agent than rosiglitazone. This observation was made on the 
basis of accumulation of intracytoplasmic triacylglycerol which was much greater in 
linoleic acid treated cells compared to those treated with the TZD. These results were 
the same in preadipocytes from both subcutaneous and omental adipose tissue depots. 
However, when biochemical characteristics of adipocyte differentiation were 
investigated, including leptin expression and secretion, and insulin-induced glucose 
uptake, none of these markers of the adipocyte phenotype were detected following 
linoleic acid treatment. This was despite the fact that these cells contained large 
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amounts of triacylglycerol as determined morphologically and by a spectrophotometric 
assay for intracellular non-polar lipid. In direct contrast, the TZD treated cells 
contained minimal lipid but all aspects of the biochemical adipocyte phenotype were 
demonstrated. This TZD result had depot specificity with subcutaneous preadipocytes 
showing a much greater response than omental cells. This depot-specificity in the 
induction of adipocyte differentiation by TZD is in accordance with previously 
published work (Adams et al 1997). The results obtained for both linoleic acid and 
rosiglitazone were specific for cells isolated from the stroma-vascular compartment of 
adipose tissue as human skin fibroblasts treated in the same way did not accumulate 
lipid or develop biochemical features of the adipocyte phenotype. 
To our knowledge this is the first account of triacylglycerol accumulation and 
biochemical features of adipose conversion occurring independently. It is unknown if 
human preadipocytes can take up and store fatty acids in vivo without undergoing full 
differentiation. If they do, this could be a means by which these cells could rapidly 
remove fatty acids from the extracellular environment thus limiting the detrimental 
effects of these fatty acids on the rest of the system. Alternatively it may be a 
mechanism whereby energy storage could be maximized at times when fatty acid 
availability exceeds the capacity of adipocytes currently present in adipose tissue. Full 
differentiation of these 'preadipocytes' may proceed more slowly in response to other 
factors present in the in vivo situation. Further work needs to be carried out to 
determine the effects of a range of fatty acids on these aspects of adipocyte 
differentiation. 
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Finally, it was concluded from this senes of experiments that the differentiation 
strategies used in future work will include the thiazoldinedione, rosiglitazone, along 
with previously described hormonal inducers of differentiation in a serum-free medium. 
7.2 Development of a technique for isolation and culture of both 
preadipocytes and microvascular endothelial cells from human 
adipose tissue. 
The second aim of this project was to develop techniques for isolation and culture of 
preadipocytes and microvascular endothelial cells from human adipose tissue biopsies 
of both subcutaneous and omental origin. 
In adipose tissue, development of the microvasculature precedes adipogenesis in both 
foetal and post-natal life (Crandall et al 1997). It is believed that this mechanism 
ensures an adequate blood and nutrient flow is maintained in the expanding fat depots 
(Lau et al1996). Studies in rat adipose tissue have suggested that paracrine interactions 
between preadipose cells and endothelial cells may be involved in regulation of adipose 
tissue growth (Lau et al 1996). Based on this evidence it was hypothesized that 
adipose-derived microvascular endothelial cells may secrete factor/s which regulate the 
growth of adipose tissue. 
To study the metabolic effects of factors produced by endothelial cells in a given tissue 
it is necessary to obtain the endothelial cells from appropriately sized vessels within that 
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tissue. This is due to the fact that endothelial cells have different biochemical 
characteristics according to the vessel size and organ in which they are located 
(Gerritsen 1987; Page et al 1992). Previous work studying paracrine effects of 
endothelial cells in different tissues has often used endothelial cells from umbilical vein 
and while these macrovascular cells are more easily isolated and cultured than 
microvascular cells the results obtained do not truly represent the involvement of 
capillary endothelial cells in the metabolic processes in a given tissue. Therefore, to 
determine if microvascular endothelial cells produce paracrine factor/s involved in 
preadipocyte proliferation and differentiation it was necessary to isolate both the 
endothelial cells and the preadipocytes from adipose tissue biopsies. As availability of 
this tissue is limited and the size of biopsies usually small it was also important to 
develop a method of isolation of both cell types from the same biopsies. This was 
achieved by modifying the preadipocyte isolation procedure that was well established in 
this laboratory (Prins et al1994). To this procedure was added immuno-selection steps 
utilizing magnetic beads coated with antibody to PECAM -1 (a cell surface molecule 
specific for microvascular endothelial cells (Hewett & Murray 1993). This 
modification allowed the magnetic separation of endothelial cells bound to beads from 
unbound preadipocytes and these two cell types were then plated and cultured 
separately. The endothelial cell cultures however, contained initially small numbers of 
contaminating cells which rapidly outgrew the endothelial cells. It was found that 
treatment of these mixed-cell cultures with trypsin caused the endothelial cells to 
rapidly lift off the culture surface leaving the more resistant contaminating cells still 
firmly attached. The endothelial cells were then transferred to fresh culture flasks. 
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Using this differential sensitivity to trypsin, homogeneous cultures of endothelial cells 
were obtained and their endothelial nature confirmed using a number of strategies (see 
Figs. 4.2, 4.3, and 4.4). The preadipocytes also obtained from this isolation procedure 
were characterized on their ability to undergo differentiation to the adipocyte phenotype 
and these cells were found to be the same, both morphologically and biochemically, as 
those isolated using a more standard procedure (see Fig. 4.5). 
The above work describes the development of a model system that offers the 
opportunity to increase understanding of the biochemistry of human preadipocyte 
proliferation and differentiation and to explore the role of endothelial cells in these 
processes. This model may also provide further information on intrinsic differences in 
the cells from omental and subcutaneous adipose tissue depots. 
7.3 Effects of adipose-derived microvascular endothelial cells on 
preadipocyte proliferation and differentiation. 
The third aim of the project was to determine if endothelial cells derived from human 
adipose tissue produce paracrine factors affecting aspects of adipose tissue growth, 
these being the processes of preadipocyte proliferation and differentiation. 
Conditioned media techniques were used to determine if endothelial cells were 
producing mitogenic factors affecting the rate of proliferation of human preadipocytes. 
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A further aim was to determine if these effects were different in cells from different 
adipose tissue depots. 
Figure 4.6 (chapter 4) shows that endothelial cells from adipose tissue do increase the 
rate of proliferation of preadipocytes, from both subcutaneous and omental sites, over 
controls. There was no depot specificity in this effect. The proliferative effect appeared 
to be relatively specific for medium conditioned by adipose-derived endothelial cells as 
conditioning of the same medium by dermally-derived endothelial cells had 
significantly less effect on preadipocyte proliferation. The mitogenic factor/s produced 
by the microvascular endothelial cells however, were not specific for preadipocytes 
because human skin fibroblasts also responded in a similar manner (Fig. 4.6). 
These findings demonstrate paracrine effects of adipose-derived endothelial cells on the 
proliferation of human preadipocytes. An increase in the rate of preadipocyte 
proliferation is one aspect of adipose tissue growth. Expansion of adipose tissue also 
requires the differentiation of preadipocytes into mature adipocytes. To further study 
the involvement of endothelial cells in adipose tissue growth co-culture experiments 
were undertaken to assess effects of these cells on preadipocyte differentiation. 
The co-culture experiments described in chapter 5 show that preadipocytes cultured in 
the same vessel as adipose-derived microvascular endothelial cells demonstrate a much 
greater differentiation potential, as judged by morphology (Fig. 5.2), G3PDH activity 
(Fig. 5.3), and Nile Red assay for intracytoplasmic lipid accumulation (Fig. 5.4), than 
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do preadipocytes cultured alone. Human skin fibroblasts, cultured either alone or in co-
culture with endothelial cells did not demonstrate any biochemical markers of adipose 
differentiation and no lipid accumulation was detected (Fig. 5.6 B shows G3PDH levels 
for human skin fibroblasts co-cultured with endothelial cells (HSF+EC) relative to 
preadipocyte cultures maintained and differentiated under identical conditions). 
Taken together, the proliferation experiments and the co-culture differentiation work 
described in chapters 4 and 5 respectively, demonstrate that microvascular endothelial 
cells from adipose tissue produce factors that are involved in regulation of human 
adipose tissue growth. As endothelial cells did not survive under the serum-free 
conditions necessary for preadipocyte differentiation it appears that the adipogenic 
effect of the endothelial cells occurred during the proliferative phase of preadipocyte 
growth. It is possible, therefore, that the mitogen/s produced by endothelial cells 
responsible for increased preadipocyte growth also 'prime' the preadipocytes for 
subsequent differentiation. 
In a series of control experiments it was demonstrated that a component of the 
endothelial cell growth medium, f3-endothelial cell growth factor (f3-ECGF), enhanced 
preadipocyte proliferation compared to the same medium minus this growth factor. 
This proliferative effect was only present when the growth factor was added to the 
medium just prior to treatment of preadipocytes. When the growth factor containing 
medium was subjected to 2 days pre-treatment at 37°C (in the absence of cells) the 
enhanced mitogenic effect of f3-ECGF was lost (Fig. 5.5 - Blank). As discussed 
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earlier, this same growth factor containing medium treated as above but in the presence 
of endothelial cells showed a marked mitogenic effect on preadipocytes (Figs. 4.6 and 
5.5). The mitogenic effect of fresh ~-ECGF was identical in magnitude to that induced 
by endothelial cell conditioned medium (see Fig. 5.5). It was concluded from these 
experiments that adipose-derived endothelial cells produce mitogenic substances 
themselves and/or produce substances that enhance or protect the activity of exogenous 
growth factors. Further work investigating the effects of this growth factor on 
preadipocyte differentiation showed no increased differentiation in cells treated with ~­
ECGF for 2 weeks prior to differentiation compared to preadipocytes not exposed to the 
growth factor. In contrast, preadipocytes co-cultured with endothelial cells for 2 weeks 
in ~-ECGF containing medium demonstrated significantly enhanced G3PDH activity 
following differentiation over those preadipocytes cultured alone (see Fig. 5.6B). 
However, treatment ofpreadipocytes with ~-ECGF for longer periods(> 4 weeks) were 
found to subsequently differentiate to the same degree as preadipocytes co-cultured 
with endothelial cells in the same growth factor containing medium over the time 
period. This was true for preadipocytes from both subcutaneous and omental adipose 
tissue depots (see Fig. 5.6A) although effects were greater in cells from subcutaneous 
sites. This effect of a growth factor on human preadipocyte differentiation was 
unexpected as many studies have reported inhibitory effects of growth factors on 
preadipose differentiation (Boone et al 2000; Gregoire et al 1998; Hanner et al 1995; 
Navre & Ringold 1989; Roncari & LeBlanc 1990b; Teichert-Kuliszewska et al1992). 
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~-ECGF is a member of the Fibroblast Growth Factor family (Burgess et all986) and is 
the precursor molecule of FGF -1 (also called acidic fibroblast growth factor or aFGF) 
which is a prototype member of this family of mitogens (Burgess et al 1986). 
Endothelial cells have been shown to produce members of the FGF family of growth 
factors including FGF-1 (Baird & Ling 1987; Powers et al 2000; Varzaneh et al 1994) 
and FGF produced by rat endothelial cells has been shown to stimulate replication of rat 
preadipocytes (Varzaneh et al 1994). FGF-1 has been shown to be involved in both 
proliferation and differentiation of a number of cell types including osteogenic stem 
cells (Iseki et al 1999) and skeletal muscle stem cells (Dusterhoft & Pette 1999). In 
view of this information and the demonstrated involvement of endothelial cells in 
human preadipocyte proliferation and differentiation, which could be mimicked by the 
FGF-1 precursor molecule, ~-ECGF, it was decided to consider FGF-1 as a candidate 
molecule which may be mediating the observed effects of endothelial cells on human 
adipogenic processess. 
7.4 Effects of Fibroblast Growth Factor-1 (FGF-1) on human 
adipogenesis 
In the next series of experiments for this dissertation the aim was to investigate FGF-1 
as a potential adipogenic molecule. 
In chapter 6 it was shown that FGF-1 enhances human preadipocyte proliferation and 
this effect was most pronounced at a concentration of lng/mL. The proliferative effect 
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ofFGF-1 at this concentration was markedly increased over that mediated by ~-ECGF 
at 10ng/mL (see Fig. 6.1). The photomicrogaph in Figure 6.2 shows that preadipocytes 
treated with FGF-1 at 1ng/mL attain a much greater cell density in vitro (B) than those 
cells grown in the absence of the growth factor (A). It was concluded from this work 
that FGF-1 has profound effects on human preadipocyte proliferation. It was also 
concluded that further work studying effects of FGF -1 on preadipocyte differentiation 
would be carried out with the growth factor at a concentration of 1 ng/mL. 
Experiments examining the effect of FGF-1 (1 ng/mL) on human preadipocyte 
differentiation in vitro demonstrated a marked positive effect of the growth factor that 
was similar in magnitude to that seen following treatment with ~-ECGF (see Figs. 6.3 
and 6.4). The adipogenic effect of these growth factors was greatest in preadipocytes 
exposed from the time of isolation up to commencement of differentiation. Figure 6.5A 
shows that when exposure of preadipocytes to either FGF-1 or ~-ECGF was delayed 
until the 2nd passage the subsequent level of G3PDH activity was reduced relative to 
cells treated for the entire period of proliferation. Conversely, if FGF-1 was removed 
from the preadipocyte proliferation medium for a period pnor to induction of 
differentiation, G3PDH activity was reduced to a similar level as that seen m 
preadipocytes which had no previous exposure to the growth factor. This was despite 
the fact that the high level of cell density and confluence reached by these preadipocytes 
during their FGF-1 treatment did not significantly alter between cessation of growth 
factor treatment and commencement of differentiation and these parameters were the 
same as in those cells maintained for the entire period in FGF-1 (this is reflected in the 
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insert in Fig. 6.5B showing the relative whole cell protein levels at the completion of 
differentiation in both treatment groups). The timing of FGF-1 treatment of 
preadipocytes was also shown to be specific to the time of proliferative growth of these 
cells as exposure during the differentiation period only had no increased effect on 
G3PDH activity (Figure 6.6) over those control cells with no exposure to FGF-1. 
However, both of these treatment groups had markedly lower G3PDH activity than 
those cells treated with FGF-1 during proliferation but differentiated in the absence of 
the growth factor. Taken together the above information would indicate that the 
increased differentiation seen in human preadipocytes following exposure to FGF-1 
during their proliferative phase of growth is not entirely dependent on the increased cell 
density and thus greater cell-cell contact occurring in these cells relative to controls and 
further the adipogenic effect of FGF-1 is one of 'priming' human preadipocytes for 
differentiation induced by other factors. 
7.5 PP ARy involvement in observed adipogenic effects of FGF -1 
The next two aims of this project revolved around delineating the role of PP ARy in the 
observed adipogenic effects seen in the present system. PP ARy is a transcription factor 
that has been shown to be central to adipogenesis (Vidal-Puig et al 1997) and the 
activity of the factor depends on the binding of ligands (Chawla et al 1994; Zhang et al 
1996). 
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To determine if FGF-1 induced activation of PPARy is the mechanism behind the 
observed effects of FGF -1 in the system described in this thesis several approaches 
were taken. In the first set of experiments preadipocytes were grown in the presence of 
FGF-1 and subsequently differentiated either in the presence or absence of 
Rosiglitazone. This compound is a member of the thiazolidinedione class of insulin-
sensitizing drugs and is a highly selective ligand of PP ARy and inducer of adipose 
conversion (Camp et al 2000; Forman et al 1995; Soret et al 1999). Results of this 
experiment showed that while preadipocytes grown in the presence of FGF-1 and 
differentiated in the absence of the thiazolidinedione demonstrated a small increase in 
G3PDH activity (over controls), the maximal effect on lipid accumulation and G3PDH 
activity was only seen in cells previously treated with growth factor and differentiated 
in the presence of thiazolidinedione. As the presence of a known PP ARy ligand was 
essential to achieve the adipogenic affects of FGF-1 this suggests that FGF-1 is not 
itself acting as a ligand, or inducing endogenous expression of a ligand for PP ARy in 
this system. This finding was further tested using an electrophoretic mobility shift 
assay looking at PP ARy DNA binding activity in preadipocytes grown in the presence 
or absence of FGF-1 (Fig. 6.8) and also PPARy activation assays using a reporter 
construct in an artificial system (transfected JEG-3 cells) (Fig. 6.9 A & B). These 
assays demonstrated no increased DNA-binding ofPP ARy in nuclear lysates from FGF-
1 treated preadipocytes compared to non-FGF-1 treated controls, no induced activity of 
a PPARy reporter construct by FGF-1, and no increased activation of the construct in 
the presence of both thiazolidinedione (Ros) and FGF-1 over that induced by 
thiazolidinedione alone. Taken together these results present strong evidence that in 
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this system FGF-1 is not acting as, or promoting production of, a ligand for PPARy. It 
is possible, however, that FGF-1 pre-treatment of preadipocytes may be acting in the 
PP ARy system in other ways. These could include stimulation of production of co-
factors necessary for PP ARy activation, or suppression of inhibitors of activation. As 
PPARy acts as a heterodimer with RXR it is also possible that FGF-1 may be exerting 
effects on RXR and thus having the observed effects on adipogenesis via this 
mechanism. Another mechanism that has not been examined is the level of expression 
of the CCAAT -enhancer binding proteins C/EBP~ and C/EBP8 in preadipocytes in 
response to FGF-1 treatment. Expression ofthese two transcription factors occurs early 
in preadipocyte differentiation and the presence of these factors is important in inducing 
expression of PPARy (see section 1.7.6). Further work is needed to determine the 
mechanisms by which FGF-1 is exerting its adipogenic actions. 
7.6 Effects of a specific FGF-1 neutralizing antibody on the 
adipogenic effects of the growth factor 
In the final work for this thesis the specificity of FGF-1 for the effects on both 
proliferation and differentiation of human preadipocytes was examined using a 
neutralizing antibody specific for FGF-1. Results demonstrated a marked decrease over 
two days in the proliferative capacity ofhuman preadipocytes in response to FGF-1 plus 
anti-FGF-1 compared to FGF-1 treatment alone (see Fig. 6.10A). The degree of 
decreased proliferation was dose dependent over the concentrations examined but was 
quite pronounced at the lowest dose of 1 Of.!g/mL for the antibody with the growth factor 
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at 1ng/mL (these concentrations were used in subsequent experimental work). Further 
studies examining the effects of the FGF -1 neutralizing antibody on FGF -1 priming of 
preadipocytes for subsequent differentiation showed no effect of the antibody on this 
aspect of adipogenesis. Morphologically the cells treated in the presence of both 
growth factor and antibody appeared different to those treated with growth factor alone 
with the cells in the antibody treatment being slower growing and failing to reach the 
same degree of confluence as the FGF-1-only treated cells. However the antibody plus 
growth factor treated cells still grew much faster than cells not exposed to growth 
factor. The failure of an FGF-1 specific neutralizing antibody to block the 
differentiation potential ofpreadipocytes grown in the presence ofFGF-1 plus antibody 
may be due to use of the antibody at a concentration that was too low over the period of 
growth required prior to differentiation of the preadipocytes. Another explanation may 
be that the signaling pathways involved in FGF-1 stimulation of preadipocyte 
proliferation are different to those causing the 'priming for differentiation' effect 
observed in these cells. There is evidence in the literature to support this concept 
showing that FGF effects on different cellular functions are mediated by different 
signaling pathways and these pathways may be different in different cell types and at 
different stages of cellular differentiation (Szebenyi & Fallon 1999). Further work is 
required to determine the specificity of FGF -1 for the demonstrated in vitro effects on 
human preadipocyte proliferation and differentiation. The results obtained in this study 
highlight the importance of studying a range of growth factors, including other 
members of the FGF family, to determine if these factors, either alone or in 
combination, can also 'prime' human preadipocytes for differentiation. 
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7.7 FGF-1 production by adipose-derived microvascular endothelial 
cells 
FGF-1 was chosen for study as a candidate molecule mediating the effects on human 
preadipocyte proliferation and differentiation observed in conditioned medium and co-
culture experiments with microvascular endothelial cells. Choice of this molecule was 
based on the fact that the FGF-1 pre-cursor molecule (P-ECGF) mimicked the 
adipogenic effects induced by endothelial cells (demonstrated in chapters 4 and 5 of this 
thesis), FGF-1 has been widely reported to be produced by microvascular endothelial 
cells in a number of systems (Baird & Ling 1987) and FGF-1 has been implicated in the 
proliferation and differentiation of mesenchymal precursor cells from other systems 
(Soulet et al 1994). To support the hypothesis that FGF-1 is produced by adipose-
derived endothelial cells, proliferation assays were carried out using medium 
conditioned by endothelial cells either with or without specific neutralizing antibody to 
FGF -1. These experiments indeed show a dramatic decrease in the level of proliferation 
of preadipocytes from both subcutaneous and omental adipose tissue depots seen in 
response to the FGF-1 neutralizing antibody (see Figure 6.11). These results provide 
circumstantial evidence that FGF -1 may be produced by endothelial cells in human 
adipose tissue. Further work examining expression ofFGF-1 by these endothelial cells 
needs to be carried out to determine if this is indeed the case. It is also important to 
determine if FGF-1 is produced, either in endothelial cells or other cell types in adipose 
tissue, in response to paracrine signals produced by mature adipocytes, an example may 
be leptin which is a molecule produced by adipocytes which is involved in monitoring 
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of energy stores (Flier 1997) and has been implicated in stimulation of angiogenesis 
(Bouloumie et al 1998). This could be a mechanism whereby leptin produced by 
hypertrophied adipocytes signals to endothelial cells in the vasculature for an 
angiogenic response to support an increase in adipose tissue mass. The endothelial cells 
may then produce growth factors, including FGF-1, which stimulates their own growth 
and that of the preadipocyte population in the immediate area. 
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CHAPTERS 
SUMMARY AND FUTURE DIRECTIONS 
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8.1 Summary 
This study examining factors influencing the in vitro proliferation and differentiation of 
human preadipocytes made the following novel findings: 
A) Human preadipocytes exposed to linoleic acid develop morphological features 
of the adipocyte phenotype but do not express any markers of biochemical 
differentiation. This appears to be the first direct evidence that in adipose cells, 
triacylglycerol storage and biochemical features of the adipocyte phenotype may be 
independently regulated. 
B) Adipose-derived microvascular endothelial cells produce factor/s which enhance 
both proliferation and differentiation of human preadipocytes. 
C) The adipogenic effects of microvascular endothelial cells can be mimicked by 
exposure of preadipocytes to members of the Fibroblast Growth Factor family, 
specifically P-ECGF and FGF-1. 
D) Both P-ECGF and FGF-1 'prime' human preadipocytes, during their 
proliferative phase of growth, for thiazolidinedione induced differentiation. 
E) FGF-1 is not a PP ARy ligand. 
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8.2 Future Directions 
Current and future work arising from this study 
1. Study the effects of a range of fatty acids on human preadipocyte differentiation 
to determine if other fatty acids, as well as linoleic acid, are also taken up and stored by 
'preadipocytes' in the absence of biochemical differentiation. The in vivo implications 
of this effect of fatty acids need to be examined. 
2. Further explore the effects ofFGF-1 in adipose tissue 
What mechanisms are responsible for the observed effects? 
•:• Determine which receptors and which signaling pathways are important in the 
adipogenic effects of FGF -1. Are the signaling pathways the same for both the 
proliferative and differentiative responses of preadipocytes to FGF -1 treatment? 
These studies are currently being undertaken and involve immunofluorescence 
and western blotting procedures for the presence of different FGF receptors and 
their localization within preadipocytes in response to FGF-1 treatment. Anti-
phosphotyrosine blotting will also be carried out on immuno-precipitated FGF 
receptors to determine the phosphorylation status of the different receptors and 
thus which receptors may be active under various conditions. Microarray 
analysis is also currently in progress to detect differences in gene expression 
158 
between preadipocytes treated with FGF-1 and those not treated with the growth 
factor. Using this strategy it may be possible to identify factors which may be 
responsible for the 'priming' effect ofFGF-1 on differentiation. 
•!• What is the importance of specific heparan sulfate proteoglycans in the system. 
•!• Are the effects of FGF-1 on human adipogenesis an important in vivo 
mechanism involved in regulation of growth of adipose tissue. Are there depot-
specific responses to FGF-1 which regulate growth of adipose-tissue stores in 
different locations in the body? 
•!• Is FGF-1 produced by adipose-derived microvascular endothelial cells or other 
cell types within adipose tissue? If so, is FGF-1 produced in response to local 
signals within adipose tissue. Are these signals the same in different adipose 
tissue depots? Current work includes RT -PCR strategies looking at expression 
of FGF-1 in isolated endothelial cells, adipocytes and preadipocytes. In situ 
hybridization will be undertaken on whole adipose tissue sections to determine 
ifFGF-1 is produced by different cell types within each adipose tissue depot. 
•!• Are the observed effects on adipogenesis, demonstrated in this study, specific 
for FGF-1? Studies are currently being undertaken to determine if other growth 
factors or combinations of growth factors have either positive or negative effects 
on regulation of human adipogenesis. 
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In conclusion, biochemical and molecular studies of human preadipocytes in 
primary culture, although tedious and difficult, are essential to determine if the 
concepts originated from rodent and cell line studies hold true in the human context. 
The systems described in this thesis for studying primary cultures of human 
preadipose cells and other cell types from adipose tissue, although more difficult, 
costly and time-consuming than the murine equivalents, provide the opportunity to 
learn more about the normal physiology and biochemistry of human tissues. They 
also hold the potential for direct study of the effects of different compounds on 
adipose tissue metabolism combined with the potential for development of 
pharmacological strategies which may be beneficial in the treatment of human 
disease. 
Little information is available in the current literature on the role of growth factors 
in human adipose tissue development and function. The findings in this study have 
expanded our understanding of the role of paracrine factors and specifically FGF -1 
in adipose tissue development and have helped to better understand the regulation of 
the adipose conversion program at the cellular level. However, more work is 
needed to extend this knowledge and use it in the development of treatment 
strategies for obesity and obesity-related disorders. 
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CHAPTER9 
APPENDICES 
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9.1 SUPPLIERS OF REAGENTS AND EQUIPMENT 
BAXTER HEALTHCARE PTY LTD, OLD TOONGABBIE, NSW, AUSTRALIA 
Ringers Solution 
BDH LABORATORY SUPPLIES, ENGLAND 
Paraformaldehyde 
BIORAD LABORATORIES PTY LTD, REGENTS PARK, NSW, AUSTRALIA 
Microplate Reader (3550) 
CELL APPLICATIONS, INC., SAN DIEGO 
Human dermal microvascular endothelial cells (CADMEC) 
CORNING COSTAR CORPORATION, CAMBRIDGE, UK 
6-well plates 
T-25 culture flasks 
T -7 5 culture flasks 
CSL BIOSCIENCES, PARKVILLE, VIC, AUSTRALIA 
Foetal bovine serum 
Trypsin-versene 
DAKO (Australia) Pty Ltd, Botany, NSW, Australia 
Anti-PECAM-1 (CD-31) (Clone JC/70A) 
Anti-von Willebrand's Factor (clone FS/86) 
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Fluorescein isothiocyanate (FITC) labeled secondary antibody (rabbit anti-mouse IgG) 
DUPONT, BOSTON, MA 
GeneScreen Plus hybridization transfer membranes 
DYNAL BIOTECH, CARLTON SOUTH, VIC, AUSTRALIA 
Dynabeads M-450 
Magnetic particle concentrator 
EASTMAN KODAK, ROCHESTER, NY 
BIOMAX MS film 
XAR film 
GENEWORKS, ADELAIDE, AUSTRALIA 
dCTP, (a32P) 
Gigaprime DNA labeling kit 
Intensifying screen 
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ICN BIOMEDICALS AUSTRALASIA PTY LTD, SEVEN HILLS, NSW, 
AUSTRALIA 
DMEM/Ham's F12 1:1 
Glutamine 
M-199 
Penicillin/Streptomycin 
KODAK (AUSTRALASIA) PTY LTD, FORTITUDE VALLEY, QLD AUSTALIA 
Colour Print Film, 400 ASA 
LINCO RESEARCH, INC. MISSOURI 
Leptin RIA kit 
NEUBAUER, WEST GERMANY 
1 mm2 micrometer grid 
NIKON, COHERENT LIFE SCIENCES, HILTON, SA, AUSTRALIA 
Eclipse TE300 Inverted Microscope 
F70 Camera 
TE-FM Bpi-Fluorescence attachment 
PHARMINGEN, BECTON DICKINSON, NORTH RYDE, NSW, AUSTRALIA 
Anti-PECAM-1 
PROMEGA, MADISON WI 
Dualluciferase assay kit 
Formazan colorimetric assay kit 
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MTS (3-( 4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-( 4-sulfophenyl)-2H-
tetrazolium 
RL-CMV 
R & D BIOSYSTEMS, MINNEAPOLIS, USA 
Anti-E-selectin (CD62E) (Clone BBIG-E4) 
Anti-FGF-1 (neutralizing antibody) 
FGF-1 
ROCHE DIAGNOSTICS AUSTRALIA PTY LTD, WEST END, QLD 
Expand Reverse Transcriptase 
Digoxigenin 
SHIMADZU SCIENTIFIC INSTRUMENTS, INC., COLUMBIA, MD 
UV -visible spectrophotometer 
SIGMA-ALDRICH PTY LTD, CASTLE HILL, NSW, AUSTRALIA 
B-ECGF CB-endothelial cell growth factor) 
B-NADH 
100 J.tm mesh 
1-methyl-3-isobutylxanthine 
250 J.tm mesh 
2-Mercaptoethanol 
Agarose (DNA grade) 
Ammonium chloride 
Biotin 
Biotin 
Bovine Serum Albumin 
Bovine Serum Albumin (fatty acid free) 
Bromophenyl Blue 
Calcium chloride 
Calcium phosphate 
Chloroform 
Collagenase Type II 
DAP (Dihydroxyacetone phosphate) 
Denhardt's solution 
Dextran sulphate 
Diethylpyrocarbonate 
DPBS (deionised PBS) 
DTT (Dithiothrietol) 
EDTA (Ethylenediamine tetraacetic acid, disodium salt) 
Ethidium bromide 
165 
Formaldehyde 
Formamide 
Gelatin 
Glucose 
Glycerol 
Glycine 
Guanidium thiocyanate 
HBSS (Hank's balanced salt solution) 
Heparin 
HEPES (N-[2-Hydroxyethyl]piperazine-N' -[2-ethanesulfonic acid]) 
Hydrocortisone (cortisol) 
Insulin 
Leupeptin 
Linoleic acid 
Magnesium chloride 
MOPS (3-[N-Morpholino]propanesulfonic acid) 
Nile Red 
Pantothenate 
Pantothenate 
Pepstatin 
Phenol 
Phosphate buffered saline 
PMSF (polydeoxyinosinic-deoxycytidylic ( di/dC) acid 
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Potassium chloride 
Potassium hydrogen carbonate 
Propidium iodide 
Proteinase K 
RNAseA 
Salmon Sperm DNA 
Sarcosyl 
SDS (sodium dodecyl sulphate) 
Sodium acetate 
Sodium chloride 
Sodium citrate 
Sodium hydrogen carbonate 
Sodium hydroxide 
Sprotinin 
TBE buffer 
Transferrin 
Trichloroacetic acid 
Triethanolamine 
Tri-reagent 
TRIS (tris[hydroxymethyl] aminomethane) 
TRIS-HCl 
Trisma base 
Trisodium citrate 
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Triton X-100 
Tumour Necrosis Factor- a 
Tween20 
SMITHKLINE BEECHAM, WELWYN, UK 
Rosiglitazone 
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9.2 ETHICS APPROVALS FOR THIS PROJECT 
a.ur 
UNIVERSITY HUMAN RESEARCH ETHICS COMMITTEE 
Ms Louise Hutley 
Centre for Molecular Biotechnology 
Department of Diabetes & Endocrinology 
Ground Fioor C Wing, Building 1 
PA Hospital, Ipswich Rd, Woolloongabba lfa::lo 
December'S, 2001 
Dear Ms Hutley 
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At its 4 December 2001 meeting, the University Human Research Ethics Committee considered the additional 
information I revisions you provided in relation to your project "Human Preadipocyte Replication and Differentiation" 
(Ref No OUT 1392/1 H). 
The Committee is satisfied that the information provided addresses its concerns, and has confirmed the full ethical 
clearance status of this project. 
Please do not hesitate to contact me if you have any further queries in relation to this matter. 
Yours sincerely 
9--
Gary Allen . 
Secretary, University Human Research Ethics Committee 
OUT Secretariat . 
Telephone: (07) 3864 2902 
Facsimile: (07) 38641818 
Email: gx.allen@qut.edu.au 
http://www.qut.edu.au/draa/or/ethics/human/index.html 
Cc: Prof Adrian Herrington, Life Sciences 
Queensland University of Technology 
GARDENS POINT CAMPUS 2 GEORGE STREET GPO BOX 2434 BRISBANE QLD 4001 PHONE (07) 3864 2111 FAX (07) 38641510 
Campuses: Gardens Point (City), Kelvin Grove, Calseldine World Wide Web: http://www.qut.edu.au/ ABN: 83 791 724 622 
QUT International: Victoria Park Road Kelvin Grove OLD 4059 Australia Phone +617 3864 3142 Fax +617 38643529 
UNIVERSITY HUMAN RESEARCH ETHICS COMMITTEE 
Ms Louise Hutley, 
School of Life Sciences 
Department of Diabetes & Endocrinology, 
5th Floor Diamantina House, 
PA Hospital, Ipswich Rd, 
Wqolloongabba Old 41 02 
1 0 June, 1998 
Dear Ms Louise Hutley, 
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At its 5 June 1998 meeting, the University Human Research Ethics Committee considered the 
additional information/revisions you. provided in relation to your project "Human preadipocyte 
replication and differentiation" (Ref No OUT 1392H). 
The Committee is satisfied that the information provided addresses its concerns. 
Please do not hesitate to contact me if you have any further queries in relation to this matter. 
Yours sincerely 
(A h.-. 
l:rv Allen 
Secretary, l!niversity Human Research Ethics Committee 
OUT Secretariat 
Telephone: (07) 3864 2902 
Facsimile: (07) 3864 1818 
Email: gx.allen@qut.edu.au 
Cc: Prof Adrian Herington, School of Life Sciences, OUT Gardenes Point 
Queensland University of Technology 
GARDENS POINT CAMPUS 2 GEORGE STREET GPO BOX 2434 BRISBANE Q 4001 AUSTRALIA PHONE (07) 3864 2111 FAX (07) 3864 1510 
Campuses: Gardens Point (city), Kelvin Grove, Carseldine World Wide Web: http://www.qut.edu.au/ 
OUT International: Locked Bag No 2 Red Hill Q 4059 Australia Phone +61 7 3864 3142 Fax +61 7 3864 3529 
QUEENSLAND HEALTH 
PRINCESS ALEXANDRA HOSPITAL 
Ipswich Road 
Woolloongabba 
Brisbane Old Australia 41 02 
Telephone (07) 3240 2111 
Facsimile (07) 3240 5577 
Ms L J-Iutley 
Department of Diabetes and Endocrinology 
5th Floor, Diamantina House 
PRINCESS ALEXANDRA HOSPITAL 
Dear Ms Rutley 
RE: RESEARCH PROTOCOL: 161197 
"Human Preadipocyte Replication and Differentiation" 
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PRINCESS ALEXANDRA HOSPITAL 
AND DISTRICT HEALTH SERVICE 
ENQUIRIES 
PHONE 
FAX 
QUA REF 
YOUR REF 
Dr K Ferguson 
3240 5856 
3240 2420 
KF 
12 December 1997 
At the meeting of the Princess Alexandra Hospital Research Ethics Committee held on 2 
December 1997, the Committee approved the above protocol. This Committee is constituted 
and operates in accordance with current NHMRC Guidelines. 
If any substantial change is made to the protocol, this will need to be approved by the 
Committee. Submission of an amendment or extension to the protocol must give sufficient 
time and detail for formal consideration. The Committee must also be informed of any 
problems that arise during the course of the project which may have ethical implications. 
Serious advers<'; events must be notified to the Committee as soon as possible. If the study has 
not commenced within two years approval will lapse. 
A NHMRC requirement is that all projects be reviewed annually. ·Accordingly, a short 
questionnaire will be sent to you every 12 months after initial approval and your assistance in 
completing and returning this promptly would be appreciated. 
When the study involves patient contact, it is your responsibility as the principal investigator 
to notify the relevant consultant and request their approval. 
A copy of this letter should be presented when required as confirmation of the approval of the 
PAH Research Ethics Committee. 
Princess Alexandra Hospital 
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QUEENSLAND 
GOVERNMENT 
L7 
PRINCESS ALEXANDRA HOSPITAL 
and DISTRICT HEALTH SERVICE 
ENQUIRIES 
PHONE 
FAX 
OUR REF 
YOUR REF 
Ipswich Road 
Woolloongabba Qld 41 02 
Brisbane Australia 
Telephone (07) 3240 2111 
Facsimile (07) 3240 5577 
Investigators: 
PATIENT INFORMATION SHEET 
Study into regulation of Fat Cell Growth 
Ms Louise Rutley, Princess Alexandra Hospital, Dept Endocrinology 
A/Prof John B Prins, Princess Alexandra Hospital, Dept Endocrinology 
Prof Donald P Cameron, Princess Alexandra Hospital, Research Division 
Prof Adrian C Herington, Queensland University of Technology 
QUEENSlAND HEAlT 
Obesity is a major risk factor for the development of diabetes and heart disease, however 
very little is known about how fat cells grow. We are undertaking a study to investigate 
factors which play a role in fat cell growth in humans. 
We would like to invite you to participate in our study looking at things which influence 
fat cell growth. To carry out this study we need to obtain small samples of fat tissue form 
volunteers. This is easily and safely done when a person is having an operation for an 
unrelated problem, as in your case. The removal of small amounts of fat will not affect 
your outcome from surgery, or interfere with routine surgical care. A small sample of 
blood will also be taken along with the routine preoperative tests. As some medical 
conditions can affect the way fat cells grow we also need to take a limited medical history 
from you as well as obtain your weight, height, waist and hip measurements. 
Confidentiality will be maintained and no information will be released in any form which 
would allow the recognition of your participation. The research will not be of direct 
benefit to you as an individual, but will aid our understanding of obesity and its causes. 
Participation in this study is voluntary and if you choose not to participate this will not 
affect your operation or standard of care. If you have any concerns about the ethical 
conduct of this research, please feel free to contact the Secretary of the Research Ethics 
Committee of either the Princess Alexandra Hospital (tel: 3240 5856) or Queensland 
University of Technology (tel: 3864 2902). 
This study is being undertaken by Louise Rutley as part of her doctoral studies with 
Queensland University of Technology, under the supervision of Professor A. Herington. 
The work will be carried out at Princess Alexandra Hospital under the supervision of 
Associate Professor J.B. Prins and Professor D.P. Cameron. 
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QUEENSLAND 
GOVERNMENT 
{_ __ ~ 
PRINCESS ALEXANDRA HOSPITAL 
and DISTRICT HEALTH SERVICE 
Ipswich Road 
Woolloongabba Old 41 02 
Brisbane Australia 
Telephone (07) 3240 2111 
Facsimile (07) 3240 5577 
Study into regulation of Fat Cell Growth 
ENQUIRIES 
PHONE 
FAX 
OUR REF 
.YOUR REF 
QUEENSLAND HEALTH 
CONSENT FORM 
I, . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . consent to taking part in the study 
entitled, "Human Preadipocyte Replication and Differentiation". 
I have read the information sheet provided and have had my queries satisfactorily 
answered by the chief investigator of the study, Louise Rutley. 
Participant's signature Witness 
Date: ........................................... . Date: .......................................... . 
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